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ABSTRACT 
SYNTHESIS OF TRIAZOLE CANNABIDIOL (CBD) ANALOGUES  
Cancer is the leading cause of death worldwide and current treatment options often lead to painful 
and unpleasant side-effects. The active constituents isolated from medicinal plants have been 
successfully developed into various chemotherapeutic agents. The medicinal plant of interest in this 
research project, the cannabis plant, along with the constituents isolated, known as cannabinoids, 
have shown promising proapoptotic, anti-proliferative and anti-angiogenic effects. Interest in non-
psychoactive cannabinoids, in particular cannabidiol (CBD), has significantly increased in recent 
years. CBD offers the hope of improved anticancer therapies that selectively target cancer cells 
without affecting normal cells, thereby eliminating the unwanted side-effects associated with 
conventional therapies. 
This project involved the design and synthesis of CBD analogues by mimicking the main 
pharmacophoric groups found on the structure of CBD. The main difference between the natural 
occurring cannabinoid and the analogues in this study, was the replacement of the benzene ring at 
the core of the structure with a 1,2,3-triazole ring using click chemistry. A triazole moiety can provide 
improved solubility and bioavailability, while helping to exploit the chemical space around the 
compound. Three different systems (Scaffold A, B and C) were explored throughout this project. The 
transitions between these systems involved systematic alterations of functional groups on the 
general structure of each system, as well as the introduction of stereochemistry in the synthesis of 
Scaffold C. Important reactions used during the synthesis of these scaffolds included an epoxide 
ring opening via nucleophilic substitution, a Michael reaction, an Appel reaction, a nucleophilic 
substitution reaction resulting in an inversion of stereochemistry, as well as copper- and ruthenium-
catalyzed azide alkyne cycloaddition reactions. These reactions provided the 1,4- and 1,5-, as well 
as 1,4,5-polysubstituted 1,2,3-triazole CBD analogues.  
The anticancer activity of these compounds was subsequently evaluated against the MCF-7 cell line, 
as well as the HeLa cell line. None of the CBD triazole analogues of this study showed particularly 
appealing activity against these cancer cell lines. One analogue did however show potentially 
interesting activity against the MCF-7 cell line, and two analogues had an IC50 value below 100 μM 
against the HeLa cell line, with the most promising analogue providing an IC50 value of 74.3 μM. In 
addition, all compounds tested were completely devoid of toxicity below concentrations of 100 μM. 
The results obtained provide valuable insight into the future design of triazole CBD analogues.  
SYNTHESIS OF SUBSTITUTED CYCLOPARAPHENYLENES (CPPS)  
The synthesis of complex macrocycles and the study of the structural characteristics and properties 
displayed by these compounds is a fascinating research field. Cycloparaphenylenes (CPPs) are 
macrocycles which consist of benzene rings connected through para-linkages. This project focused 
on the synthesis of functionalized CPPs as these macrocycles could provide new host−guest 
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possibilities, possible use in chemosensors and nanoporous materials and the option of connecting 
these CPP macrocycles to various surfaces. 
A method was developed for the synthesis of substituted [8]CPPs containing a thioether functionality, 
which provides the option of effortlessly transforming the substituents throughout the synthesis to 
give access to the previously synthesized ether-containing [8]CPP macrocycle. The series of 
reactions used during the synthesis of this CPP linker system included a Sonogashira coupling 
reaction, a dibromination reaction and a macrocyclization reaction, among others.  
A linear test system was developed with a similar backbone structure to the substituted CPPs. The 
synthesis of the linear test system allowed investigation of the optimum route for the formation of the 
thioether functionality, which was then directly applied to the CPP linker system to gain access to 
the sulfur-containing CPP macrocycle.  
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UITTREKSEL 
SINTESE VAN TRIASOOL KANNABIDIOL (CBD) ANALOË  
Kanker is tans wêreldwyd die hoofoorsaak van sterftes. Die verskeie vorme van behandeling wat 
beskikbaar is lei dikwels tot pynlike en onaangename newe-effekte. Die aktiewe komponente, wat 
van medisinale plante verkry is, is reeds suksesvol tot verskeie chemoterapeutiese middels 
ontwikkel. Die medisinale plant in hierdie navorsingsprojek ter sprake, is die cannabis plant, asook 
die komponente, kannabinoïede, wat uit hierdie plant geïsoleer is. Dit toon belowende 
proapoptotiese, anti-proliferatiewe en anti-angiogeniese effekte. Belangstelling in nie-psigoaktiewe 
kannabinoïede, in besonder kannabidiol (CBD), het aansienlik verhoog in die afgelope paar jaar. 
CBD bied hoop op verbeterde anti-kankerterapieë, wat kankerselle selektief teiken, sonder om 
normale selle te beïnvloed. Dit skakel dus die ongewenste newe-effekte, geassosieer met 
konvensionele terapie, uit.  
Hierdie projek behels die ontwerp en sintese van CBD analoë deur die farmakoforiese groepe, wat 
in die struktuur van CBD gevind word, na te boots.  Die hoof verskil tussen die kannabinoïd wat 
natuurlik voorkom, en die analoë in hierdie studie, is die vervanging van die benseenring, in die kern 
van die struktuur, met ŉ 1,2,3-triasool ring, deur middel van kliek chemie. ‘n Triasool komponent kan 
verbeterde oplosbaarheid en biobeskikbaarheid bied, terwyl dit terselfdertyd help om die chemiese 
spasie rondom die verbinding te benut. Drie verskillende sisteme (Steier A, B en C) is tydens hierdie 
projek ondersoek. Die oorgang tussen sisteme behels die sistematiese wysiging van funksionele 
groepe op die algemene struktuur van elke sisteem, sowel as die invoer van stereochemie in die 
sintese van Steier C. Belangrike reaksies wat tydens die sintese van die steiers gebruik is sluit in ŉ 
epoksied ring-opening, deur middel van nukleofiele vervanging, ŉ Michael-reaksie, ŉ Appel-reaksie, 
ŉ nukleofiele vervangingsreaksie wat lei tot ‘n inversie van stereochemie, asook koper- en rutenium-
gemedïeerde azied alkyn sikloaddisie reaksies. Hierdie reaksies het die 1,4- en 1,5-, sowel as 1,4,5-
gesubstitueerde 1,2,3-triasool CBD analoë verskaf. 
Die anti-kanker aktiwiteit van hierdie verbindings is vervolgens teen die MCF-7 sellyn, asook die 
HeLa sellyn, geëvauleer. Geen van die CBD triasool analoë in hierdie studie het besondere 
belowende aktiwiteit teen die twee sellyne getoon nie. Een verbinding het egter potensieël 
interessante aktiwiteit teen die MCF-7 sellyn getoon en twee analoë het  ŉ IC50 waarde minder as 
100 μM, teen die HeLa sellyn gehad. Die mees belowende analoog het ‘n  IC50 waarde van 74.3 μM 
verskaf teen die HeLa sellyn. Daarbenewens is alle verbindings wat getoets is, heeltemal vry van 
toksisiteit onder konsentrasies van 100 μM. Die resultate verskaf waardevolle insig in toekomstige 
ontwikkeling van triasool CBD-analoë.  
SINTESE VAN GESUBSTITUEERDE SIKLOPARAFENILENE (CPPS)  
Die sintese van kompleks makroringe, asook die studie van die strukturele kenmerke en eienskappe 
wat hierdie verbindings toon, is ŉ baie interessante navorsingsveld. Sikloparafenilene (CPPs) is 
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makroringe wat bestaan uit benseenringe wat deur para-skakeling verbind word. Hierdie projek fokus 
op die sintese van gefunksioneerde CPPs omdat hierdie makroringe nuwe gasheer-gas 
moontikhede, moontlike gebruik in chemosensors en nano-poreuse materiale, asook die opsie om 
hierdie CPP makroringe met verskeie ander oppervlaktes te verbind, kan bied.    
ŉ Metode is ontwikkel vir die sintese van gesubstitueerde [8]CPPs wat n tioeter funksionaliteit bevat, 
wat die opsie bied om die substituente deur die loop van die sintese te transformeer om toegang tot 
die vorige gesintetiseerde eter-bevattende [8]CPPs te verskaf. Die reeks reaksies wat tydens die 
sintese van hierdie CPP skakelsisteem gebruik is, sluit ‘n Sonogashira-koppelingsreaksie, ŉ 
dibrominasie-reaksie en ŉ makrosikloserings-reaksie, onder andere, in. 
ŉ Lineêre toetssisteem is ontwikkel met ŉ soortgelyke ruggraatstruktuur as die gesubstitueerde 
CPPs. Die sintese van die lineêre toetssisteem het die geleentheid gebied om die optimale roete vir 
die formasie van die tioeter funksionaliteit te ondersoek, wat toe direk op die CPP skakelsisteem 
toegepas is om toegang tot die swael-bevattende CPP makroring te verkry.  
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PREFACE  
A NOTE TO THE READER 
My MSc degree has truly been a unique journey. I had the opportunity to work on four different 
projects, of which some were in slightly different fields of specialization. Two of these projects also 
gave me the opportunity to work in two European countries for extended periods.  
Of the four projects I worked on during my MSc, two are discussed in this document, as can be seen 
in the joined title of this dissertation.  
THESIS LAYOUT 
The first project, which is also the main project of my MSc, is titled “Synthesis of triazole cannabidiol 
(CBD) analogues”. This is an organic chemistry project which focused on the synthesis of small 
molecules as potential anti-cancer agents. Pages 1 to 123 contains all the information of this project, 
including the introduction (Chapter 1 and 2), results and discussion (Chapter 3), biological evaluation 
(Chapter 4), conclusion and future work (Chapter 5), experimental (Chapter 6), as well as the 
appendix pertaining to the work of this project (labelled as Appendix 1). All the experimental work for 
this project was conducted at Stellenbosch University, under the supervision of Prof. Willem A. L. 
van Otterlo and Prof. Gareth Arnott, except for the biological tests. The bioactivity of these 
compounds was independently determined by our collaborators at the CSIR in Pretoria and at NMT 
in the United States of America. 
The second project discussed in this document, is titled “Synthesis of substituted 
cycloparaphenylenes (CPPs)”. This project focused on designing novel synthetic routes for the 
synthesis of these unique macrocycles. The reactions involved in this project, as well as the possible 
applications of these macrocycles are completely different when compared to the main project 
discussed in this dissertation. Pages 124 to 164 contains all the information of this project, including 
the introduction (Chapter 7), results and discussion (Chapter 8), conclusion and future work (Chapter 
9), experimental (Chapter 10), as well as the appendix for this project (labelled as Appendix 2). For 
this project I spent approximately 4 months in Giessen, Germany, at the Justus Liebig University as 
part of the Liebig-College Scholarship in the research group of Prof. Dr Hermann A. Wegner. 
Please note – In order to show the complete division between these two projects, the compound 
numbering and NMR spectra numbering for the second project was restarted at 1. 
Finally, a combined reference list can be found in pages 165 to 174 containing all the references 
used for both of these projects.  
ADDITIONAL PROJECTS AND PUBLICATIONS 
Apart from the two projects discussed in this document, I was involved in another two research 
endeavors. During my MSc degree at Stellenbosch University, I had the opportunity to work with Dr 
Tanya Mabank, Prof. Ivan R. Green and Prof. Willem A. L. van Otterlo on finalizing some important 
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aspects of a ring closing metathesis project. This research, titled "Observations concerning the 
synthesis of heteroatom-containing 9-membered benzo-fused rings by ring-closing metathesis", was 
published in Tetrahedron in 2017.1 
The final project which I was involved in focused on the isolation and characterization of alkaloids 
from an indigenous unexplored South African plant. The initial experimental work for this project was 
conducted at Stellenbosch University with Prof. Ivan R. Green and Prof. Willem A. L. van Otterlo, 
after which I got the opportunity to continue with this project in the research group of Prof. 
Antonio Evidente at the University of Naples Federico II, Naples, Italy. The manuscript for this 
research, titled “Alkaloids isolated from Haemanthus humilis Jacq., an indigenous South African 
Amaryllidaceae: Anticancer activity of coccinine and montanine” was accepted on 28 January 2019 
by the South African Journal of Botany and has been send to production.2  
During my MSc I attended two conferences, one local (Frank warren, 2016 in Grahamstown, South 
Africa) and one international (IUPAC Postgraduate Summer School on Green Chemistry 2018 in 
Venice, Italy), where I presented my main MSc project (Synthesis of triazole cannabidiol (CBD) 
analogues) by means of poster presentations. At the IUPAC Summer school on Green Chemistry 
2018 in Venice, Italy, I received a certificate of recognition from Eni (main sponsor of the summer 
school) for the research presented in the poster presentation.  
INTERPRETATION OF NMR SPECTRA 
Please note that the atom numbering of the compounds in this dissertation is different compared to 
the numbering used when naming these compounds. This was done in an attempt to simplify the 
NMR spectra analysis, allowing the comparison of the same atom on different compounds in a more 
convenient way.
                                               
 
1 B. A. Aderibigbe, I. R. Green, T. Mabank, M. Janse van Rensburg, G. L. Morgans, M. A. Fernandes, J. P. 
Michael and W. A. L. van Otterlo, Tetrahedron, 2017, 73, 4671–4683. 
2 M. Masi, S. Van slambrouck, M. Janse van Rensburg, P. C. James, J. G. Mochel, P. S. Heliso, A. S. Albalawi, 
A. Cimmino, W. A. L. van Otterlo, A. Kornienko, I. R. Green and A. Evidente, in press, on invitation to S. Afr. 
J. Bot., January 2019. 
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SYNTHESIS OF TRIAZOLE CANNABIDIOL (CBD) ANALOGUES 
   
INTRODUCTION TO CANCER AND CANNABIS  
1.1. CANCER 
1.1.1. DEFINITION OF CANCER  
The American Cancer Society’s formal definition describes cancer as ‘a group of diseases 
characterized by uncontrolled growth and spread of abnormal cells’.1 Cancer is one of the leading 
causes of mortality worldwide, causing more deaths than AIDS, tuberculosis and malaria combined. 
Although considerable progress has been made in cancer treatment, a universal cure is still out of 
reach.2,3 
Cancer can affect people across the globe, of any race or age; and the severity of the global cancer 
epidemic is demonstrated in recent cancer statistics.1 
1.1.2. CANCER STATISTICS 
In 2008, the International Agency for Research on Cancer, estimated that 12.7 million new cancer 
cases and 7.6 million cancer deaths occurred, of which 63% of cancer deaths occurred in less 
developed countries.4,5 This might be due to late diagnoses in less developed countries along with 
limited access to the necessary treatment centers, as shown in Figure 1:1. 
 
Figure 1:1   Number of patients at treatment centers in 2008.5 
The 2012 statistics, estimated that 14.1 million new cases and 8.2 million deaths occurred; of which 
more than half of the morbidity and mortality rates were once again assigned to less developed 
countries, as illustrated in Figure 1:2.3  
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Figure 1:2   Estimated global morbidity and mortality rates in 2012.3 
To visualize the impact cancer has on the South African population, cancer statistics for African 
countries were also consulted. An estimated 715 000 new cases and 542 000 deaths occurred in 
2008; with the highest overall death rates being assigned to Southern Africa (Table 1:1).6 
Table 1:1   Cancer Death rates in Africa, 2008.6  
  
All 
Africa 
Sub-
Saharan 
 Africa 
Southern 
 Africa 
Eastern 
 Africa 
Middle 
 Africa 
Northern 
 Africa 
Western 
 Africa 
 
aRate aRate aRate aRate aRate aRate aRate 
Males 
All sites b 
95.7 98.1 172.1 105.4 78.5 89.5 80.1 
Females 
All sites b 
86.5 92.8 108.1 95.9 75.6 68.2 91.2 
  a Rates are per 100 000 and age-standardized to the world population. 
  b Excluding nonmelanoma skin cancer. 
 
Through extrapolation of these recent increasing trends, the global cancer statistics are estimated 
to increase to 20.3 million new cases and 13.2 million deaths in 2030.7  
These cancer-related mortalities also have a significant influence on the economy of developing 
countries, due to a loss in productivity. In a recent study, five economically developing countries 
were evaluated; and South Africa exhibited the highest economic impact per cancer death.8  
These statistics clearly illustrates the need for affordable new cancer treatments, especially in less 
developed countries like South Africa. When researching new cancer treatments, a thorough 
understanding of the biology involved in cancer formation and progression is required. 
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1.1.3. BRIEF CANCER BIOLOGY 
This group of diseases, consisting of more than 100 different types, are all characterized by changes, 
or mutations, to the processes involved in normal cell division; resulting in clusters of abnormal cells, 
known as tumours.9 Tumours that remain in their position of origin, are called benign tumours; but 
invasive tumours that can spread, or metastasize, to other regions in the body, are known as 
malignant tumours (Figure 1:3).10,11  
 
Figure 1:3   Benign tumours compared to malignant tumours.10  
Lifestyle and environmental factors (radiation, tobacco, infectious organisms and viruses among 
others), as well as genetic factors (gene mutations or hormones) can lead to these unwanted 
mutations, thus resulting in cancer.12  
To appreciate current insights into the biology and treatments of cancer, the history of cancer 
research must be considered.  
1.1.4. HISTORY OF CANCER 
Paleopathologists have suggested the presence of animal ‘tumours’ in prehistoric times, and some 
believe that cancer can be traced back to the beginning of mankind; however, there are no accurate 
scientific records to confirm these beliefs.13 The first written description of ‘cancer’ dates back to 
approximately 3000 BC; located in an ancient Egyptian surgery manuscript, called the Edwin Smith 
Papyrus (Figure 1:4).13 
 
Figure 1:4   The Edwin Smith Papyrus.13  
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The Edwin Smith Papyrus manuscript, described ‘cancer’ as an untreatable disease. Nevertheless, 
the ancient Egyptians did attempt treating this disease by means of cauterization, or through the use 
of salts and an arsenic paste, known as ‘‘Egyptian ointment’’. Their medical beliefs were guided by 
their trust in religion and magic, which is why ancient Egyptians believed that the “will of the Gods” 
was responsible for several diseases, including cancer.13,14  
One of the first relevant milestones in cancer history, is when Hippocrates of Cos (460-375 BC), a 
Greek physician known as the “Father of Medicine”, formulated the humoral theory of cancer. 
1.1.4.1. HUMORAL THEORY 
This theory stated that an imbalance of internal humours (believed to be blood, phlegm, yellow bile 
and black bile) was the cause of most diseases. Hippocrates believed that an excess of black bile 
was responsible for the formation of cancer. His approach towards cancer treatment was to surgically 
remove superficial tumours, but to avoid any interference with internal tumours as he believed these 
surgeries were perilous endeavours. The Hippocratic Corpus (the collected writings of Hippocrates, 
Figure 1:5) introduced the terms, karkinos and karkinoma, referring to malignant tumours and ulcer 
forming malignant tumours. These Greek terms refer to a crab, as Hippocrates thought tumours 
resemble the shape of this decapod species; and a subsequent translation to Latin led to the term - 
cancer.13,14  
 
Figure 1:5   The collected writings of Hippocrates.13  
The humoral theory remained unchallenged for over 1000 years, until René Descartes (1596-1650), 
a French philosopher and physician, proposed the lymph theory of cancer.14 
1.1.4.2. LYMPH THEORY 
The lymph theory stated that tumours originate in a localized area, after which lymph nodes are 
responsible for the development of secondary malignant tumours. A French Surgeon, Henry 
François le Dran (1685-1770) also supported the lymph theory and his treatment involved a complete 
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removal of the tumour, as well as the surrounding lymph nodes. During the lymph theory era, various 
scientists were interested in cancer epidemiology, and this led to some interesting discoveries linking 
cancer to specific lifestyle and occupational choices. For example, in 1713, Bernardino Ramazzini 
(1633-1714) revealed the link between the celibate lifestyle of nuns to the low number of cervical 
cancer cases among them.15 Subsequently, the first reported example of occupational cancer was 
described by Percival Pott (1714-1788) in 1775, when he exposed the link between chimney 
sweeping and scrotal cancer.14,16 These discoveries provided essential information for the control 
and possible prevention of cancer; and has a major influence on modern occupational safety 
regulations. 
The next significant milestone in cancer history took place in 1838, when a German physiologist, 
Johannes Müller (1801-1858), gave rise to the cellular theory of cancer.16   
1.1.4.3. CELLULAR THEORY OF CANCER 
Müller initiated this theory by proving that cancerous tissue consists of cells, rather than black bile 
or lymph, by examining tumours under a light microscope. One of Müller’s students, Rudolf Virchow 
(1821-1902), took this theory a step further by stating that cancer cells are either generated by 
chronic cellular irritation or an inherited predisposition. The cellular theory soon gained the support 
of several other scientists, including Karl Thiersch (1822-1925). Thiersch reinforced this theory in 
1865, by proving that cancer spreads through malignant cells, and not through an unknown liquid 
substance. Karl von Rokitansky (1804-1878) also made a significant contribution to this theory by 
proving that tumours consist of two main components, namely, the framework and the cancer 
mass.14,16   
Modern understanding of the biology behind cancer is a combination of the revolutionary discoveries 
made by Müller, Virchow and Rokitansky. The insights obtained from these discoveries led to major 
advances in effective cancer treatments.  
1.1.5. CANCER TREATMENTS 
When considering current treatment options, there are three main modes of treatments at our 
disposal, namely surgery, radiation therapy and chemotherapy. A number of additional treatment 
options have become available in recent years, including hormonal-, immune- and antiangiogenesis 
therapy.17,18 For the purpose of this research, only the three main treatment options will be discussed 
in greater detail.  
Surgery was the first, and for many years, the only treatment option available in the fight against 
cancer.  
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1.1.5.1. SURGERY 
One of the first breakthroughs in the history of cancer surgery was reached in 1809, by an American 
surgeon, Ephraim McDowell. McDowell disproved the belief established by Hippocrates concerning 
the treatment of internal cancer masses, by successfully removing an ovarian tumour; leading to 
numerous advances in cancer surgery. In the last two centuries, with the discovery of anaesthetics 
in 1846 and the introduction of antiseptics in 1867, cancer surgery has evolved into a successful 
treatment for localized tumours.19 The surgery related mortality rates have also significantly 
decreased with the continuous improvements made in this field. Despite these great strides, cancer 
surgery is still inadequate when attempting to treat progressive tumours and this led to the hunt for 
a new tool to use in the fight against cancer.  
1.1.5.2. RADIATION THERAPY 
Radiation therapy was set in motion by Wilhelm C. Rӧntgen (1845-1923) in 1895 with the discovery 
of X-rays, and the subsequent realization that X-rays are capable of reducing tumour growth. The 
discovery of radium shortly after, in 1898 by Antoine H. Becquerel (1852-1908), Pierre Curie (1859-
1906) and Marie S. Curie (1867-1934), combined with Rӧntgen’s breakthrough, accelerated 
research in this field. Each of these remarkable discoveries received Nobel Prizes for their 
contribution to physics.20 Radiation therapy proved successful in the treatment of breast-, skin- and 
cervical cancer; and with the introduction of fractionated radiation, the treatment of head and neck 
cancers were also accomplished in 1928. In 1950, the discovery of cobalt therapy revolutionized this 
treatment option; and as a result, cobalt is still used in modern radiation therapy.19 
In recent years, there has been major advancements in cancer surgery as well as radiation therapy; 
and although these can be used in combination, several cancers are still incurable when only relying 
on these two treatment options.21 The next option that came to light, involved the incorporation of 
chemicals into the treatment of cancer.  
1.1.5.3. CHEMOTHERAPY 
Chemotherapy was initially defined as “the science dealing with the treatment of internal parasitic 
diseases by means of preparations synthesized with the object of combining the maximum power of 
efficiency in the destruction of the greatest variety of protozoa with the minimum poisonous action 
upon the patient's tissues”.22 A few years later, a modified definition was provided, describing 
chemotherapy as “the specific treatment of infections by artificial remedies”.23 The term 
‘chemotherapy’, originated with Paul Ehrlich (1854-1915) in 1897, when he started the search for 
suitable chemicals with potential activity against cancer cells.24 The majority of research done in the 
decades to follow was aimed at model development. Finally, in 1943, an alkylating agent with the 
ability to alter the DNA of abnormal cells, was discovered. This compound, called nitrogen mustard, 
showed promise in the treatment of non-Hodgkin’s lymphoma and was the first chemical used as an 
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anti-cancer agent. This initiated the search for more selective and reliable chemical drugs; slowly 
leading to the development of modern combination chemotherapy.24,25 Chemotherapy has 
developed into a very effective cancer treatment, which can either be used independently or in 
combination with the aforementioned options. It is known to increase the lifespan of patients; and in 
combination with radiation therapy, several cancers have been cured.24  Nevertheless, the 
effectiveness of these chemicals is often limited to a specific type of cancer; and the price associated 
with this treatment limits this option to a certain group of patients. Chemotherapy is also associated 
with several unpleasant side-effects, which can significantly reduce the patient’s quality of life.26 
In the search for cheaper, less toxic chemotherapeutic drugs with reduced side-effects; natural 
products, specifically medicinal plants, have become a promising source of inspiration. 
1.2. MEDICINAL PLANTS 
A medicinal plant can be defined as “any plant used in order to relieve, prevent or cure a disease or 
to alter a physiological and pathological process”; or alternatively as “any plant employed as a source 
of drugs or their precursors”.27 Natural products, including various plant species with interesting 
biological properties, have been used in traditional medicine for thousands of years. Several 
developing countries, including the majority of the African population, still rely on plant-based 
traditional medicine (phytomedicines) to treat various diseases.28,29  Although the focus of modern 
drug discovery has partially shifted towards synthetic organic techniques and molecular modelling, 
medicinal plants remain an important component due to their incomparable chemical diversity and 
bioactivity.30 It is now known that each medicinal plant contains a set of unique pharmacologically 
active compounds which give rise to the observed bioactivity of that specific plant. The isolation of 
these compounds has become a vital aspect in modern drug discovery. 
1.2.1. ISOLATION OF PHARMACOLOGICALLY ACTIVE COMPOUNDS FROM PLANT SPECIES 
The isolation of these active compounds started in the nineteenth century; when morphine became 
the first pure pharmacologically active compound to be isolated from a plant. Friedrich Sertürner 
isolated morphine from opium poppy (Papaver somniferum L., Figure 1:6 A) in 1805, but the 
elucidation of its chemical structure (Figure 1:6 B) was only achieved in 1923.28–30  
 
Figure 1:6   A: Opium poppy (Papaver somniferum L.);31  B: Structure of morphine.32  
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After the successful isolation of morphine, numerous plant active compounds have been isolated 
and successfully developed into a variety of therapeutic materials, including chemotherapeutic 
agents.33 The earliest pharmaceutical drugs from this category include cocaine (isolated from 
Erythroxylum coca), codeine (from Papaver somniferum L.), digitoxin (from Digitalis purpurea) and 
quinine (from Cinchona calisaya Wedd.).26 This approach, in which the active compounds are used 
directly in their natural form, does however come with certain drawbacks. The isolation process is 
highly time consuming, structure elucidation requires expertise, and only limited amounts of pure 
compound is obtained from each plant. In addition, the cultivation of medicinal plants in less 
developed countries are not well regulated, leading to a decline in biodiversity.34 These factors 
subsequently affect the sustainability of the plant population as well as the resulting pharmaceutical 
drugs. In order to overcome these restrictions, an alternative option came to light where the isolated 
active compounds can also be used as drug templates or precursors.27,29  
Thus far, great success has been achieved in this field and various plant derived drugs are currently 
being used for a number of different diseases.  
1.2.2. PLANT-DERIVED DRUGS 
Some well-known plant derived active compounds currently on the market are summarized in Table 
1:2. This table also provides the specific plant from which these compounds were isolated (or 
alternatively, the name of the isolated compound which acted as a template), as well as the disease 
for which each drug is used. 
Table 1:2   Examples of plant derived drugs. 
Name of active 
compound 
Source of inspiration/ 
Plant  
Medicinal use 
Arteether35  
Derivative of artemisinin, 
isolated from Artemisia annua 
Malaria 
Galantamine36  
Isolated from Galanthus 
nivalis and Galanthus 
woronowii 
Alzheimer’s disease 
Apomorphine hydrochloride37  
Derivative of morphine, 
isolated from Papaver 
somniferum L. 
Parkinson’s disease 
Tiotropium bromide38  
Derivative of atropine, 
isolated from Atropa 
belladonna 
COPD (chronic obstructive 
pulmonary disease)  
Nitisinone39   
Derivative of leptospermone 
isolated from Callistemon 
citrinus  
Tyrosinemia 
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Apart from the above-mentioned bioactive compounds, several plant-derived active compounds 
have shown promising anti-cancer activity and has been developed into successful cancer 
treatments. 
1.2.3. PLANT-DERIVED CHEMOTHERAPEUTIC DRUGS  
This trend was initiated with the isolation of two vinca alkaloids from Catharanthus roseus G. Don., 
namely vincristine and vinblastine (Figure 1:7).12,40 These alkaloids showed promising anti-cancer 
activity and were subsequently developed into novel anticancer drugs. Vincristine is used in the 
treatment of leukaemia, while vinblastine is used for breast-, lung- and testicular cancer.12 The 
efficiency shown by these alkaloids prompted a wider investigation, and this led to the development 
of novel analogues, namely vindesine and vinorelbine, which is used in combination with other 
chemotherapeutic agents.40  
 
Figure 1:7   Structure of the vinca alkaloids; Vincristine (R = CHO) and Vinblastine (R = CH3).40  
The success achieved with the vinca alkaloids, instigated the search for more efficient plant derived 
chemotherapeutic agents. Relevant compounds already developed into successful anti-cancer 
treatments, include teniposide and etoposide (derivatives of podophyllotoxin, isolated from P. 
peltatum Linnaeus, and P. emodii Wallich), as well as Topotecan (derivative of camptothecin, 
isolated from Camptotheca acuminata Decne). The structures of the above-mentioned compounds 
are illustrated in Figure 1:8.40,41   
A B C 
Figure 1:8   Structure of A: Teniopside; B: Etoposide; C: Topotecan.40 
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The medicinal potential concealed in Mother Nature can clearly be seen when considering the 
chemotherapeutic drugs approved in the last 70 years as more than half were derived from natural 
products.26,28 One of the most renowned plant derived compounds approved as an anticancer drug, 
is known as paclitaxel (Taxol®,  
Figure 1:9 A). This taxane diterpene was initially isolated by Wani and co-workers from Taxus brevifolia Nutt. ( 
Figure 1:9 B) in 1967 (published in 1971)42 and was subsequently approved as an ovarian cancer 
treatment in 1992.43 Despite the drug resistance associated with this compound, paclitaxel is now 
obtained through a semi-synthetic procedure and is currently used in the treatment of various 
cancers (including ovarian-, breast- and non-small-cell lung cancer).12,26,28 A potent semi-synthetic 
analogue of paclitaxel, namely docetaxel (Figure 1:9 C), has also been developed and is primarily 
used in the treatment of breast cancer.12  
 
 
Figure 1:9   A: Structure of paclitaxel (Taxol®);43 B: Bark of Taxus brevifolia Nutt; C: Structure of docetaxel.44  
The success achieved thus far, clearly illustrates the potential of medicinal plants in the development 
of novel chemotherapeutic agents.  
The medicinal plant of interest in this research project is one of the most controversial bioactive 
plants yet to be discovered, namely Cannabis (C. sativa). 
1.3. THE CANNABIS PLANT 
“It is a plant - this thing that we are about to discuss: a green plant, a very abundant and ubiquitous 
plant, an unusually valuable economic plant, possibly a dangerous plant, certainly in many ways a 
mysterious plant.”45 
1.3.1. TAXONOMY AND BOTANY OF CANNABIS  
The Cannabis genus (a member of the Cannabaceae family46 was originally divided into three 
distinct species, namely Cannabis sativa L., Cannabis indica Lam. and Cannabis ruderalis Janisch.47 
Nowadays, Cannabis is often treated as a monotypic species, namely Cannabis sativa (C. sativa) 
with various subspecies and varieties, for example, C. sativa subsp. sativa or C. sativa subsp. indica 
var. kafiristanica.46,48,49 Even with the publication of several articles on the classification of Cannabis, 
including a recent comprehensive review,50 more research needs to be conducted to determine the 
C A B 
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exact taxonomy of the Cannabis plant.51 For the purpose of this research, the latter taxonomy will be 
used, in which the term “C. sativa” refers to the monotypic species with various subspecies and 
varieties. In addition, the less scientific term, “marijuana”, refers to the plant when used as a 
recreational drug.  
C. sativa is predominantly classified as a dioecious plant, meaning an individual plant is either 
classified as male (staminate) or female (pistillate); however, monoecious plants are occasionally 
encountered where an individual plant bears both male and female flowers.45,46 Although the entire 
plant (excluding the seeds) contains pharmacologically active compounds, the dried resin extracted 
from the glands of the female flowers contains the highest concentration of these compounds (Figure 
1:10).46  
 
Figure 1:10   Example of a female plant of C. sativa with visible clusters of individual flowers.46  
1.3.2. HISTORY OF CANNABIS  
This is but a brief summary of the history of C. sativa, for a more in-depth account, please consult 
the review article published by Russo in 2007.52  
Through archaeological findings and scientific writings, it has been determined that C. sativa found 
its origin in Central Asia, more particularly in China. For more than 10 millennia, the Chinese 
population have realized the tremendous potential of this triple-purpose economic plant.53 Initially, 
only the C. sativa stem was used to produce strong fibers (for ropes, cloths and paper); but shortly 
after, the value of the C. sativa seeds as edible oils was also recognized. Later on, it was discovered 
that the resin from its flowers (as well as other parts of the plant) could be used for medicinal 
purposes.45  As a result, the cultivation of this useful plant started in China more than 6000 years 
ago; and some of the earliest medicinal texts mentioning C. sativa, were found in approximately 
2000-year-old Chinese literature.53,54  
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The medicinal use of C. sativa started circulating through Asia, and finally in the 19th century, an Irish 
physician, William B. O’Shaughnessy, observed the therapeutic properties of C. sativa while working 
in India. O’Shaughnessy then conducted animal and human trials with C. sativa extracts and found 
that these extracts contains a wide variety of medicinal properties. After the publication of these 
results in Europe in 1842, the medicinal use of C. sativa experienced a dramatic increase.55 The 
United States of America (USA) officially authorized the medicinal use of C. sativa in 1851, and by 
mid-20th century, more than twenty-five C. sativa-based medications could be easily obtained for a 
number of different maladies.55,56 This new trend led to the search for more reliable and consistent 
C. sativa-based drugs which resulted in a number of patented preparations, indicated either as a 
sedative, an antispasmodic or an analgesic drug (some of which are illustrated in Figure 1:11).57  
 
Figure 1:11   Labels of two patented C. sativa-based drugs.57  
Several obstacles were however encountered with these drugs; and as a result, C. sativa research 
started to decline. One of these stumbling blocks was the method of administration as these C. sativa 
extracts proved to be non-water-soluble. These drugs were also often prescribed without 
standardized quality and dosage control, resulting in various unwanted side-effects. Above all these, 
the most significant obstacle was the social and political bias surrounding the use of C. sativa due 
to the psychotropic effects displayed by this plant.46 
1.3.3. LEGAL ASPECTS SURROUNDING CANNABIS  
In 1914, the first relative political intervention with the use of C. sativa took place in the USA, with 
the approval of the Harrison Narcotics Tax Act. Due to the fact that this act stipulated specific 
regulations for the distribution and production of narcotic drugs; society started viewing C. sativa as 
a dangerous drug, and the medicinal use systematically decreased.58  
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By 1937, the medicinal use of C. sativa was outlawed in the USA, under the Marijuana Tax Act; and 
similar legislations were approved throughout the Occident.55,59 After numerous invalidation 
attempts, the Marijuana Tax Act was ultimately overturned in 1969, more than 3 decades after its 
approval, due to a violation of the Fifth Amendment. However, the following year, the USA Controlled 
Substance Act was passed as part of the Comprehensive Drug Abuse Prevention and Control Act 
of 1970, labelling C. sativa (marijuana) as a “Schedule I” drug with no medicinal use (Table 1:3).58  
Table 1:3   USA Controlled Substance act criteria: “marijuana” classified as Schedule I. 
 
1.3.3.1. THE SOUTH AFRICAN PERSPECTIVE 
When briefly considering the political history of C. sativa, out of a South African perspective, it is 
interesting to note that the use of C. sativa was prohibited 9 years before the approval of the 
Marijuana Tax Act in the USA. In South Africa, the use of C. sativa was outlawed in 1928, with the 
approval of the Medical, Dental and Pharmacy Act; which was subsequently modified in 1954, with 
increased consequences for transgression. In the decades to follow, two additional acts were 
approved, firstly the Abuse of Dependence-producing Substances and Rehabilitation Centres Act 
(in 1971), followed by the Drugs and Drug Trafficking Act (in 1992). Both of these provided hefty 
prison sentences for possession and dealing of C. sativa preparations.60,61   
1.3.3.2. DECRIMINALIZATION OF CANNABIS  
Despite these political restrictions, research on the plant and its constituents have continued across 
the globe, providing ample evidence for the undisputed medicinal value of C. sativa. These new 
scientific insights are slowly shifting the social and legal perspectives, leading to a movement known 
as the “decriminalization of Cannabis”, in an effort to change the legal status of C. sativa. The 
medicinal use of C. sativa, under medical prescription, has already been legalized in several 
Schedule VClassification Schedule I Schedule II Schedule III Schedule IV
Uses
Abuse Potential
Psychological 
or 
Physiological 
Dependence
No Medical Use
Very High
Severe 
Psychological or 
Physiological 
Low 
Psychological or 
Physiological 
Gradual 
Decrease
Medical Use
Gradual 
Decrease
Very Low
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countries (including Switzerland, India, Uruguay, Spain, Canada, Australia, and over 20 states in the 
USA).62,63   
South Africa joined this movement in February 2014, with the introduction of the Medical Innovation 
Bill.64 In March 2017, inconsistencies were found between the Drugs and Drug Trafficking Act and 
the Medicine and Related Substances Act, declaring certain sections invalid, thus ruling in favour of 
the private use of C. sativa by adults.65 Even though these political restrictions have long delayed 
the study of C. sativa in South Africa; this research will certainly start gaining more support, following 
this landmark judgement. With well-constructed scientific research, it is certainly possible to 
distinguish between the medicinal and narcotic use, as shown with the opiates isolated from Papaver 
somniferum L., as mentioned earlier.  
Although many aspects of the chemistry of C. sativa is already known, novel research is essential 
for the development of successful C. sativa-based or C. sativa-derived medical treatments. The wide 
variety of medicinal properties hidden within this plant, the exact mechanism of action, as well as the 
constituents responsible for these properties is still under investigation. 
1.4. CHEMISTRY OF CANNABIS  
1.4.1. CANNABIS CONSTITUENTS 
The dried resin from the female flower, the most abundant source of pharmacologically active 
compounds found within the cannabis plant, contains a variety of constituents including flavonoids, 
terpenes, and cannabinoids.66 The bio-activity of C. sativa has thus far mainly been assigned to the 
cannabinoid constituents; and therefore, for the purpose of this research, only the cannabinoids will 
be discussed in more detail.   
C. sativa was the first plant from which cannabinoids were successfully isolated. Assuming other 
members of the Cannabaceae family could also contain cannabinoids would be a reasonable 
deduction; however, this is not the case. The Humulus genus, a member of the Cannabaceae family, 
acts as a good example. Despite various similarities between these two genera, no cannabinoids 
have thus far been found within the Humulus plant.67,68 It is therefore commonly thought that 
cannabinoids are exclusively found within the C. sativa plant; but some exceptions have been 
reported. The presence of a few cannabinoid constituents has not only been confirmed in other plant 
species (including Helichrysum umbraculigerum Less.), but also in a few fungal and liverwort 
species.69,70 Nevertheless, the C. sativa plant produces the greatest quantity and diversity of 
cannabinoids compared to any other source found in nature. The C. sativa plant is therefore a vital 
tool when investigating this diverse group of chemical compounds.  
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1.4.2. DEFINING THE TERM “CANNABINOID” 
“Cannabinoid” does not only refer to the naturally occurring constituents (phytocannabinoids) 
isolated from the plant, but also to manufactured analogues (synthetic cannabinoids), as well as 
endogenous analogues produced within the animal and human body (endocannabinoids).71 The 
majority of these chemical compounds are either part of, or are able to interact with a unique 
pleiotropic signaling system, known as the endocannabinoid system.  
1.4.3. THE ENDOCANNABINOID SYSTEM 
The endocannabinoid system (ECS) is a neuromodulatory system found within most mammalian 
species, known to be involved in several aspects of basic physiology and pathology. The ECS 
comprises of endocannabinoid ligands (along with the enzymes responsible for its biosynthesis, 
transport and degradation), as well as their specific binding sites known as the cannabinoid 
receptors.72  
1.4.3.1. THE CANNABINOID RECEPTORS 
The discovery of the ECS was initiated in 1988 with the identification of the first cannabinoid receptor, 
‘cannabinoid-binding receptor type 1’ (CB1), by Howlett and co-workers.73 This breakthrough 
expedited research in this field; and only a few years later, Munro and co-workers discovered a 
second cannabinoid receptor, ‘cannabinoid-binding receptor type 2’ (CB2).74  
The cannabinoid receptors, CB1 and CB2, are both members of the G-protein-coupled receptor 
family.75 The CB1 receptor is predominantly located in the central nervous system, with the highest 
concentrations found in the hippocampus and cerebellum. As a result, the CB1 receptor plays a role 
in regulating pain and the release of various neurotransmitters, among other important functions.76 
On the other hand, the CB2 receptor is mainly found in the immune system; especially in the tonsils 
and spleen, with a variety of functions including inflammation regulation.59  
After the discovery of CB1 and CB2, scientists started searching for endogenous ligands responsible 
for the activation of these receptors; thereby producing specific biological responses.  
1.4.3.2. ENDOCANNABINOIDS 
In contrast to other neurotransmitters which are produced in advance, and stored until needed; 
endocannabinoids are produced on demand, causing immediate changes in intercellular signaling 
upon receptor binding.72   
The first endogenous ligand successfully isolated, is known as N-arachidonoyl-ethanolamine (AEA, 
Figure 1:12 A), and shows high affinity for the CB1 receptor.77  Another important endocannabinoid, 
with a high affinity for both the CB1 and CB2 receptors, was subsequently isolated and identified as 
2-arachidonoyl-glycerol (2-AG, Figure 1:12 B).78,79 When considering the structural similarities 
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between AEA and 2-AG, it is interesting to note that these bioactive lipids have distinctly different 
enzymatic routes.72 
A number of additional endocannabinoids, including O-arachidonoylethanolamine and N-
arachidonoyldopamine has been identified, but AEA and 2-AG are regarded as the ‘major 
endocannabinoids’.80 It is now known that endocannabinoids are non-psychoactive compounds 
involved in a number of important functions within the human body. These ligands, along with the 
cannabinoid receptors, could therefore be a potentially interesting therapeutic target; however, their 
short half-life and lipophilic nature is problematic for the development of endocannabinoid-based 
therapies.81  
When considering the presence of these cannabinoid-like structures within the human body, their 
affinity towards the cannabinoid receptors, and their role in the regulation of several bodily functions, 
the bioactivity of phytocannabinoids and their possible interaction with the endocannaboinoid system 
also comes to mind. The focus of the current research project is specifically directed towards the 
medicinal potential, particularly the anti-cancer activity of phytocannabinoids, in order to use the 
chosen phytocannabinoid as a template in the design of synthetic cannabinoids with potential anti-
cancer activity. This focus will be discussed in more detail in the following section.  
1.4.4. PHYTOCANNABINOIDS 
A wide variety of these naturally occurring cannabinoids have been found within the C. sativa plant. 
When considering the isolated cannabinoids in their original form, as well as the additional 
cannabinoids formed under degradation, more than 90 phytocannabinoids have been identified.66  
Each compound in this diverse group has a different chemical structure, which determines the 
specific mechanism of action and pharmacological profile of said cannabinoid.80   
The first report on the anticancer-activity of phytocannabinoids surfaced in 1975, when Muton et al. 
discovered that phytocannabinoid administration inhibited the growth of Lewis lung 
adenocarcinomas in animal models.82 In the last few decades, it has been shown that certain 
phytocannabinoids, as well as a number of synthetic cannabinoids possess proapoptotic, anti-
proliferative and anti-angiogenic effects.83  
  
A B 
Figure 1:12   A: Structure of AEA; B: Structure of 2-AG.79 
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One of the cannabis constituents that showed promising antineoplastic activity is the notorious 
phytocannabinoid, known as (−)-trans-Δ9-tetrahydrocannabinol (THC, Figure 1:13), which is also the 
main psychoactive constituent found in the cannabis plant. Raphael Mechoulam, known as the 
‘father of cannabis research’ was the first to successfully isolate,84 determine the structure,84 and 
successfully complete the total synthesis of THC.85 THC has shown high affinity for both the CB1 and 
CB2 receptor, and the observed psycho-active effects is believed to be caused through the activation 
of the  CB1 receptor.46  
Figure 1:13   Structure of THC.84 
These unwanted psycho-active side-effects limits the clinical use of THC-based treatments. For this 
reason, interest in non-psychoactive phytocannabinoids such as cannabidiol (CBD) has significantly 
increased in recent years. This interest will be further explored in the section to follow. 
1.5. CANNABIDIOL 
Although CBD was already isolated from the cannabis plant in 1940 by Adams et al.,86 the intensive 
study of this phytocannabinoid staggered for many years. This can clearly be seen by the fact that 
the structure of CBD (Figure 1:14) was only elucidated 23 years after its initial isolation.87 The 
cannabis pioneer, R. Mechoulam, was once again at the forefront of this structure elucidation.   
Figure 1:14   Structure of CBD.87 
CBD and THC have similar structural characteristics and share several therapeutic properties. 
Nevertheless, one major difference between these two phytocannabinoids, is the minimal energy 
conformation adopted by these compounds. CBD adopts a conformation in which the two rings are 
perpendicular to each other (Figure 1:15 A), while THC adopts a rigid planar conformation (Figure 
1:15 B).88,89 It is believed that these conformational differences prohibit CBD from binding to, or 
activating the CB1 receptor, thereby accounting for the lack of psychotropic activity of this 
phytocannabinoid.89 
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The in vitro and in vivo anticancer activity of CBD has recently been demonstrated by showing that 
CBD is capable of selectively inhibiting the growth and migration of human gliomas and breast 
carcinomas, while having no effect on normal cell lines.90,91  
When considering these exciting reports on the anticancer activity of CBD, it is interesting to note 
that this phytocannabinoid has little to no direct affinity for either one of the cannabinoid receptors.92 
It has however been speculated that the anticancer effects of CBD could be due to indirect activation 
of the CB2 receptor, as well as the possible activation of the transient receptor potential vanilloid 
type-1 and type-2 (TRPV1 and TRPV2) channels.93,94 It is however important to note that the exact 
mechanism of action of phytocannabinoids, including CBD, is still under investigation. For a detailed 
review on the reported anticancer activity of CBD in several types of cancers and their possible mode 
of action in each of these cases, please refer to the review by Massi et al.95   
The promising activity displayed by CBD, encourages the development of CBD-based anticancer 
treatments as CBD provides access to new treatment options without the unpleasant side effects 
affiliated with conventional therapies. As already mentioned, a number of major disadvantages are 
associated with natural product-based treatments including the time-consuming and expensive 
isolation process and the unsustainability of this route.34 Taking this into consideration, we placed 
our interest in the design of synthetic CBD analogues in the hope that these synthetic cannabinoids 
show similar or even improved anticancer activity compared to CBD, while retaining the non-
psychotropic property of this phytocannabinoid.  
Often the design of synthetic drugs is based on the interaction of a ligand with a receptor known to 
control a specific function and the affinity of a ligand to the specific receptor is often calculated in 
advance through molecular modeling. However, with the uncertainty surrounding the mechanism of 
A B 
Figure 1:15   Minimal energy conformation of A: CBD; and B: THC.88 
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action of phytocannabinoids, current designs of synthetic cannabinoids are based on the structure, 
and pharmacophoric groups on the structure of the phytocannabinoid exhibiting promising activity.  
This research project is specifically directed towards the design and synthesis of CBD analogues, 
modified with a triazole moiety, as potential anticancer agents. The next section (Chapter 2) will 
therefore provide a brief introduction to click chemistry and discuss the rationale behind the design 
of the triazole CBD analogues of the study, followed by the aim and objectives set out for this project. 
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CLICK CHEMISTRY AND PROJECT AIM  
2.1. A BRIEF INTRODUCTION TO “CLICK CHEMISTRY” 
The term “click chemistry”, was defined by Sharpless and co-workers in 2001.96 According to this 
definition, “click chemistry” is a collection of selective and highly reliable reactions capable of rapidly 
combining small separate units to produce larger molecules through irreversible carbon-heteroatom 
bond formations. These researchers also provided a list of stringent criteria that must be adhered to 
in order for a reaction to be subsumed under the umbrella of “click chemistry”.96 These criteria specify 
that a “click chemistry” reaction must use readily available substrates and benign solvents to provide 
the desired product stereospecifically and in a high yield. In addition, the product purification must 
be effortless and these reactions must only produce harmless by-products.96 
A variety of well-known chemical transformations which adhere to these criteria have been identified. 
These include a number of oxidative addition reactions to carbon-carbon multiple bonds (for instance 
dihydroxylations, sulfenyl halide additions, aziridinations and epoxidations), as well as a number of 
nucleophilic ring-opening reactions of strained heterocycles (including aziridines and epoxides). 
Another important group of chemical transformations that meet these criteria are cycloaddition 
reactions of unsaturated species, including hetero-Diels-Alder reactions, as well as Huisgen dipolar 
cycloadditions.96,97  
Among the products obtained from these chemical transformations, the 1,2,3-triazole moiety is of 
most interest in this project. The Huisgen [3+2] 1,3-dipolar cycloaddition reaction is one method that 
can be used for the 1,2,3-triazole synthesis. This involves the concerted addition of organic azides 
with terminal alkynes at elevated temperatures. Although this was a remarkable transformation at 
the time of its discovery in 1893,98 this is a slow reaction and usually provides a mixture of the 1,4- 
and 1,5 regioisomers as depicted in Scheme 2:1.99  
 
Scheme 2:1   Schematic representation of the general Huisgen azide-alkyne cycloaddition at elevated 
temperatures.99 
This lack of regioselectivity was subsequently addressed by two separate research groups, namely 
Sharpless and co-workers, as well as Meldal and co-workers, who simultaneously published in 
2002.100,101 These researchers reported a copper(I)-mediated azide-alkyne cycloaddition reaction to 
obtain the 1,4-isomer regioselectively and in high yields. 
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 COPPER-CATALYZED AZIDE ALKYNE CYCLOADDITION (CUAAC)  
The CuAAC reaction is regarded as a prime example of “click chemistry” and is therefore frequently 
called the “click” reaction. This cycloaddition reaction has a broad scope and a remarkable tolerance 
for a variety of different solvents.100 Various copper catalysts can be used for the CuAAC reaction 
on the condition that a copper(I) [Cu(I)] species is formed before the addition of the two substrates. 
One option is using a Cu(I) catalyst directly, for example, copper(I) halides; however, these copper 
sources require the addition of a stabilizing ligand (often a basic compound) and the reaction is 
frequently conducted in the absence of light to counteract the instability of the Cu(I) species.102 The 
use of a Cu(II) pre-catalyst, for example, copper(II) sulphate pentahydrate, has also been reported.100 
The in situ generation of the Cu(I) species through the use of a pre-catalyst normally requires the 
addition of a mild reducing agent, but eliminates the need for a stabilizing ligand.77 In addition, the 
use of certain Cu(II) pre-catalysts, in particular, copper(II) acetate, in alcohol solvents, without the 
deliberate addition of a reducing agent, has also been reported.104,105 Brotherton et al. initially 
speculated that a catalytic amount of the Cu(I) species was generated via the reduction of the Cu(II) 
species through the oxidation of the alcohol solvent used (Scheme 2:2 A).104 However, after 
successful triazole formation was observed in an alcohol solvent not prone to oxidation, these 
researchers presented a second hypothesis for the formation of the Cu(I) species. This hypothesis 
stated that catalytic amounts of the Cu(I) species was generated through a Glaser coupling reaction, 
or more accurately in this case an Eglinton reaction, between the Cu(II) pre-catalyst and the terminal 
alkyne (Scheme 2:2 B).104  
Scheme 2:2   Reduction of the Cu(II) pre-catalyst (Cu(II)(OAc)2) to the Cu(I) species in alcohol solvents.104 
A possible mechanism for the CuAAC reaction was first reported by Sharpless and co-workers in 
the same paper in which they introduced the copper-mediated cycloaddition reaction.100 This was 
followed by a modified mechanism by Fokin and co-workers in 2005.106 This modified mechanism 
was widely accepted, until Fokin and co-workers reported a new mechanism in 2013, which included 
a dinuclear copper intermediate, not seen in the previous versions.107 This latest proposed 
mechanism for the CuAAC reaction is depicted in Scheme 2:3. This sequence begins with the 
coordination of the terminal alkyne to the Cu(I) species to form a π-complex. The active complex (a 
σ-bound dinuclear copper acetylide) is subsequently formed upon entry of a second Cu(I) species. 
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This is followed by the reversible coordination of the organic azide to the dinuclear copper acetylide. 
These researchers have proven that the direct cycloaddition does not take place, but that a step-
wise annulation event rather occurs during which the β-carbon of the acetylene takes part in a 
nucleophilic attack at the nitrogen distal to the azide substituent. This leads to the formation of the 
first carbon-nitrogen bond. A second carbon-nitrogen bond is subsequently formed between the α-
carbon of the acetylene and the nitrogen proximal to the azide substituent, resulting in a copper 
triazolide intermediate. Subsequent protonation provides the 1,4-disubstituted 1,2,3-triazole 
compound and regenerates the Cu(I) species.107 
Scheme 2:3   Most recent proposed mechanism reported for the CuAAC reaction.107 
After the successful implementation of the CuAAC reaction and the successes seen with this reaction 
in chemistry, biology and material science applications, selective access to the complementary 
isomer, the 1,5-disubstituted triazole, was investigated. Although a few procedures for the 
regioselective synthesis of the 1,5-isomer have previously been reported, including the reaction of 
bromomagnesium acetylides and organic azides,108 these methods lack the scope and convenience 
of the CuAAC process. Jia and co-workers subsequently started searching for a catalytic procedure 
for this conversion and were the first to report a ruthenium-mediated azide-alkyne cycloaddition 
(RuAAC) reaction, which provides the 1,5-isomer regioselectively.109  
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 RUTHENIUM-CATALYZED AZIDE ALKYNE CYCLOADDITION (RUAAC)  
Jia, Fokin, Sharpless and co-workers investigated a variety of ruthenium catalysts for the selective 
synthesis of 1,5-disubstituted 1,2,3-triazoles from organic azides and terminal alkynes. Initially these 
researches discovered a cyclopentadienyl ruthenium complex, CpRuCl(PPh3)2, that could be used 
as a catalyst to provide the desired product. Even though this catalyst provided mainly the 1,5-
isomer, the formation of the complimentary 1,4-isomer was also observed as minor product. In the 
search for a more selective catalyst, this complex was subsequently modified by exchanging the 
cyclopentadiene (Cp) group with the pentamethylcyclopentadiene derivative (Cp*). By using this 
modified catalyst, Cp*RuCl(PPh3)2, a higher conversion of the starting materials was observed and 
the desired 1,5-regioisomer was obtained exclusively.109  
It has been speculated that the electronic and steric properties of the Cp* group contributes to the 
stabilization of the higher formal oxidation states of the ruthenium atom, causing the bystander 
ligands to be more labile, thereby facilitating the formation of the active azide-[Cp*RuCl]-alkyne 
complex (see mechanism in Scheme 2:4 below).110 A further investigation on different 
pentamethylcyclopentadienyl ruthenium chloride [Cp*RuCl] complexes revealed that (Cp*RuCl2)2, 
Cp*RuCl(NBD), Cp*RuCl(PPh3)2 and Cp*RuCl(COD) are the most efficient catalysts for the selective 
formation of 1,5-disubstituted 1,2,3-triazoles from primary azides and terminal alkynes. Two of these 
[Cp*RuCl]-based catalysts, namely Cp*RuCl(PPh3)2 and Cp*RuCl(COD), proved to be superior as 
these also showed successful coupling with secondary azides. Unfortunately, the reaction rates and 
the product yields were much lower when compared to primary azides. This cycloaddition was also 
attempted with tertiary azides, but these proved to be much less reactive and most of the attempted 
tertiary azides did not participate in the coupling reaction.110  
These researchers (Jia, Fokin, Sharpless and co-workers) also studied the solvent effect and found 
toluene, THF, benzene, 1,2-dichloroethane and dioxane to be compatible, but discovered that protic 
solvents negatively affect the yield and selectivity of this reaction.109 From these results it is clear 
that the RuAAc reaction is more sensitive to solvents and the steric effects of the participating azide 
substituents when compared to the CuAAC reaction. After successfully establishing the suitable 
catalysts and solvents for this conversion, Jia, Fokin, Sharpless and co-workers explored the use of 
internal alkynes in this cycloaddition reaction. Due to the presence of copper(I) acetylide intermediate 
in the CuAAC reaction (Scheme 2:3), this transformation is limited to the use of terminal alkynes as 
already mentioned. The [Cp*RuCl] catalysts, or the two superior catalysts in particular, 
(Cp*RuCl(PPh3)2 and Cp*RuCl(COD)) have the remarkable ability of engaging internal alkynes in 
catalysis, thereby providing access to 1,4,5-trisubstituted 1,2,3-triazoles.109–111  
A possible mechanism for the RuAAC reaction was proposed in 2008 by Fokin and co-workers 
(Scheme 2:4, illustrated with a terminal alkyne for simplicity).110 The ability to use internal alkynes 
ruled out the involvement of a ruthenium acetylide intermediate as seen in the CuAAC reaction.109 
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These researchers proposed that the two bystander ligands of the ruthenium catalyst are displaced 
upon addition of the alkyne and azide reagents, resulting in the activated azide-[Cp*RuCl]-alkyne 
complex. Azides prone to decomposition can react with the ruthenium catalyst to form a [Cp*RuCl]-
tetrazenide complex which has no catalytic activity. To prevent the formation of this complex, the 
alkyne must be introduced before the azide. The azide and alkyne in this complex subsequently 
undergo oxidative coupling forming the metallacycle, or in this case a ruthenacycle intermediate. 
The new carbon-nitrogen bond is formed between the nitrogen distal to the azide substituent and 
the less sterically hindered carbon of the alkyne. When working with internal alkynes, the 
electronegativity of the substituents also plays a role in this bond-forming step. In addition, it has 
been speculated that internal alkynes containing a hydrogen bond donor group forms additional 
hydrogen bonds with the chloride atom on the ruthenium centre.111 All these factors can influence 
the outcome of the cycloaddition reaction which is why the oxidative coupling step is thought to 
govern the regioselectivity of this cycloaddition reaction. The regioselectivity of internal alkynes will 
be discussed in more detail in Section 3.1.6. The resulting metallacycle intermediate then undergoes 
reductive elimination to provide the 1,5-disubstituted 1,2,3-triazole compound (in the case of terminal 
alkynes) and regenerates the ruthenium catalyst.110  
 
Scheme 2:4   Possible mechanism for the RuAAc reaction.110    
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Note that this mechanism is valid for all the ruthenium catalysts mentioned above (which are all 18-
electon ruthenium complexes). Nolen and co-workers reported a set of coordinatively unsaturated 
16-electron ruthenium complexes, which could also be used for the RuAAC reaction and proposed 
a slightly different mechanism for these complexes.112 However, only the 18-electon ruthenium 
complexes and the mechanism shown in Scheme 2:4 is of importance in this project.  
These two regioselective “click” reactions have recently been shown to be valuable tools in various 
different disciplines, as they have found applications in dendrimer synthesis,113 activity-based protein 
profiling,114 and cell surface engineering.115 The triazole functional group generated through these 
“click” reactions have also demonstrated diverse biological functions, and is an increasingly common 
structural unit in various bioactive molecules, including anticancer agents.116,117  
Our interest in cannabinoids (as discussed in Chapter 1), combined with our interest in the triazole 
moiety, led us to investigate previously designed triazole cannabinoid analogues and the 
applications for which they were designed.  
2.2. PROPOSED TRIAZOLE CANNABINOID ANALOGUES 
To our knowledge, the first report discussing the synthesis of potential triazole cannabinoid 
analogues, was published in 2007 by Di Marzo and co-workers.118 Examples of the analogues 
designed in this study can be seen in Figure 2:1.  
 
Figure 2:1   First reported of potential triazole cannabinoid analogues.118    
Two years later, Hung and co-workers presented a fully substituted symmetrical triazole cannabinoid 
analogue (Figure 2:2) which showed high levels of in vitro activity for the CB1 receptor. This 
compound was designed as a novel anti-obesity drug.119 
 
Figure 2:2   Potential triazole cannabinoid analogue designed as an anti-obesity drug.119 
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Around the same time, Trudell and co-workers reported the synthesis of a possibly triazole 
cannabinoid analogue containing an ester functionality, as can be seen in Figure 2:3.120 This 
analogue was designed as a potential treatment against drug abuse.  
Figure 2:3   Potential triazole cannabinoid analogue targeting drug-abuse.120 
None of the abovementioned proposed cannabinoid analogues were specifically designed as an 
anti-cancer treatment, and the structure of these compounds have more aromatic character than 
that of the traditional phytocannabinoids (THC and CBD) known to have anti-proliferative and pro-
apoptotic effects. By combing the literature for previously synthesized cannabinoid analogues with 
potential anti-cancer activity, we came across a paper published in 2013, in which Szafrański et al. 
synthesized a set of novel 1,4-disubstituted triazole cannabinoid ligands with varying lengths of 
lipophilic side chains (Figure 2:4).121 The strategy involved a CuAAC reaction between a previously 
synthesized 1,2-azido alcohol and different terminal aliphatic alkynes to obtain the hexyl, heptyl, 
octyl, decyl and dodecyl side chain triazole cannabinoid analogues.  
Figure 2:4   Approach used by Szafrański et al.121 
In this paper, the cannabinoid on which they based their scaffold, was a synthetic cannabinoid 
(known as CP55940) with similar pharmacophoric groups as that of the cannabinoid of interest in 
this project, CBD. One of the main differences between these structures, is the length of the lipophilic 
side chain, as the synthetic cannabinoid has a longer side chain compared to CBD. The main change 
the researchers made to the structure was to replace the benzene ring present at the centre of most 
cannabinoids, including CP55940, THC and CBD, with a triazole ring.121  
Unfortunately, relatively low affinities towards the CB1 and CB2 receptor was reported for these 
analogues synthesized by Szafrański et al. This might be a result of the longer side chain than that 
found in the phytocannabinoids like CBD, as well as the lack of other important pharmacophoric 
groups found in the structure of CBD.  
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2.3. AIM AND OBJECTIVES  
In this research project, the issue of low potency shown by Szafrański et al.’s compounds will be 
addressed by considering all functional groups on the structure of CBD and designing novel triazole 
CBD analogues with the same side chain length as found on the structure of CBD. Although we 
initially considered molecular modelling in our quest to design new CBD analogues, only the crystal 
structure of CB1 (PDB: 5TGZ) was solved at the time of this research.122 However, as already 
mentioned, activation of the CB1 receptor causes the unwanted psycho-active effects.46 As luck 
would have it, the crystal structure of CB2 (PDB: 5TGZ) only became available in 2019,123 just before 
submission of this dissertation. Future work might therefore include molecular modelling to design 
novel CBD analogues selective for the CB2 receptor.  
When we considered pharmacophoric groups of interest on the structure of CBD, six main groups 
could be identified; the lipophilic tail (pentyl side chain), a benzene ring, the phenolic hydroxyl group, 
the cyclohexyl ring, the methyl group attached at the top of the cyclohexyl ring and the isopropenyl 
group attached to the bottom of the cyclohexyl ring (Figure 2:5).  
When designing the CBD analogues for this study, two significant changes to these main 
pharmacophoric groups will be considered. The first and most important change will be to incorporate 
a triazole ring at the core, instead of the benzene ring. This change is possible as a similar spatial 
distribution can be achieved when incorporating a triazole ring.121 Several natural products and 
pharmaceutical drugs have been modified with a triazole moiety to diversify the drug structure and 
exploit the chemical space around the compound.124 This modification has also shown to provide 
improved solubility and bioavailability, and offer the additional option of attaching a biotin label or a 
fluorophore to the structure at a later stage in the synthesis.124 The second modification will be to 
investigate the presence of an additional hydroxyl group at the top of the cyclohexyl ring, instead of 
the methyl group found in CBD. It has been shown that this alteration resulted in increased activity 
and selectivity of certain phytocannabinoids including THC and CBD.46 The general structure of the 
triazole CBD analogues that will be investigated is depicted in Figure 2:5 B. This figure also shows 
a comparison between the analogues designed in this study and the structure of CBD (Figure 2:5 
A), while emphasizing the two main changes that will be considered. 
 
Figure 2:5   A: CBD with relative functional groups; B: General structure of triazole CBD analogues in this study.  
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To this end, three different systems (Scaffold A, B and C) will be investigated during this project, 
each with a unique structure and purpose. The design of each of these systems will be discussed 
below in sections 2.4.1, 2.4.2 and 2.4.3, and the syntheses of these three systems will be discussed 
in sections 3.1, 3.2 and 3.3. 
2.4. RATIONALE BEHIND DESIGN OF TRIAZOLE CBD ANALOGUES  
In this project, we will initially investigate a model system (Scaffold A) containing a set of triazole 
CBD analogues based on the scaffold designed by Szafrański et al.121  
 SCAFFOLD A 
The lipophilic tail and the cyclohexyl ring are considered the two most important groups for the 
synthesis of Scaffold A. The pentyl side chain, which Szafrański et al. did not investigate, will be 
used as the standard length throughout this project, because this is the same side chain length found 
in the structure of CBD. An additional aspect that will be considered in the synthesis of Scaffold A, 
is to include the cyclohexanol group, similar to the scaffold reported by Szafrański et al.121  
The 1,4- and 1,5-, as well as the 1,4,5-polysubstituted 1,2,3-triazoles, will be investigated by making 
use of both CuAAC and RuAAC methods. In the 1,5-disubstituted triazole, the pentyl side chain will 
adopt a different orientation to where we would normally expect it to be. The primary reason for 
investigating the 1,5-disubstituted triazole is to test the RuAAC reaction and find the optimum 
reaction conditions for the RuAAC reaction for this system. With optimized RuAAC conditions in 
hand, we hope to synthesize the 1,4,5-trisubstituted triazole analogue which will introduce an 
additional hydroxyl group at the center of the structure to mimic the phenol hydroxyl group found in 
the CBD structure. The general approach that will be followed to synthesize Scaffold A is illustrated 
in Scheme 2:5. 
 
Scheme 2:5   General approach for the synthesis of Scaffold A. 
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 SCAFFOLD B 
In the next section, we will explore novel CBD triazole analogues, while still focussing on the three 
main functionalities as in Scaffold A (the lipophilic tail, the cyclohexyl ring as well as the cyclohexanol 
group). The main difference between the analogues of Scaffold A and Scaffold B, will be the position 
of the cyclohexanol group. In Scaffold B, the cyclohexanol group will be one carbon atom further 
away from the triazole functionality than in Scaffold A (where the cyclohexanol group is attached to 
the carbon adjacent to the triazole ring). This was done in order to have the hydroxyl group in the 
same position as the methyl group on the cyclohexane ring in the structure of CBD. For this scaffold, 
only the 1,4- and 1,5-disubstituted triazoles will be explored, as the main aim of this section is to 
compare the difference in activity with this hydroxyl shift. Once activity results of Scaffold A can be 
obtained, we can determine whether the 1,4,5-trisubstituted 1,2,3-triazole analogues (with the 
additional hydroxyl group at the center of the structure) would be a viable option to explore in Scaffold 
B. The general approach for the synthesis of Scaffold B is shown in Scheme 2:6. 
 
Scheme 2:6   The general approach for the synthesis of Scaffold B. 
 SCAFFOLD C 
In the last section, the three main functionalities focused upon in Scaffold A and B (the lipophilic tail, 
the cyclohexyl ring as well as the cyclohexanol group) will still be taken into consideration, along with 
an additional group found on the structure of CBD. There are three main differences between the 
general structure of Scaffold C and the general structures of the previous two scaffolds. The first is 
the methyl group present at the top of the cyclohexane ring instead of the cyclohexanol group, and 
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the second is the introduction of an isopropyl group at the bottom of the cyclohexyl ring. The isopropyl 
group will be introduced to mimic the isopropenyl group at the same position on the structure of CBD. 
Since many groups in the general structure of these analogues have been altered during the design 
of Scaffold C, compared to the structure of CBD, it was decided to rather incorporate the methyl 
group at the top section of the cyclohexyl ring, as this is the exact group found in the structure of 
CBD. In doing so, the Scaffold C analogues can be directly compared to CBD. This will enable us to 
determine the influence of the changes we set out to make (the triazole ring and the isopropyl group) 
on the activity of these compounds. The third difference between the general structure of Scaffold C 
compared to the previous two systems, is the introduction of stereochemistry on substituents found 
on the cyclohexyl ring, similar to that of CBD. For this scaffold, only the 1,4-disubstituted triazoles 
will be explored, as the main aim of the synthesis of this scaffold is to compare the activity difference 
between these chiral triazole compounds and the previous two scaffolds (A and B). This will provide 
information on whether the isopropyl group at the bottom of the cyclohexyl ring is an important 
functional group to consider when designing CBD analogues in the future. The general approach for 
the synthesis of Scaffold C is illustrated in Scheme 2:7. 
 
Scheme 2:7   The general approach for the synthesis of Scaffold C. 
Upon successful synthesis of the proposed analogues, biological tests will be conducted by our 
collaborators to determine the activity of these compounds on cancer cell lines. These results should 
potentially give a good indication on which functional groups play the most important role and will 
provide valuable insight into future design of CBD analogues by this click approach. 
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RESULTS AND DISCUSSION 
3.1. SYNTHESIS OF SCAFFOLD A 
 SYNTHESIS OF (±)-TRANS-2-AZIDOCYCLOHEXAN-1-OL 1 
The synthesis of Scaffold A started with the transformation of cyclohexene oxide into the trans 1,2-
azido alcohol (±)-1 (Scheme 3:1) based on the procedure published by Krasnova and Yudin.125,126 
An epoxide functionality is more electrophilic than linear ethers due to the added ring strain. The 
nucleophilic attack causes the carbon-oxygen bond to break, resulting in a ring opening and thereby 
relieving the ring strain. Since the azide anion is a strong nucleophile, no acid catalyst was needed 
to activate the epoxide as would be required when working with weaker nucleophiles. After work-up 
and purification by column chromatography, the pure 1,2-azido alcohol (±)-1 was obtained in a high 
yield of 95%.  
Scheme 3:1   Synthesis of 1,2-azido alcohol (±)-1 for Scaffold A. 
NMR spectra 1 and 2, located in Appendix 1, were used to characterize product (±)-1. In the 1H 
spectrum, a multiplet was observed at 3.36 – 3.30 ppm which represented the proton of the carbon 
attached to the hydroxyl group. The multiplet seen at 3.15 – 3.09 ppm corresponded to the proton of 
the carbon atom next to the nitrogen atom (of the azide functionality) and the broad singlet at 2.48 
ppm could be assigned to the proton of the hydroxyl group. These two peaks appeared at a slightly 
higher chemical shift value due to the electronegativity of the oxygen and nitrogen atoms to which 
they were connected.127 The 13C spectrum also contained two deshielded peaks at 73.46 ppm and 
66.98 ppm which represented the carbon attached to the hydroxyl group and the carbon attached to 
the nitrogen atom (of the azide moiety), respectively.127 If this conversion was unsuccessful, these 
two carbon atoms would have been in the same chemical environment and only one peak would 
have been observed. All other proton and carbon atoms were accounted for, and were in accordance 
with previously reported spectral data.125 
The 1,2-azido alcohol (±)-1 was subsequently subjected to an initial CuAAC reaction to test the 
triazole formation. The general structure aimed for throughout this project contained an aliphatic 
pentyl side chain as previously mentioned; however, all of these desired structures were not UV 
active, making the tracking of reactions by TLC very difficult. For this reason, an alkyne derivative 
containing a UV active group (phenylacetylene) was specifically chosen for this test reaction.  
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 SYNTHESIS OF (±)-TRANS-2-(4-PHENYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-OL 
2  
The pure 1,2-azido alcohol (±)-1 was subsequently subjected to a standard CuAAC reaction with 
phenylacetylene as the chosen UV active alkyne (Scheme 3:2). Copper(II) sulphate pentahydrate 
was used as a copper source along with sodium ascorbate as a reducing agent (see Chapter 2 – 
Click Chemistry Introduction). This specific copper source was chosen for this test reaction because 
it was the same copper source used by Szafrański et al. with this specific azide.121 In literature, a 
solvent mixture of dimethyl sulfoxide and water was used for this reaction; however, it was decided 
to alter the solvent system to a mixture of methanol and water. This copper source has been shown 
to be compatible with a mixture of water and other polar solvents (including methanol or butanol), 
which indicated this to be an appropriate alteration.97 By using methanol instead of dimethyl 
sulfoxide, the work-up and purification procedure of this novel triazole compound was made simpler. 
After work-up and removal of the organic solvent, the residue was purified by recrystallization (in a 
minimum amount of ethyl acetate), to obtain the pure UV active triazole (±)-2 in an acceptable yield 
of 63%.  
 
Scheme 3:2   Test reaction for CuAAC reaction with a UV active alkyne.  
Product (±)-2 was characterized by studying NMR spectra 3 and 4 in Appendix 1. The 1H NMR 
spectrum showed a singlet at 7.76 ppm which represented the proton attached to the unsubstituted 
carbon of the triazole ring. Additionally, three multiplets were observed in the aromatic region (7.73 
– 7.27 ppm) which corresponded to the five protons of the phenyl ring. It was also interesting to note 
that the proton atoms of the carbons attached to the hydroxyl group and the nitrogen atom (of the 
newly formed triazole ring) both appeared more downfield compared to the spectrum of compound 
(±)-1 (which contained the azide functionality). These high chemical shift values could be a result of 
the magnetic anisotropy induced by the nearby triazole ring. Compared to the spectrum of (±)-1, the 
13C NMR spectrum presented six new peaks in the aromatic region, which corresponded to the two 
carbon atoms of the triazole ring as well as the six carbon atoms of the phenyl ring. As expected, 
only four peaks appeared for the six phenyl carbons. This was a consequence of the free rotation 
around the triazole-phenyl bond, causing a plane of symmetry along the center of the phenyl ring. 
The four carbons on either side of this plane therefore appeared as only two peaks, as the carbons 
across from each other were seen as chemically equivalent. The substituted carbon atom of the 
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triazole ring was represented by the largest chemical shift value (147.18 ppm) found in this spectrum. 
This can be explained by the combined ring current effects of the triazole ring and the attached 
phenyl ring. We worked on the assumption that the obtained product was indeed the 1,4-
disubstituted regioisomer, as a large volume of literature has proven that the CuAAC reaction 
provides the 1,4-regioisomer selectively.100–105 However, two-dimensional NMR experiments, in 
particular the nuclear overhauser effect spectroscopy (NOESY) sequence must be conducted to 
confirm this assumption.  Furthermore, the mass spectroscopic analysis result confirmed successful 
synthesis of product (±)-2, as the result of 244.1452 amu was in agreement with the calculated value 
of 244.1450 amu. This high resolution mass spectrometry (HRMS) result, labeled as Mass Spectrum 
1, can be seen in Appendix 1. 
After the successful synthesis of the UV active triazole (±)-2, along with confirmation of the triazole 
formation, the synthesis of the 1,4-disubstituted triazole CBD analogue (±)-3 was investigated. 
 SYNTHESIS OF (±)-TRANS-2-(4-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-OL 
3  
Optimization of the copper-catalyzed azide alkyne cycloaddition (CuAAC) reaction  
As can be expected, a wide collection of literature procedures are available on this cycloaddition 
reaction. As a result, a variety of copper sources (both Cu(I) and Cu(II) sources) along with different 
reaction conditions were investigated in this project. This was done to obtain the optimum yield and 
the most convenient method for the CuAAC reaction between the 1,2-azido alcohol (±)-1 and the 
chosen alkyne (1-heptyne) used to synthesize the desired 1,4-disubstituted 1,2,3-triazole (±)-3 of 
Scaffold A. Due to the similarities between the three scaffolds of this study, the outcome of this 
optimization can be directly applied to Scaffold B and C. Each method will be discussed below and 
characterization of compound (±)-3 will follow. 
 CUAAC WITH COPPER(I) SULPHATE PENTAHYDRATE 
The first CuAAC procedure explored for the synthesis of compound (±)-3 utilized the same copper 
source as above, in the synthesis of compound (±)-2. As already mentioned, this was also the same 
copper source used by Szafrański et al. in the synthesis of a similar group of compounds.97,121 The 
1,2-azido alcohol (±)-1 was reacted with the chosen alkyne, 1-heptyne, along with copper(II) sulphate 
pentahydrate and sodium ascorbate as a reducing agent (Scheme 3:3, see Chapter 2 – Click 
Chemistry Introduction). Initially, the copper source and reducing agent were dissolved in water and 
left to stir, allowing time for the reduction to occur. We assumed that the CuAAC reaction provides 
the 1,4-regioisomer as per above explanation. After standard work-up and purification by column 
chromatography, the pure 1,4-disubstituted analogue (±)-3 was obtained in a good yield of 79%.  
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Scheme 3:3   Synthesis of 1,4-disubstituted triazole (±)-3 with CuSO4.H2O.    
Although this was a pleasing result, the set-up of this reaction was fairly time-consuming and we 
were curious to see what yield would be obtained with different copper sources. 
 CUAAC WITH COPPER(I) IODIDE 
Various literature procedures using copper(I) iodide in CuAAC reactions have been 
published.102,128,129 When using the Cu(I) catalyst, a stabilizing ligand (frequently a basic compound) 
is required and the reaction must preferably be conducted in the absence of light, (see Chapter 2 – 
Click Chemistry Introduction). Three different reaction conditions with copper(I) iodide as copper 
source were investigated and are discussed below. During all three reaction conditions investigated, 
N,N-diisopropylethylamine (DIPEA) was used as base.  
 
The first set of reaction conditions investigated, was the copper(I) iodide-catalyzed click reaction 
using dichloromethane as a solvent while running the reaction at room temperature (Scheme 3:4).128 
Under these conditions, a low yield of 39% was obtained after work-up and purification by column 
chromatography. 
 
Scheme 3:4   Synthesis of 1,4-disubstituted triazole (±)-3 with CuI (DCM at RT).    
Despite this poor yield, the successful recovery of both starting materials during the purification step, 
acted as a decent consolation prize. The presence of the residual starting materials indicated that 
the reaction either needed to run for a longer period or needed more heat energy (to increase the 
reaction rate) so that it would go to completion in the time period utilized. Since the reaction was 
already permitted to run for 18 hours; increasing the reaction time was deemed not to be a feasible 
option. However, adding additional heat energy into the system, by means of an increased reaction 
temperature, was a viable modification. 
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The second set of reaction conditions investigated was the copper(I) iodide-catalyzed click reaction, 
still using dichloromethane as a solvent, but setting the reaction to a slightly elevated temperature of 
40 °C (Scheme 3:5). By just increasing the temperature from room temperature to 40 °C, the reaction 
yield was significantly increased, as a yield of 83% was obtained under these conditions. 
 
Scheme 3:5   Synthesis of 1,4-disubstituted triazole 3 with CuI (DCM at 40 °C). 
Even though an acceptable yield was obtained during this attempt, a higher yield (88%) was obtained 
by Szafrański et al.,121 even when working on a much larger scale. In a subsequent attempt at 
optimizing the CuAAC reaction for this system, a solvent with a higher boiling point (but still 
compatible with the copper(I) iodide-catalyzed click reaction) was investigated, allowing us to add 
even more heat energy into the system. 
 
The third set of reaction conditions explored was to use copper(I) iodide with acetonitrile as solvent 
and setting the reaction to a temperature of 65 °C (Scheme 3:6). This option was considered after 
finding literature in which acetonitrile was used as a solvent with this copper source.102,129 For this 
reaction a slight increase in the yield was observed in comparison to the previous conditions 
described, as a yield of 86% was obtained for product (±)-3. 
 
Scheme 3:6   Synthesis of 1,4-disubstituted triazole (±)-3 with CuI (MeCN at 65 °C). 
Although good yields were obtained while using the copper(II) sulphate pentahydrate or the 
optimized copper(I) iodide-catalyzed conditions (described in the three different reactions above), 
both require the addition of an additive (whether it be a reducing agent or a stabilizing ligand). 
Furthermore, the copper(I) iodide-catalyzed reaction has the additional requirement in which the 
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reaction must be conducted in the dark (see Chapter 2 – Click Chemistry Introduction). Due to these 
drawbacks it was decided to investigate a third copper source. 
 CUAAC WITH COPPER(II) ACETATE  
In the final method investigated for the synthesis of compound (±)-3, the 1,2-azido alcohol (±)-1 was 
reacted with the chosen alkyne, 1-heptyne, along with copper(II) acetate at 30 °C (Scheme 3:7).104 
After standard work-up and purification by flash chromatography, the pure 1,4-disubstituted triazole 
(±)-3 was obtained in a good yield of 89%.  
 
Scheme 3:7   Synthesis of 1,4-disubstituted triazole (±)-3 with Cu(OAc)2. 
Although optimum reaction conditions for all three copper sources were determined with acceptable 
yields (79% and above), the present set of reaction conditions had additional benefits. When using 
copper(II) acetate, no additional additives (for example reducing agents or basic compounds) were 
required (see Chapter 2 – Click Chemistry Introduction),104 which in turn made the set-up and 
reaction work-up faster and less troublesome. Another benefit of this method, is the fact that a good 
yield (89%) was obtained even under a reaction temperature of 30 °C. The copper(II) acetate-
catalyzed conditions would therefore be used for all the CuAAC reactions throughout this project. 
The assumption that these conditions will also be compatible with Scaffold B and C is valid as the 
azide and alkyne structures used in system B and C are relatively similar to that used for optimization 
in System A. 
NMR spectra 5 and 6, found in Appendix 1, were used to characterize the 1,4-disubstituted triazole 
(±)-3. In the 1H NMR spectrum, a signal was observed at 7.28 ppm which represented the proton 
attached to the unsubstituted carbon in the triazole ring. It was interesting to note that the triazole 
proton of (±)-3 (with the pentyl side chain substituent) appeared more upfield in comparison with (±)-
2 (which contained the phenyl ring substituent). This could be due to the lack of the phenyl ring 
current present in compound (±)-2. In addition, a multiplet was observed at 4.09 – 3.95 ppm which 
represented the two protons of the carbons attached to the hydroxyl group (H1) and the nitrogen 
atom (H2, newly formed triazole ring). In the 13C NMR spectrum of (±)-3, the substituted carbon atom 
of the triazole ring was observed at the highest chemical shift value of 147.48 ppm. Furthermore, the 
unsubstituted carbon atom of the triazole ring could be seen at 120.55 ppm. The 13C spectrum also 
contained two deshielded peaks at 72.41 ppm and 66.80 ppm, which corresponded to the carbons 
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adjacent to the hydroxyl group (C1) and the nitrogen atom (C2, newly formed triazole ring), 
respectively. All other proton and carbon atoms were accounted for, and the NMR spectroscopic 
data was consistent with values provided in literature.121 This compound was further characterized 
with Mass Spectrum 2, located in Appendix 1. The mass spectroscopic analysis confirmed isolation 
of product (±)-3, as the result of 238.1920 amu corresponded favourably with the calculated value of 
238.1919 amu. 
The optimization attempts for the CuAAC reaction are summarized in Table 3:1 below. During all 
attempts, the alkyne was initially added to the active copper source and the mixture was left to stir 
to allow coordination of the alkyne (1.1 equiv., see Chapter 2 – Click Chemistry Introduction). This 
was followed by the addition of the azide (1.0 equiv.). In addition, the reaction time for all five attempts 
was held constant at 18 hours. 
Table 3:1   Summary of CuAAC reaction conditions attempted with azide (±)-1, 1,2-azido alcohol, and the chosen 
alkyne, 1-heptyne, for the synthesis of the 1,4-disubsituted triazole (±)-3. 
Attempts 
Copper source 
(0.3 equiv.) 
Additive Solvent 
Temp. 
 (°C) 
Yield  
(%) 
1 CuSO4.H2O Sodium ascorbate MeOH: H2O (4:1) 30 79 
2 CuI DIPEA DCM RT 39 
3 CuI DIPEA DCM 40 83 
4 CuI DIPEA MeCN 65 86 
5 Cu(OAc)2 - MeOH: H2O (1:1) 30 89 
The next step involved the synthesis of the 1,5-disubstituted triazole (±)-4. This compound contained 
the same pentyl side chain as shown for compound (±)-3 (and also in the structure of CBD), but in a 
different position on the triazole ring.  
3.1.4. SYNTHESIS OF (±)-TRANS-2-(5-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-
OL 4 
Optimization of the ruthenium-catalyzed azide alkyne cycloaddition (RuAAC) reaction  
In this reaction, the 1,2-azido alcohol (±)-1 was reacted with the alkyne, 1-heptyne, along with a 
ruthenium catalyst to obtain the 1,5-disubstituted triazole (±)-4, exclusively (Scheme 3:8). Once 
again, we worked on the assumption that the 1,4-regioisomer was obtained under the CuAAC 
reaction and by comparing the NMR spectra it was clear that the product obtained under the RuAAC 
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reaction conditions was different than the product obtained above. The catalyst chosen for this 
reaction was chloro(pentamethylcyclopentadienyl)(cyclooctadiene)-ruthenium(II), Cp*RuCl(COD). 
The cyclooctadiene ligands of this catalyst are easier to displace than ligands of other applicable 
catalysts (see Chapter 2 - Click Chemistry Introduction for mechanism), which is why this catalyst is 
considered superior to other ruthenium catalysts.110 The Cp*RuCl(COD) catalyst has also been 
shown to achieve successful coupling, with high yields and 100% regioselectivity, under milder 
reaction conditions compared to other pertinent catalysts.110 
 
Scheme 3:8   Synthesis of 1,5-disubstituted triazole (±)-4.  
Different solvents and temperatures were investigated in order to obtain the best possible yield for 
this specific system, as illustrated in Table 3:2. All three solvents investigated were shown to be 
compatible with the chosen catalyst, Cp*RuCl(COD).110,130 During all of these attempts, the alkyne 
was added to the ruthenium catalyst solution in a Schlenk tube and the mixture was left to stir, to 
allow the coordination of the alkyne, 1-heptyne (1.0 equiv., see Chapter 2 - Click Chemistry 
Introduction). This was followed by the addition of the azide (±)-1 (1.0 equiv.). In addition, all attempts 
were carried out with a reaction time of 24 hours. In order to make a viable comparison, all six 
attempts were also done at the same scale: azide, (±)-trans-2-azidocyclohexan-1-ol (±)-1: 200mg. 
Each method will once again be discussed, followed by the characterization of compound (±)-4. 
Table 3:2   Summary of RuAAC reaction conditions attempted with azide (±)-1, (±)-trans-2-azidocyclohexan-1-ol, 
and the chosen alkyne, 1-heptyne, for the synthesis of the 1,5-disubsituted triazole (±)-4. 
Attempt Solvent 
Solvent 
vol. (mL) 
Cat. amount 
(mol%) 
Degas 
method 
Temperature 
(°C) 
Yield (%) 
1 THF 8 10 N2a 50 36 
2 Toluene 8 10 N2a 80 39 
3 Toluene 8 10 FPTb 80 51 
4 Toluene 8 4 FPTb 80 51 
5 Dioxane 8 4 FPTb 60 63 
6 Dioxane 4 4 FPTb 60 57 
   a = Solvent was purged with nitrogen for 45 min as a degassing method. 
   b = Solvent was subjected to the freeze-pump-thaw technique in combination with nitrogen purging, as a      
degassing method.  
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In the first attempt, 8 mL of dry tetrahydrofuran was used along with 10 mol% of the chosen catalyst, 
Cp*RuCl(COD). The solvent was degassed by passing nitrogen gas through the reaction vessel for 
45 minutes to provide an inert atmosphere and the reaction was set to 50 °C. Unfortunately, a low 
yield (36%) was obtained under these conditions due to the incomplete consumption of both starting 
materials (as seen on TLC). Despite of the low yield obtained in the first attempt for the desired 1,5-
disubstituted triazole (±)-4, both unreacted starting materials were successfully recovered and 
subsequently used in further attempts.  
It was then decided to change the reaction solvent to one with a higher boiling point, so that additional 
energy could be added into the system. This was done in the hopes that the reaction would be driven 
to completion by faster reaction kinetics. The second attempt therefore involved 8 mL of anhydrous 
toluene and the reaction was set to 80 °C, while keeping all other variables constant. This did 
however not make a significant difference to the yield as only 39% was obtained under these 
conditions, still owing to incomplete consumption of both starting materials. Even after successful 
recovery of the azide and alkyne fractions, the search for a procedure providing an acceptable 
conversion continued.  
This led us to investigate the degassing method used, as certain common contaminants (for example 
water or molecular oxygen) present in the reaction vessel, might be deactivating the catalyst leaving 
behind the residual unreacted starting materials. As a result, the third attempt involved altering the 
degassing method from solely passing nitrogen through the reaction set-up to a combination of the 
freeze-pump-thaw (FPT) technique and nitrogen purging. All other variables were kept constant. In 
this case a more significant yield increase was observed, from 39% to 51%, confirming that nitrogen 
purging alone was not a sufficient degassing method. All future attempts were therefore conducted 
with the FPT degassing technique in combination with nitrogen purging.  
After finding a set of conditions providing a yield above 50%, it was decided to investigate the amount 
of catalyst needed in this cycloaddition reaction. In the fourth attempt, the catalyst amount was thus 
decreased from 10 mol% to 4 mol%, while keeping all other variables constant. In a pleasing result, 
this had no influence on the yield and therefore all future RuAAC reactions were conducted with 4 
mol% of the Cp*RuCl(COD) catalyst.  
Once the catalyst amount was optimized to more economical and environmentally friendly 
proportions, we set out to further improve the yield for this cycloaddition reaction. During the fifth 
attempt, a third solvent, 1,4-dioxane, was investigated and the reaction temperature was set to 60 
°C while keeping all other variables constant. We were pleased to obtain another significant increase 
in the reaction yield (from 51% to 63%), even when working at a lower reaction temperature than 
compared to the fourth attempt.  
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In a final attempt at optimizing the reaction conditions, we investigated the amount of solvent needed 
for this cycloaddition reaction to proceed at an acceptable yield. We therefore decreased the solvent 
volume from 8 mL to 4 mL in the sixth attempt to see what affect this would have on the yield. If the 
yield was not negatively influenced, we would have been able to decrease the amount of solvent 
used for this coupling reaction. Unfortunately, by implementing this final modification, the yield 
decreased from 63% to 57%.  
As a result, it was decided to use the fifth attempt as our optimized reaction conditions for the RuAAC 
reaction throughout the rest of this project. The purification procedure involved when using 1,4-
dioxane was also faster and easier compared to the other two solvents investigated, as no work-up 
step was required and the reaction residue could directly be loaded onto the column. This is possible 
as 1,4-dioxane is a fairly non-polar solvent and can therefore easily be eluted from the column by 
using a weak mobile phase, which would not affect the retention of the more polar triazole 
compounds. 
NMR spectra 7 and 8, located in Appendix 1, were examined during the characterization of product 
(±)-4. Figure 3:1 contains the numbered structures of (±)-3 and (±)-4. These atom numbers will be 
referred to during the NMR spectroscopy discussion of compound (±)-4 below. 
 
Figure 3:1   Numbered structure of the 1,4- and 1,5-disubstituted triazoles (±)-3 and (±)-4. 
In the 1H NMR spectrum of (±)-4, a singlet was observed at 7.39 ppm which represented the proton 
of the unsubstituted carbon atom in the triazole ring. A multiplet was also seen at 3.94 – 3.85 ppm 
assigned to the proton of the carbon attached to the hydroxyl group (H1). Another multiplet integrating 
for three protons appeared at 2.72 – 2.54 ppm. This multiplet was assigned to the proton of the 
carbon attached to the nitrogen atom (H2, newly formed triazole ring), as well as the two protons of 
the aliphatic carbon of the side chain directly attached to the triazole ring (H9). The presence of these 
two separate multiplets in the spectrum of the 1,5-disubstituted triazole (±)-4, was fascinating, as the 
H1 and H2 protons were seen as an overlapping multiplet at 4.09 – 3.95 ppm in the spectrum for the 
1,4-disubstituted triazole (±)-3. This separation was observed because of an upfield shift of the H2 
proton of the 1,5-disubstituted triazole (±)-4. The precise reason for this upfield shift cannot be 
provided with certainty, but the new position of the pentyl side chain is definitely the main aspect to 
consider. In the 1,5-disubstituted triazole (±)-4, the side chain was adjacent to the nitrogen atom 
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attached to the carbon of the proton under discussion (H2). The conformation adopted by (±)-4, due 
to the new side chain position, might have altered the way in which the nitrogen lone pairs were able 
to interact, thus affecting the shift on the neighbouring carbon, C2 (and the corresponding proton, 
H2). 
In the 13C NMR spectrum of (±)-4, a peak was seen at 138.24 ppm which represented the substituted 
carbon atom of the triazole ring (C7). The unsubstituted triazole carbon atom was also accounted for 
at 131.82 ppm (C8). The carbon peak of C7 appeared slightly more upfield, and that of C8 appeared 
slightly more downfield in comparison to the spectrum of the 1,4-disubstituted triazole (±)-3. Note 
that the unsubstituted triazole carbon of the 1,4-disubstituted triazole analogue (±)-3 was in close 
proximity to the cyclohexyl ring, but in the 1,5-disubstituted triazole analogue (±)-4, the unsubstituted 
triazole carbon is further away from the cyclohexyl ring. With this in mind, this observation could 
once again be attributed to the conformational change between the two triazole analogues ((±)-3 
and (±)-4) and the resulting effect on the nitrogen lone pairs. All other proton and carbon atoms were 
accounted for. Mass spectroscopic analysis further confirmed a successful reaction with the obtained 
result of 238.1921 amu corresponding well to the calculated value of 238.1919. This HRMS result 
can be seen in Mass Spectrum 3 in Appendix 1. 
Although the synthesis of (±)-4 was initially seen as a test reaction to determine the optimum reaction 
conditions for this regioselective cycloaddition reaction, it was considered of interest to compare the 
1,4- and 1,5-disubstituted triazole compounds ((±)-3 and (±)-4) to see what effect this side chain shift 
would entail.  
After successful optimisation of the RuAAC reaction conditions, the chosen method could then be 
directly applied in the synthesis of the 1,4,5-trisubstituted triazole analogue (±)-7. The synthesis of 
the desired 1,4,5-trisubstituted triazole 7 involved the reaction of azide 1 with an internal alkyne, oct-
2-yn-1-ol 5, to provide a triazole analogue with an additional hydroxyl group at the core of the 
structure to mimic the phenolic hydroxyl group of CBD (Figure 3:2).  
 
Figure 3:2   Comparison between CBD and 1,4,5-trisubstituted triazole (±)-7. 
The next step was therefore to synthesize the desired internal alkyne, oct-2-yn-1-ol 5, needed for 
the synthesis of the 1,4,5-trisubstituted triazole (±)-7. 
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3.1.5. SYNTHESIS OF INTERNAL ALKYNE, OCT-2-YN-1-OL 5 
The synthesis of the internal alkyne 5 was accomplished by reacting 1-heptyne with n-butyllithium in 
dry tetrahydrofuran to form the corresponding lithium acetylide, which was subsequently reacted with 
paraformaldehyde (Scheme 3:9).131,132 After work-up and purification by column chromatography, 
the desired propargyl alcohol 5 was isolated in a reasonable yield of 67%.  
 
Scheme 3:9   Synthesis of the internal alkyne 5. 
NMR spectra 9 and 10 (Appendix 1) were used to characterize this internal alkyne. In the 1H NMR 
spectrum, a multiplet was observed at 4.24 ppm which represented the two protons in between the 
hydroxyl group and the triple bond. This multiplicity was unexpected; however, some splitting was 
also reported in literature which suggested possible long range coupling to the protons on the 
opposite side of the triple bond.131 A broad multiplet could also be seen at 1.80 – 1.77 ppm which 
we assigned to the hydroxyl group. Although one would expect the hydroxyl group to appear at a 
higher chemical shift value, the shift for this functional group is known to vary; and a discrepancy 
can be seen between different literature reports on the exact position of the hydroxyl group of this 
particular compound, oct-2-yn-1-ol 5.131,133 In addition, both peaks seen at a higher chemical shift 
value (compared to the hydroxyl group) integrated for two protons each, and were therefore 
undoubtedly assigned to the four protons on either side of the triple bond.  
In the 13C NMR spectrum of 5, two peaks could be seen at 86.73 ppm and 78.40 ppm, which 
represented the two carbon atoms of the triple bond, with the higher chemical shift peak resulting 
from the triple bond carbon closer to the hydroxyl group. Another significant peak was seen at 51.49 
ppm, which corresponded to the carbon atom in between the triple bond and the hydroxyl group. All 
other relative nuclei were accounted for in the respective spectra. The NMR spectroscopic data 
corresponded to previously reported results.131 
With the desired internal alkyne in hand, the synthesis of the 1,4,5-trisubstituted triazole (±)-7 was 
attempted by making use of the optimized RuAAC reaction conditions. 
3.1.6. SYNTHESIS OF (±)-TRANS-2-[4-(HYDROXYMETHYL)-5-PENTYL-1H-1,2,3-TRIAZOL-
1-YL]CYCLOHEXAN-1-OL 6 AND (±)-TRANS-2-[5-(HYDROXYMETHYL)-4-PENTYL-1H-
1,2,3-TRIAZOL-1-YL]CYCLOHEXAN-1-OL 7 
For the synthesis of the desired 1,4,5-trisubstituted triazole (±)-7, the 1,2-azido alcohol (±)-1 was 
reacted with the synthesized internal alkyne, oct-2-yn-1-ol 5, under the optimized RuAAc reaction 
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conditions (8 mL of dioxane, 4 mol% of the Cp*RuCl(COD) catalyst, FPT degassing, 60 °C reaction 
temperature, Scheme 3:10). 
When internal alkynes are used during these cycloaddition reactions, both regioisomers can be 
obtained. Exclusive regioselectivity is not usually observed with internal alkynes lacking a specific 
directing group. When some regioselectivity is exhibited by this type of internal alkyne, it could be 
attributed to either steric or electronic effects. However, when working with internal alkynes 
containing a hydrogen bond donor group (like a propargylic alcohol as found in the internal alkyne 
5) substantial regioselectivity is usually observed, which can be contributed to a hydrogen bond 
formation between the propargylic alcohol and the chloride ligand on the ruthenium catalyst (see 
Chapter 2 – Click Chemistry Introduction).110  
As per the above explanation, we expected this reaction to yield compound (±)-7 as the major 
product along with compound (±)-6 as the minor product. However, in our hands, this was not the 
case. Contrary to our expectations, no regioselectivity was observed, as both compounds (±)-6 and 
(±)-7 were isolated at a low yield of 6%. 
 
Scheme 3:10   Synthesis of 1,4,5-trisubstituted triazoles (±)-6 and (±)-7. 
NMR spectra 11, 12, 13 and 14 (Appendix 1) were subsequently studied during the characterization 
of compounds (±)-6 and (±)-7.  
Note that these two compounds were tentatively assigned with the available 1H and 13C NMR 
spectra. For a more accurate assignment, or for confirmation of the assignment made in this report, 
two-dimensional NMR spectra must be obtained. The most important two-dimensional NMR 
spectroscopy experiments that must be conducted, are the homonuclear correlation spectroscopy 
(COSY) sequence, as well as the heteronuclear single-quantum correlation spectroscopy (HSQC) 
sequence. These two experiments will provide information on the proton-proton coupling between 
adjacent proton nuclei, as well as the proton-carbon coupling between directly attached proton and 
carbon nuclei, respectively. Additionally, the heteronuclear multiple bond correlation (HMBC) 
experiment could also be considered, as this would provide long range proton-carbon coupling 
information. These experiments were not conducted during the scope of this study. Distinct 
differences were observed between the 1H and 13C NMR spectra of (±)-6 and (±)-7, which allowed 
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the characterization of these two compounds. These observed differences and the consequential 
assignments are discussed below.     
The numbered structures of (±)-6 and (±)-7, along with the relative pharmacophoric groups, are 
illustrated in Figure 3:3. These atom numbers and relative pharmacophoric groups will be referred 
to during the NMR spectroscopy discussion of compound (±)-6 and (±)-7 below. 
 
Figure 3:3   Numbered structure of two 1,4,5-trisubstituted triazoles (±)-6 and (±)-7, with the relative 
pharmacophoric groups. 
In the 1H NMR spectra, NMR spectrum 11 for compound (±)-6 and NMR spectrum 13 for compound 
(±)-7, the cyclohexanol group could be seen as broad singlets at 4.43 and 4.30 ppm, respectively. 
The cyclohexanol group (H14) of (±)-7 might have appeared slightly more shielded due to the 
possibility of additional hydrogen bonding to the nearby triazole hydroxyl group.  
The protons of the carbon in between the triazole ring and the triazole hydroxyl group (H15), were 
observed as a singlet at 4.55 ppm for compound (±)-6 (NMR Expansion 3:1A), and as an unexpected 
multiplet (or more accurately, overlapping geminal coupled doublets) at 4.62 – 4.48 ppm for 
compound (±)-7 (NMR Expansion 3:1B).  
 
 
NMR Expansion 3:1   A: Singlet observed for H15 in spectra of (±)-6; B: Overlapping germinal doublets observed 
for H15 in spectra of (±)-7. 
One would expect to see a singlet for H15 for both (±)-6 and (±)-7 with no additional coupling due to 
the absence of neighboring proton nuclei. When first considering the conformation of (±)-6, the 
A                                                                 B 
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carbon atom of the protons under discussion (H15), was positioned away from any other functional 
groups and could therefore not have any interactions that might have led to additional coupling. 
These two H15 protons of (±)-6 also appeared chemically equivalent due to free rotation around the 
bond between C8 and C15, which appeared as a singlet integrating for two protons as one would 
expect to see. However, when considering the conformation of (±)-7, this same carbon atom 
attached to H15 was positioned more to the center of the structure, in a closer proximity to the 
cyclohexanol group (H14). Although a definitive explanation for this observation in (±)-7 could not be 
provided with the resources at hand, this multiplicity could be a result of an additional hydrogen 
bonding possibility between the cyclohexanol group (H14) and the triazole hydroxyl group (H16, which 
is adjacent to the carbon atom of the protons under discussion). It was thought that this possible 
interaction as well as the specific conformation illustrated for compound (±)-7, locks the two protons 
of H15 in chemically non-equivalent positions by restricting the free rotation around the bond between 
C8 and C15. This also enhances the diastereotopic effect of these two protons due to the nearby 
chiral center. Theoretically one would expect to observe geminal doublets; however, we reported 
this peak as a multiplet as the two doublets appeared overlapped. As already mentioned, two-
dimensional NMR spectroscopic results must be obtained to confirm this theory. For both 
compounds (±)-6 and (±)-7, these protons labeled as H15, appeared at a higher chemical shift value 
than normally expected for methylene groups, due to the magnetic anisotropy caused by the 
adjacent triazole ring.  
The triazole hydroxyl group was seen as a broad singlet at 5.82 ppm for compound (±)-6 and as a 
broad singlet at 3.56 ppm for compound (±)-7. The difference observed in the chemical shift values 
was expected, as the conformation of (±)-6 caused the triazole hydroxyl group to face away from the 
crowded core of the structure. This also excluded the possibility of hydrogen bonding between the 
cyclohexanol group and the triazole hydroxyl group. Both of these conformational traits of (±)-6 
caused the triazole hydroxyl group to appear more deshielded compared to the triazole hydroxyl 
group of (±)-7. 
The proton of the carbon attached to the cyclohexanol (H1) and the proton of the carbon attached to 
the nitrogen atom (H2, new formed triazole ring) were seen as a multiplet at 4.10 – 3.95 ppm for 
compound (±)-6. However, for compound (±)-7, these two peaks were seen as separate multiplets 
at 4.23 – 4.15 ppm (H2) and 3.88 – 3.80 ppm (H1). H1 of compound (±)-7 might have appeared at a 
slightly lower chemical shift (more shielded) due to possible hydrogen bonding to the nearby triazole 
hydroxyl group. All other proton atoms were accounted for. 
In the 13C NMR spectra, NMR spectrum 12 for compound (±)-6 and NMR spectrum 14 for compound 
(±)-7, the two carbon atoms that form part of the triazole ring (C7 and C8) were observed at 144.93 
ppm and 133.37 ppm for compound (±)-6 and only one aromatic peak was seen at 136.46 ppm for 
compound (±)-7. The absent peak in the spectrum of compound (±)-7 could be due to an inadequate 
Stellenbosch University https://scholar.sun.ac.za
Chapter 3 – Triazole CBD analogues – Results and Discussion 
46 
 
acquisition time during the NMR spectroscopy experiment based on the concentration of this specific 
NMR spectroscopy sample. This is a problem often encountered for quaternary carbons with no 
protons attached. These carbon atoms (C7 and C8) are found at such high chemical shift values due 
to the deshielding effect caused by the magnetic anisotropy induced by the triazole ring. 
The carbon in between the triazole ring and the triazole hydroxyl group (C15) was observed at 51.42 
ppm for compound (±)-6 and 55.56 ppm for compound (±)-7. The deshielding effect observed for (±)-
7 may once again be a result of the additional hydrogen bonding possibility between the triazole 
hydroxyl group and the cyclohexanol group, as already explained. The carbon atom attached to the 
cyclohexanol group (C1) and the carbon attached to the nitrogen atom (C2, newly formed triazole 
ring) was observed at approximately 73 ppm and 64 ppm for both compound (±)-6 and (±)-7. C1 was 
assigned to the higher chemical shift value in both cases as a result of the electronegativity of the 
oxygen atom of the adjacent hydroxyl group, causing C1 to be more deshielded. All other carbon 
atoms were accounted for. In addition, Mass Spectrum 4 (to be seen in Appendix 1), also confirmed 
the successful formation of the 1,4,5-trisubstituted triazoles as the mass spectroscopic value of 
268.2037 amu corresponded well with the calculated value of 268.2025 amu. 
The low yields obtained during this reaction were once again due to incomplete consumption of both 
starting materials, as determined by TLC. The poor yields obtained, even under a relatively long 
reaction time of 24 hours, indicated that this reaction was a slow process by nature. Although both 
starting materials were salvaged during the purification process, the yields obtained were not 
satisfactory, and the lack of regioselectivity meant that the desired compound could not be obtained 
as the major product under these conditions. Another possible explanation for this low yield might 
be the presence of two directing groups (the cyclohexanol group and the triazole hydroxyl group) 
which could have led to coordination to the catalyst thereby shutting down the catalytic cycle. Future 
attempts at this synthesis might therefore involve protection of the one hydroxyl group, preferably 
the cyclohexanol group, to prevent this coordination. It would be recommended to repeat this 
reaction and explore different options which could possibly provide an improved yield and selectivity.  
Firstly, one would need to consider the reaction conditions and the changes that can be implemented 
to provide an improved yield. The solvent used, as well as the ideal solvent volume for this specific 
scale of 200 mg of the 1,2-azido alcohol (±)-1, has already been optimized. For this reason, it would 
not be advisory to alter these parameters. However, possible options for improving the yield could 
include increasing the amount of internal alkyne used, and either increasing the reaction time or the 
reaction temperature in an attempt to drive this reaction to completion. As the reaction was already 
allowed to run for 24 hours, adjusting the reaction temperature would once again be deemed to be 
the better option. The additional heat energy could drive this reaction to completion through faster 
reaction kinetics.  
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When considering the regioselectivity of this reaction, internal alkynes containing propargyl alcohols 
normally produce the desired isomer as the major product, with the propargyl alcohol in the 5-position 
on the 1,2,3-triazole ring, as already explained. However, for this specific system, this was not the 
case. This could possibly be explained by an additional interaction of the propargyl alcohol with the 
nearby cyclohexanol group. In order to address this lack of regioselectivity, two other internal alkynes 
will be discussed which could potentially provide the desired isomer as the major product.  
The first option would be to synthesize an internal alkyne with a tertiary amine functionality in the 
propargylic position instead of the alcohol functionality used in 5. This group is also known to promote 
the formation of the desired isomer with the propargyl substituent in the 5-position on the 1,2,3-
triazole ring.111,130 The amine functionality might have a different coordinating interaction with the 
nearby cyclohexanol group compared to the propargyl hydroxyl group, thereby resulting in a higher 
selectivity for the desired isomer. Making use of this internal alkyne would however require additional 
steps after the cycloaddition, in order to transform the amine functionality into the required hydroxyl 
group. This could be achieved by first converting the tertiary amine into a primary amine,134 followed 
by a subsequent conversion into the primary alcohol135 to obtained the desired triazole CBD 
analogue (±)-7. The general process proposed for the reaction with the propargyl amine alkyne is 
depicted in Scheme 3:11. 
 
Scheme 3:11   First option to address the lack of regioselectivity (internal alkyne with a propargyl amine). 
Another option would be to synthesize an internal alkyne with the required propargyl alcohol on the 
one side (as in compound 5), along with an additional electron-withdrawing group on the other side 
of the triple bond. Internal alkynes with a strong electron-withdrawing group, for instance a carbonyl 
group, are known to produce the isomer with the electron-withdrawing group on the 4-position on 
the 1,2,3-triazole ring.111,130 Keeping in mind that the propargyl alcohol usually favours the 5-position, 
this internal alkyne would then consist of two directing groups both favouring the formation of the 
preferred isomer, with the hydroxyl group in the 5-position on the 1,2,3-triazole ring. This option 
would however also require an additional step in which the carbonyl group must be subjected to a 
deoxygenation reaction to reduce the ketone functionality to the desired aliphatic side chain. This 
could be achieved through either a Clemmensen or a Wolff-Kishner reduction.136  
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The general scheme which would be involved when employing the internal alkyne containing an 
electron-withdrawing group (a ketone), as well as the propargyl alcohol on opposite sides of the triple 
bond, is illustrated in Scheme 3:12. 
 
Scheme 3:12   Second option to address the lack of regioselectivity, using an internal alkyne with an electron-
withdrawing group and a propargyl alcohol. 
The yield and selectivity of this reaction was not further explored during the scope of this research 
as sufficient amounts of each regioisomer was isolated for biological tests. If larger amounts would 
be required in the future, this reaction will need to be studied in more detail, and the suggestions 
provided above could be used as initial attempts at optimization. 
After the successful synthesis of the 1,4- ,1,5- and 1,4,5-polysubstituted triazole analogues aimed 
for in Scaffold A, the synthesis of Scaffold B (in which the cyclohexanol group occupied a new 
position) was investigated.  
3.2. SYNTHESIS OF SCAFFOLD B 
As illustrated in the ligand design for Scaffold B, these analogues consisted of the same three 
pharmacophoric groups as that of Scaffold A, but with the cyclohexanol group in a different position. 
The azide needed for the synthesis of the triazole analogues of this system, was 3-azidocyclohexan-
1-one 11. Initially, a synthetic route was designed in which this desired β-azido ketone 11 could be 
obtained in four steps.  
3.2.1. ATTEMPTED SYNTHESIS OF AZIDE 11 IN FOUR STEPS 
This four-step synthetic route, involved the epoxidation of an α,β-unsaturated ketone, 2-cyclohexen-
1-one, to obtain the α,β-epoxyketone 8, followed by a reductive cleavage to acquire the 
corresponding β-hydroxy ketone 9. This β-hydroxy ketone 9 would then be subjected to a mesylation 
reaction yielding 10, followed by a nucleophilic substitution reaction to finally access the desired β-
azido ketone 11 (Scheme 3:13). Note that during the discussion of this system, the starting material, 
2-cyclohexen-1-one, used for the synthesis of the β-azido ketone 11, will be labeled as 11SM. 
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Scheme 3:13   General scheme for the four-step synthesis of azide 11. 
Details of the reactions involved, as well as the results obtained for each of these steps are discussed 
in the sections to follow. 
 SYNTHESIS OF 2,3-EPOXYCYCLOHEXANONE, (7-OXABICYCLO[4.1.0]HEPTAN-2-ONE) 8 
The first step involved in the attempted synthesis of the required azide 11, was the Weitz-Scheffer 
epoxidation of an electrophilic α,β-unsaturated ketone to obtain the corresponding α,β-epoxyketone 
8. This transformation was achieved by reacting 2-cyclohexen-1-one (11SM) with a hydrogen peroxide 
solution, in the presence of a catalytic amount of aqueous sodium hydroxide (Scheme 3:14).137  
 
Scheme 3:14   Synthesis of α,β-epoxyketone 8. 
The Weitz-Scheffer reaction is considered to be a reliable transformation, since the basic mechanism 
involved in the epoxidation of electrophilic α,β-unsaturated carbonyls was already published in 
1921.138 This epoxidation proceeded through a two-step addition-elimination mechanism (as 
determined through kinetic studies)139 as depicted in Scheme 3:15. This process started with the 
addition of deprotonated hydrogen peroxide (in the presence of sodium hydroxide) to the β-carbon 
of the α,β-unsaturated ketone 11SM. This addition led to a β-peroxyenolate intermediate which 
subsequently underwent an intramolecular ring closure. During the intramolecular ring closure, a 
new carbon-oxygen bond was formed causing the weak oxygen-oxygen bond to break, during which 
the hydroxide ion acted as a leaving group.140 After standard work-up and purification by column 
chromatography, the pure α,β-epoxyketone 8 was obtained in a yield of 66%.  
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Scheme 3:15   Weitz-Scheffer epoxidation of the α,β-unsaturated ketone 11SM to form the α,β-epoxyketone 8. 
Characterization of product 8 was achieved by studying the NMR spectra 15 and 16, located in 
Appendix 1. In the 1H NMR spectrum, a multiplet was observed at 3.53 – 3.50 ppm which represented 
the proton of the β-carbon (the epoxide carbon furthest away from the carbonyl functionality). 
Another noteworthy peak was seen as a doublet at 3.13 ppm which corresponded to the proton 
attached to the α-carbon (the epoxide carbon adjacent to the carbonyl group). In the 13C NMR 
spectrum, a peak was observed at 205.85 ppm which indicated the presence of the carbonyl group. 
In addition, two peaks were seen in the region of 55 ppm which represented the two epoxide carbons. 
All other proton and carbon atom signals were accounted for and the NMR spectroscopic data was 
in accordance with literature.140 The next step involved the conversion of the α,β-epoxyketone 8 into 
the corresponding β-hydroxy ketone 9.  
 SYNTHESIS OF 3-HYDROXYCYCLOHEXAN-1-ONE 9 
This transformation was achieved by subjecting the α,β-epoxyketone 8 to an organoselenium-
mediated reductive cleavage, in which diphenyl diselenide was used along with an appropriate 
reducing agent (Scheme 3:16).140 
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Scheme 3:16   Organoselenium-mediated reductive cleavage for the synthesis of the β-hydroxy ketone 9. 
Note that the desired product of this reductive cleavage, the β-hydroxy ketone 9, consisted of an 
Aldol structural unit, which means that there was a possibility for the retro-aldol reaction to occur.141 
The general mechanism for the retro-aldol reaction is shown in Scheme 3:17. This unwanted side 
reaction, would cause a carbon-carbon bond to break (between the α- and β-carbon), normally 
resulting in two separate molecules, one with an aldehyde functionality (resulting from the hydroxyl 
fraction) and one with a ketone functionality.  
 
Scheme 3:17   General scheme for the retro-aldol reaction. 
However, with the cyclic structure of the β-hydroxy ketone 9, two separate fractions would not be 
obtained under the retro-aldol reaction, but rather an open chain structure with a ketone on the one 
side and an aldehyde on the other, as illustrated in Scheme 3:18. 
 
Scheme 3:18   Possible outcome of the unwanted retro-aldol reaction for the β-hydroxy ketone 9. 
With this in mind, acetic acid was included with the previously mentioned reagents to suppress this 
unwanted retro-aldol reaction.142  
Yoshikoshi and co-workers reported a possible mechanism for this organoselenium-mediated 
reductive cleavage; however, additional reports were also consulted for the specifics involved.142–145 
Scheme 3:19 depicts this mechanism for the specific system under discussion. The first step 
involved the in situ generation of a phenyl selenium anion, as a phenyl selenyl/borane complex 
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Na+[(PhSe)BH3], simplified to PhSe in the mechanism shown. The phenyl selenium anion was 
obtained by reducing diphenyl diselenide (PhSeSePH) with sodium borohydride. The resulting 
phenyl selenium anion (PhSe) then participated in a nucleophilic substitution at the α-carbon of the 
α,β-epoxyketone 8, to provide the corresponding β-hydroxy selenide. This was followed by a 
subsequent nucleophilic attack of the second phenyl selenium anion (PhSe) onto the selenium atom 
found on this β-hydroxy selenide. This led to the formation of the β-hydroxy enolate which readily 
converted into the more stable β-hydroxy ketone resonance structure 9.142 
 
Scheme 3:19   A possible mechanism for the reductive cleavage which yielded the β-hydroxy ketone 9.142  
After standard work-up and purification by column chromatography, the β-hydroxy ketone 9 was 
obtained in a yield of 63%, along with the regenerated diphenyl diselenide (PhSeSePH) which was 
recovered in a yield of 90%. Literature has stated that the recovered diphenyl diselenide 
(PhSeSePH) could be reused in future reactions;142 however, this has not been tested during the 
scope of this project. Under these conditions, only the desired product 9 was obtained, no enones 
(α,β-unsaturated ketones) or selenenylated ketone derivatives were observed as by-products. In 
addition, the unwanted retro-aldol product was also not observed.  
NMR spectra 17 and 18, located in Appendix 1 were used to characterize product 9. In the 1H NMR 
spectrum, a multiplet was observed at 4.18 – 4.10 ppm which represented the proton on the carbon 
attached to the hydroxyl group. This deshielding effect was due to the electronegativity of the 
attached oxygen atom. Compared to the spectrum of the corresponding α,β-epoxideketone 8, this 
proton appeared more downfield, as would be expected. The α,β-epoxideketone 8 is a 
conformationally rigid system, and even though it was also attached to an oxygen atom, the 
deshielding effect was less due to the added ring strain. In addition, a broad singlet was observed at 
3.09 ppm which corresponded to the proton of the hydroxyl group. In the 13C NMR spectrum, the 
carbonyl peak was observed at 210.75 ppm and the carbon atom attached to the hydroxyl group 
was observed at 69.68 ppm. The carbon adjacent to the hydroxyl group also appeared more 
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downfield compared to the spectrum of the corresponding α,β-epoxideketone 8, which was once 
again attributed to the ring strain of the epoxide moiety. All other proton and carbon peaks were 
accounted for, and NMR spectroscopic data was consisted with the values provided in literature.146  
In the next step we attempted the conversion of the β-hydroxy ketone 9 into the corresponding 
methanesulfonate derivative 10. 
 ATTEMPTED SYNTHESIS OF 3-OXOCYCLOHEXYL METHANESULFONATE 10 
The β-hydroxy ketone 9 was reacted with methanesulfonyl chloride along with triethylamine in the 
hopes of obtaining the corresponding electrophilic derivative 10 through a mesylation reaction, as 
illustrated in Scheme 3:20.147  
 
Scheme 3:20   Attempted mesylation reaction to obtain 10. 
Before standard work-up procedures were performed, TLC indicated a complete conversion of the 
β-hydroxy ketone 9 into a less polar compound. This outcome was expected, as the desired 
methanesulfonate derivative 10 would be less polar than the β-hydroxy ketone 9. In spite of this 
observation, neither the β-hydroxy ketone 9 nor the methanesulfonate derivative 10, or any other 
side-products were present in the flask after work-up and concentration under high vacuum. 
Although this baffled us initially, it was believed that the structure of the methanesulfonate derivative 
10 caused this compound to be highly volatile. If this was the case, then the formed product, as 
indicated by TLC could have been vaporized during the use of the rotary evaporator in combination 
with the high vacuum pump under concentration of the reaction residue. However, another possibility 
is that the formed product was lost in the aqueous layer during the work-up procedure. 
If the methanesulfonate derivative 10 were successfully isolated, the next step would have been a 
nucleophilic substitution reaction with sodium azide, during which the mesyl group would have acted 
as a leaving group to obtain the required β-azido ketone 11. The introduction of a different leaving 
group instead of the mesyl group was briefly considered and possible alternatives to counteract this 
volatility problem included either a tosyl or a triflate group. However, after examining the four-step 
procedure designed for the synthesis of the required azide 11, relatively low yields were obtained for 
the first two steps (66% for the epoxidation and 63% for the reductive cleavage). Furthermore, the 
mesylation attempted in the third step proved to be problematic as explained above. As a result, a 
literature search was conducted, and an alternative route was revealed in which the desired β-azido 
ketone 11 could be obtained in only one step. 
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3.2.2. SYNTHESIS OF AZIDE 11 IN ONE STEP 
 SYNTHESIS OF 3-AZIDOCYCLOHEXAN-1-ONE 11 
In this section, the one step transformation of the α,β-unsaturated ketone, 2-cyclohexen-1-one (11SM) 
into the β-azido ketone 11, as illustrated in Scheme 3:21, will be discussed.  
 
Scheme 3:21   General scheme for the synthesis of the β-azido ketone 11 in one step. 
Three different methods were explored for this intermolecular conjugate addition, also known as an 
example of an aza-Micheal reaction. The reaction conditions and results obtained for these three 
methods will be discussed below, and the characterization of the β-azido ketone 11 will follow.  
 
The first procedure explored for this conversion, involved the reaction of 2-cyclohexen-1-one (11SM) 
with sodium azide and acetic acid, in the presence of a Lewis base catalyst (Scheme 3:22).148 
 
Scheme 3:22   First attempted synthesis of azide 11 with NaN3. 
An azide source frequently used for this transformation is hydrazoic acid (HN3); however, HN3 is 
known to be a highly toxic and explosive compound.149 The present method therefore involved the 
in situ generation of HN3 through a disproportionation reaction between glacial acetic acid and 
sodium azide, as reported by Zhou and co-workers.148,150 The set-up of this reaction thus required 
the premixing of these two reagents, which generated the active hydrazoic acid nucleophile, HN3, 
along with sodium acetate as by-product. Subsequent addition of the α,β-unsaturated ketone (11SM), 
in the presence of a Lewis base catalyst, led to conjugate addition to form the β-azido ketone 11. 
The retention factor (Rf) values of the starting material, cyclohex-2-en-1-one (11SM) and the desired 
product, 3-azidocyclohexan-1-one (11) were very similar, irrespective of the mobile phase used. This 
made it very difficult to say for certain whether all the starting material was being consumed during 
the course of the reaction. To compensate for this, the reaction time was significantly increased 
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compared to the prescribed literature time, but it could still not be said with certainty whether the 
reaction was complete. In literature, the pure azido ketone was obtained within 6 hours, without any 
further purification; but in our hands, some starting material was still present even after running the 
reaction for 24 hours. After experimenting with different TLC stains, as well as various stain 
combinations, we found that staining the TLC plate with 10% triphenylphosphine in dichloromethane, 
followed by immediate staining with ninhidrin, selectively indicated the presence of a compound 
containing an azide functionality. 
After standard work-up and various purification attempts, the pure β-azido ketone 11 could 
unfortunately not be separated from the unreacted starting material, cyclohex-2-en-1-one (11SM). 
The same reaction was also attempted with pyridine as base instead of triethylamine, as literature 
reported this to be a compatible catalyst for this reaction.148 It was thought that the introduction of a 
bulkier base could help drive the reaction to completion, by positively influencing the activation of 
the unsaturated ketone. Unfortunately, the same problem was encountered as before. 
By combing the literature, we found another procedure for this transformation which required 
trimethylsilyl azide (TMSN3), along with a polystyrene-supported ammonium fluoride catalyst, namely 
Amberlite IRA900F.151  
 
The second attempt for this one step transformation, involved the in situ generation of a polymer-
supported organocatalyst, Amberlite IRA900N3, by reacting Amberlite IRA900F with TMSN3 under 
solvent free conditions (Scheme 3:23).151  
 
Scheme 3:23   Second attempted synthesis of azide 11 with Amberlite IRA900F and TMSN3. 
This procedure was reported by Vaccaro and co-workers in 2006, along with a possible 
mechanism.151 This mechanism, as applied to the specific system under discussion, can be seen in 
Scheme 3:24. This process initially involved an exchange reaction between a polystyrene-supported 
ammonium fluoride (Amberlite IRA900F) and trimethylsilyl azide (TMSN3) to form the corresponding 
Amberlite IRA900N3 organocatalyst. Thereafter, the azido anion which formed part of this newly 
generated organocatalyst, acted as a Lewis base and coordinated to the silicon atom on a second 
TMSN3 molecule. This resulted in a pentavalent azido-silicate species with a highly activated silicon-
nitrogen bond capable of reacting with the α,β-unsaturated ketone (11SM). After the conjugated 
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addition of the activated azide ion, the corresponding β-azido silyl enol ether derivative was obtained, 
which was readily converted into the more stable β-azido ketone 11. 
 
Scheme 3:24   Mechanism reported by Vaccaro and co-workers for the azidation of 11SM with amberlite IRA900F 
and TMSN3.151  
The active catalyst in this reaction (Amberlite IRA900N3), could be recovered and re-used (in up to 
five consecutive cycles) with no loss of efficiency.151 However, this was not tested during the scope 
of this project.  
To our dismay, this procedure led to the same problem as explained in the first attempted synthesis 
of the β-azido ketone 11, in which residual starting material, the α,β-unsaturated ketone (11SM), 
remained present even after a prolonged reaction time. When taking in to account the conversion 
and purification problems already explained, as well as the cost associated with the Amberlite 
IRA900F catalyst, a third procedure for this conversion was explored. 
 
The third attempt, based on a procedure published by Miller and co-workers, involved the reaction 
of the α,β-unsaturated ketone (11SM) with equimolar amounts of trimethylsilyl azide (TMSN3) and 
glacial acetic acid, in the presence of a tertiary amine catalyst (Scheme 3:25).152 TMSN3 is 
considered to be a safer azide transfer reagent compared to HN3 and NaN3.153  
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Scheme 3:25   Third attempt for the synthesis of azide 11 in one step with TMSN3. 
The reported mechanism152 of this procedure is similar to that explained in section 3.2.2.1.1 for the 
first attempt at this transformation. This procedure also involved the in situ generation of HN3 through 
a disproportionation reaction between glacial acetic acid and an azide source (in this case TMSN3). 
The set-up of this reaction therefore also required the premixing of these two reagents to yield the 
active azide nucleophile, HN3, along with trimethylsilyl acetate (TMSOAc) as byproduct. Subsequent 
addition of the α,β-unsaturated ketone 11SM in the presence of an amine catalyst, then led to 
conjugate addition to form the β-azido ketone 11. 
In literature, the crude reaction mixture was directly applied to a silica plug and eluted with a solution 
of Hexane: EtOAc, 55:45.152 During various attempts to obtain the pure product, the solvent was 
removed by evaporation and the crude mixture was dry loaded onto a silica column. Purification was 
attempted with varying gradients of Hexane: EtOAc, 95:5 – 50:50. Even under these varied 
purification conditions, the same problem was encountered as in the first two attempts for this 
transformation. In a subsequent attempt, the reaction time was significantly increased (72 hours), 
but residual starting material was still detected. The desired product, azidocyclohexan-1-one 11, 
could still not be separated from the unreacted starting material, cyclohex-2-en-1-one (11SM). 
Evaluation by way of NMR spectroscopy showed a 5:1 ratio of the product, 3-azidocyclohexan-1-
one 11 to residual starting material, cyclohex-2-en-1-one (11SM), under these conditions.  
The same reaction was carried out at 30 °C (instead of room temperature) with a slightly higher 
equivalent of Et3N (0.35 equiv.) and stirred for 24 hours (instead of 72 hours). We hoped that a slight 
increase in the temperature and in the amount of Lewis base used, would improve the conversion 
by driving the reaction to completion. Unfortunately, we obtained an even worse conversion, in which 
only a 2:1 ratio of product to unreacted starting material was observed (determined from NMR 
spectra). From these results it is clear that this is a very slow reaction. In our hands the temperature 
(note that we only attempted a slight increase) or catalyst amount did not significantly influence the 
conversion, but a long reaction time is a critical factor as the 5:1 ratio was obtained when running 
the reaction for 72 hours. 
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NMR spectra 19 and 20, found in Appendix 1, were used to characterize the β-azido ketone 11. Note 
that the NMR spectra under discussion concerned the crude spectra of the 5:1 mixture of product 
11 to the starting material 11SM. 
 
The noteworthy peaks which resulted due to the residual starting material (11SM) will be discussed 
first for each spectrum, followed by the peaks for the desired product 11. 
In the 1H NMR spectrum, a significant peak indicating the presence of the starting material 11SM was 
observed as a multiplet at 6.99 – 6.95 ppm. This peak represented the proton of the β-carbon (the 
alkene carbon furthest away from the carbonyl functionality). A second multiplet was observed at 
6.01 – 5.97 ppm due to the proton attached to the α-carbon (the alkene carbon adjacent to the 
carbonyl group). Both of these protons were present at such high chemical shift values due to the 
anisotropy of the adjacent double bond. In the same 1H NMR spectrum, a notable peak of the desired 
product 11 was observed as a multiplet at 3.90 – 3.84 ppm. This peak corresponded to the proton 
of the β-carbon attached to the nitrogen atom (of the azide moiety).100 The chemical shift of the 
proton of the β-carbon moved more upfield compared to the spectrum of 11SM. This proton appeared 
slightly more shielded due to the absence of the double bond, but still at a relatively high chemical 
shift value due to the electronegativity of the attached nitrogen atom.  
In the 13C NMR spectrum, a peak of the starting material 11SM appeared at 199.78 ppm which 
represented the carbonyl carbon. In addition, two peaks were observed at 150.74 ppm and 129.97 
ppm. These two peaks represented the β-carbon (the alkene carbon furthest away from the carbonyl 
functionality) and the α-carbon (the alkene carbon adjacent to the carbonyl group), respectively. In 
the same 13C NMR spectrum, the carbonyl carbon of the desired product 11 was observed at 207.55 
ppm. Another noteworthy peak of the desired product 11 was observed at 59.61 ppm. This peak 
corresponded to the β-carbon attached to the azide functionality.100 This slight downfield shift 
observed for the carbonyl carbon peak was expected as the electron density around conjugated 
carbonyl carbon nuclei (as found in 11SM), are known to be more than the electron density around 
saturated carbonyl carbon nuclei (as found in 11). This means that the conjugated carbonyl carbon 
nucleus (11SM) would appear more upfield.154 All other proton and carbon atoms for both 11SM and 
11 were accounted for. The NMR spectroscopic data was also in accordance with previously 
reported spectra.151,152 
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The NMR spectroscopic results confirmed the successful formation of the β-azido ketone 11; 
unfortunately, due to the purification problems encountered, the conversion from cyclohex-2-en-1-
one (11SM) into 3-azidocyclohexan-1-one 11 could not be quantified. It was therefore decided that 
the crude 3-azidocyclohexan-1-one 11 would be used directly in the next step. This was possible 
because the residual 2-cyclohexen-1-one (11SM) would not interfere with the following step, as it had 
no functionalities that could be utilized in the click reaction.  
 SYNTHESIS OF 3-(4-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-ONE 12 
As mentioned above, the crude β-azido ketone 11 still containing residual α,β-unsaturated ketone 
11SM was subsequently subjected to a copper-mediated click reaction to obtain the corresponding 
1,4-disubstituted triazole 12.  
In a further attempt to quantify the conversion of the α,β-unsaturated ketone 11SM into the β-azido 
ketone 11, two of the three azidation methods were subjected to the subsequent copper-mediated 
click reaction. The yields obtained for triazole 12 was therefore calculated over two steps, based on 
cyclohex-2-en-1-one 11SM. The two azidation methods chosen, were discussed in section 3.2.2.1.1 
and 3.2.2.1.3. The method which involved the use of the organocatalyst (Amberlite IRA900F) was 
not explored further as this specific catalyst was a more expensive reagent than needed during the 
other two methods. Another disadvantage of the method utilizing Amberlite IRA900F, was the 
appearance of an additional spot (as observed by TLC) which indicated the formation of an unwanted 
side-product. The formation of additional side-products was not observed in the two methods chosen 
for further investigation.  
The CuAAC conditions optimized for Scaffold A, as discussed in section 3.1.1.3, was used to obtain 
the 1,4-disubstituted triazole 12. Seeing that the conditions for the CuAAC reaction following these 
two aza-Micheal reactions were identical, the yields obtained could therefore allow us to compare 
the two azidation procedures. The reaction conditions and results obtained during the synthesis of 
12 with these two procedures will be discussed below, and the characterization of the 1,4-
disubstituted 1,2,3-triazole 12 will follow.  
 FIRST SYNTHESIS OF 3-(4-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-ONE 12 
In the first method investigated for the synthesis of the 1,4-disubstituted triazole 12, the α,β-
unsaturated ketone 11SM was converted into the β-azido ketone 11 by using the sodium azide 
procedure described in section 3.2.2.1.1. The inseparable mixture was then reacted with the chosen 
alkyne, 1-heptyne, under the optimized copper-mediated click reaction conditions (copper(II) 
acetate, MeOH: H2O in a 2:1 ratio, 30 °C, Scheme 3:26Scheme 3:26   First synthesis of the 1,4-
disubstituted triazole 12, using sodium azide for the aza-Micheal reaction.). After standard work-up 
and purification by flash chromatography, the pure 1,4-disubstituted triazole 12 was obtained in a 
yield of 35%, based on cyclohex-2-en-1-one 11SM.  
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Scheme 3:26   First synthesis of the 1,4-disubstituted triazole 12, using sodium azide for the aza-Micheal 
reaction. 
 SECOND SYNTHESIS OF 3-(4-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-ONE 
12 
In the second method investigated for the synthesis of the 1,4-disubstituted triazole 12, the α,β-
unsaturated ketone 11SM was converted into the β-azido ketone 11 by using the trimethylsilyl azide 
procedure described in section 3.2.2.1.3. The inseparable mixture was subsequently subjected to a 
CuAAC reaction with the chosen alkyne, 1-heptyne, under the optimized copper-mediated click 
reaction conditions (copper(II) acetate, MeOH: H2O in a 2:1 ratio, 30 °C, Scheme 3:27). After 
standard work-up and purification by column chromatography, the pure 1,4-disubstituted triazole 12 
was obtained in a slightly improved yield of 38%, based on cyclohex-2-en-1-one 11SM. 
 
Scheme 3:27   Second synthesis of the 1,4-disubstituted triazole 12, using trimethylsilyl azide for the aza-
Micheal reaction. 
By comparing these two procedures, a slightly better yield was obtained when using trimethyl azide 
compared to the sodium azide method. It should be acknowledged that when working on such a 
small scale (cyclohex-2-en-1-one: 0.3 g), minor changes to the product mass could have a significant 
influence on the yield obtained. The product mass could have been influenced during various stages 
in the reaction, including the work-up and purification steps. When considering all of these factors, 
no definitive conclusion can be drawn regarding which one of these two methods were superior. 
The characterization of 12 was achieved by studying the NMR spectra 21 and 22, located in 
Appendix 1.  
In the 1H NMR spectrum, a singlet was observed at 7.27 ppm, which represented the proton of the 
unsubstituted carbon of the triazole ring. In addition, a multiplet was seen at 4.83 – 4.73 ppm which 
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corresponded to the proton of the carbon attached to the nitrogen atom (of the newly formed triazole 
ring). This proton atom appeared more downfield compared to the spectrum of 11 (which contained 
the azide functionality). The higher chemical shift value observed for 12 could be a result of the 
magnetic anisotropy induced by the nearby triazole ring causing this proton in 12 to appear more 
deshielded. All other proton atoms were accounted for. 
In the 13C NMR spectrum, a peak was observed at 206.82 ppm which represented the carbonyl 
carbon. In addition, two peaks were seen at 148.58 ppm and 119.12 ppm, which were assigned to 
the two triazole carbon atoms, with the higher chemical shift value resulting from the substituted 
carbon in the triazole ring. Another noteworthy peak was observed at 58.74 ppm which represented 
the proton of the carbon attached to the nitrogen atom (of the newly formed triazole ring). This carbon 
appeared slightly downfield compared to the spectrum of 11 (which contained the azide 
functionality). The higher chemical shift value for 12 could once again be attributed to the magnetic 
anisotropy induced by the nearby triazole ring causing this carbon in 12 to appear more deshielded. 
All other carbon atoms were accounted for. Compound 12 was also characterized by examining 
Mass Spectrum 5 located in Appendix 1. The mass spectroscopic result of 236.1768 amu was in 
agreement with the calculated value of 236.1763 amu, further confirming the success of this reaction. 
As previously explained, we assumed that the CuAAC reaction provided the 1,4-regioisomer due to 
substantial literature preference for this transformation. However, two-dimensional NMR 
spectroscopy experiments are recommended for future attempts at this synthesis, to confirm this 
assumption. With the 1,4-disubstituted triazole 12 in hand, sights were set on the synthesis of the 
1,5-disubstituted triazole 13. 
3.2.4. SYNTHESIS OF 3-(5-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-ONE 13 
During the synthesis of the 1,5-disubstituted triazole 13, the α,β-unsaturated ketone 11SM was 
converted into the β-azido ketone 11 by using the sodium azide procedure described in section 
3.2.2.1.1. The two azidation procedures used during the synthesis of the 1,4-disubstituted triazole 
12 provided similar yields, but this specific method was chosen because sodium azide is considered 
to be a safer and more stable azide source and was readily available.153  
The inseparable mixture was subsequently reacted with the chosen alkyne, 1-heptyne, along with 
the Cp*RuCl(COD) catalyst under the optimized RuAAC reaction conditions, as discussed in Section 
3.1.4. The route followed during the synthesis of the 1,5-disubstituted triazole 13 can be seen in 
Scheme 3:28. Working on the assumption that the CuAAC reaction provided the 1,4-regioisomer as 
mentioned above, the NMR spectra of the product obtained during the aforementioned reaction was 
compared to the spectra obtained during the RuAAC reaction. This allowed us to determine which 
of the two regioisomers was the major product in this reaction. 
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Scheme 3:28   Synthesis of the 1,5-disubstituted triazole 13. 
When comparing the results from the CuAAC and RuAAC reactions in Scaffold A, much lower yields 
were obtained for the RuAAC reaction, as the highest yield obtained for Scaffold A was only 63%. 
With this in mind, the low yield of 35% obtained over two steps during the synthesis of the 1,4-
disubstituted triazole 12 for Scaffold B under the CuAAC conditions, already suggested that the 
RuAAC reaction conditions would provide a very low yield for this system. When also taking into 
consideration the problems encountered during the conversion of the α,β-unsaturated ketone 11SM 
into the β-azido ketone 11 as already explained, a high yield was not predicted; however, the 
exclusive formation of the 1,5-disubstituted triazole 13 was expected.  
After standard work-up and attempted purification by column chromatography, the pure 1,5-
disubstituted triazole 13 could unfortunately not be successfully isolated. High-resolution mass 
spectrometry (HRMS) did however indicate the formation of a compound with the mass that was 
expected for 13, see Mass Spectrum 6 in Appendix 1. The expected accurate mass calculated for 
C13H22N3O+ was 236.1763 amu and the spectroscopic value obtained for the [M+H]+ ion was 
236.1770 amu. During purification, 38% of the inseparable azide mixture was recovered which 
indicated a very low conversion into the desired triazole 13. Note that this percentage recovered is 
an approximation as it was based on the theoretical yield for the β-azido ketone 11. A more polar 
compound, which was represented by a single spot on the TLC plate, was subsequently isolated in 
a very low yield of 5%. Evaluation by way of NMR spectroscopy showed that this was a mixture of 
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the desired 1,5-disubstituted triazole 13 and the regioisomer 1,4-disubstituted triazole 12 in a 2:1 
ratio, with compound 13 being the major product. This was definitely unexpected, as the 1,4-
regioisomer was not detected in Scaffold A under the RuAAC conditions. 
NMR spectra 23 and 24, found in Appendix 1, were used to characterize these two products 12 and 
13. The numbered structures of 12 and 13 are depicted in Figure 3:4. These atom numbers will be 
referred to during the NMR spectroscopy discussion below. 
 
Figure 3:4   Numbered structure of the 1,4- and 1,5-disubstituted triazoles 12 and 13. 
In the 1H NMR spectrum, all the peaks that were previously assigned to 12 (as discussed in section 
3.2.3.2.) were observed at the expected chemical shift values. All additional peaks corresponded to 
the 1,5-disubstituted triazole 13. These peaks included a singlet at 7.45 ppm which represented the 
proton of the unsubstituted triazole carbon (H8). This proton appeared slightly downfield compared 
to the proton of the unsubstituted carbon atom of the 1,4-disubstituted triazole 12. A similar trend 
was observed between the 1,4- and 1,5-disubstituted triazoles of Scaffold A. Another noteworthy 
peak was observed as a multiplet at 4.52 – 4.42 ppm which represented the proton of the carbon 
attached to the nitrogen atom (of the triazole ring, H3). This proton appeared more upfield when 
compared to the 1,4-disubstituted triazole 12. A similar trend was also observed between the 1,4- 
and 1,5-disubstituted triazoles of Scaffold A. As previously explained for Scaffold A, the side chain 
of the 1,5-disubstituted triazole 13, was adjacent to the nitrogen atom attached to the carbon of the 
proton under discussion. The conformation adopted by 13, due to this specific side chain position, 
might have altered the way in which the nitrogen lone pairs were able to interact, thus affecting the 
shift on the neighbouring carbon (C3) and the corresponding proton atom (H3). 
In the 13C NMR spectrum, all 13 peaks assigned to the 1,4-disubstituted triazole 12 (as discussed in 
section 3.2.3.2.) were observed at the expected chemical shift values. All additional peaks observed 
corresponded to the structure of the 1,5-disubstituted triazole 13. An important signal was observed 
at 207.16 ppm, which represented the carbonyl carbon (C1) of 13. Although the carbonyl carbons of 
12 and 13 appeared at similar chemical shift values, a clear distinction could be seen between these 
two peaks. The two triazole carbons (C7 and C8) of 13 was observed at 136.46 and 132.12 ppm, with 
the highest chemical shift once again being assigned to the substituted triazole carbon (C7). When 
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comparing the chemical shift of these two carbons to the corresponding carbon positions on 12, C7 
moved more downfield and C8 more upfield due to the side chain shift from C8 to C7 from 12 to 13. 
A similar trend was observed between the 1,4- and 1,5-disubstituted triazole of Scaffold A. In 
addition, a significant shift was also observed for the carbon atom connected to the nitrogen atom 
(of the triazole ring, C3) compared to compound 12. C3 was seen at 55.99 ppm for 13 and at 58.74 
ppm for 12. This upfield shift could once again be due to the specific position of the pentyl side chain 
and the resulting availability of the nitrogen lone pairs. For other minor chemical shift differences 
observed between these regioisomers, see Section 6.2.4. 
As mentioned in Section 2.4.1., the main aim of the synthesis of this scaffold was to assess the effect 
of the hydroxyl position by comparing the 1,4-disubsituted triazole analogues of Scaffold A with those 
of Scaffold B. The 1,5-disubsituted triazole 13 was explored as an additional analogue, but the low 
yield and selectivity observed during this synthesis redirected our focus on completing the synthesis 
of the 1,4-disubsituted triazole CBD analogue. 
The final reaction needed to complete the synthesis of Scaffold B, was a reduction in which the 
ketone functionality at the top of the cyclohexyl ring would be converted into a hydroxyl group. 
3.2.5. SYNTHESIS OF 3-(4-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-OL 14 
For the synthesis of the desired triazole CBD analogue of Scaffold B, the 1,4-disubstituted triazole 
12 was reacted with lithium aluminium hydride in tetrahydrofuran (Scheme 3:29).155 After standard 
work-up and purification, the pure compound 14 was obtained in a yield of 88%.  
 
Scheme 3:29   Reduction to obtain the 1,4-disubtituted triazole CBD analogue 14. 
NMR spectra 25 and 26, located in Appendix 1, were used to characterize the triazole CBD analogue 
14. In the 1H NMR spectrum, a singlet was observed at 7.27 ppm which corresponded to the proton 
of the unsubstituted carbon atom of the triazole ring. The chemical shift of the proton is identical to 
that found in the spectrum of 12. In addition, a multiplet was seen at 4.52 – 4.40 ppm which 
represented the proton of the carbon atom attached to the nitrogen atom (of the triazole ring). A 
second multiplet appeared at 3.86 – 3.73 ppm in the spectrum of 14 which was not present in the 
spectrum of 12. This multiplet represented the proton atom of the carbon attached to the oxygen 
atom (newly formed hydroxyl group). In addition, the proton of the hydroxyl group was observed as 
part of in overlapping multiplet at 2.75 – 2.41 ppm.  
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In the 13C NMR spectrum, two peaks were observed at 148.32 ppm and 118.39 ppm, which 
represented the substituted- and unsubstituted carbon atoms of the triazole ring, respectively. The 
carbon atom attached to the nitrogen atom (of the triazole ring) was also observed at 58.11 ppm. 
Compared to the spectrum of 12, the disappearance of the carbonyl peak was a good indication that 
14 was obtained successfully. In addition, a new peak was observed at 68.97 ppm, which 
represented the carbon attached to the oxygen atom (newly formed hydroxyl group). The 13C NMR 
spectrum obtained after purification also suggested that the product obtain was not a mixture of 
diastereomers, but rather one diastereomer with its mirror image. Only slight traces of the other 
diastereomer was visible in the 13C NMR spectrum. All other proton and carbon atoms were 
accounted for.  
After successfully synthesizing the 1,4-disubstituted triazole 14 aimed for in Scaffold B (with the 
hydroxyl group in the same position as the methyl group on the structure of CBD), the synthesis of 
Scaffold C was investigated.  
3.3. SYNTHESIS OF SCAFFOLD C 
As explained in the ligand design of Scaffold C, three changes were made in this system compared 
to Scaffold A and B. These differences included the introduction of stereochemistry on the cyclohexyl 
ring, an additional isopropyl substituent, as well as a methyl group at the top of the cyclohexyl ring 
instead of the hydroxyl group. After searching for possible starting materials which would inherently 
consist of these main pharmacophoric groups, we came across (1R,2S,5R)-2-Isopropyl-5-
methylcyclohexanol, ()-menthol. Two different routes were then set out for this system to obtain two 
enantiomeric azides which could provide two different chiral triazole CBD analogues as depicted in 
Scheme 3:30. To obtain the one azide, the chosen starting material, ()-menthol, would be subjected 
to a mesylation reaction to obtain the methanesulfonate derivative 15. Compound 15 would then 
subsequently be transformed into the corresponding azide 16 through a nucleophilic substitution 
reaction. This nucleophilic substitution reaction would involve an inversion of the stereochemical 
configuration at the carbon connected to the azide moiety. To obtain the enantiomer of 16, ()-
menthol would then be subjected to a double inversion strategy. This will involve an Appel reaction 
to obtain 17, during which the first inversion would take place. Thereafter, a similar nucleophilic 
substitution reaction would be explored to convert 17 into the corresponding azide 18, which would 
once again involve an inversion of configuration. It should be noted that the axial and equatorial 
orientations of these compounds were confirmed by Sankararaman and co-workers by means of 
single crystal XRD data.156 Subjecting these two azides (16 and 18) to a CuAAC reaction with the 
chosen alkyne, 1-heptyne, would then provide two triazole analogues with opposite stereochemistry 
at the carbon attached to the triazole ring. Please note that the numbering used in the triazole 
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analogues of Scaffold C in the scheme below is based on the numbering of the corresponding azides. 
This was done to illustrate the different R and S conformations that will be obtained in the final 
analogues by using these diastereomeric azides.  
 
Scheme 3:30   The two routes set out for the synthesis of Scaffolds C. 
The synthesis of compounds based on Scaffold C therefore started with the formation of the 
methanesulfonate derivative 15. 
3.3.1. SYNTHESIS OF (1R,2S,5R)-2-ISOPROPYL-5-METHYLCYCLOHEXYL 
METHANESULFONATE 15 
The convenient starting material, ()-menthol, was converted into the corresponding 
methanesulfonate derivative 15, in the presence of methanesulfonyl chloride and triethylamine as 
illustrated in Scheme 3:31.156 After standard work-up and purification by flash chromatography, the 
pure product 15 was obtained in a good yield of 89%. 
 
Scheme 3:31   Mesylation reaction to obtain 15. 
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NMR spectra 27 and 28, located in Appendix 1, were used to characterize this compound. The 
numbered structures and chair conformation, which will be referred to during the NMR spectroscopy 
discussion, is depicted in Figure 3:5. Please note that these atom numbers are different to the 
numbering used when naming this compound. 
 
Figure 3:5   Numbered structure and chair conformation of 15. 
In the 1H NMR spectrum, a triplet of doublets, with coupling constant values of 10.9 Hz and 4.6 Hz, 
was observed at 4.55 ppm which represented the proton of the carbon adjacent to the methane 
sulfonate group (H1). This splitting pattern was expected. When the chair conformation of this 
cyclohexyl ring was examined, the isopropyl group was in an equatorial position. It is well known that 
the most stable chair conformation is one in which the largest group adopts an equatorial position. 
This therefore also meant that both the methyl group and methanesulfonyl group were in an 
equatorial position in the chair conformation of 15. When we considered the coupling to neighbouring 
proton nuclei, the axial proton under discussion (H1) coupled to the axial proton of the carbon 
attached to the isopropyl group (H2), as well as to the axial and equatorial protons of C6. The coupling 
of the two adjacent axial protons resulted in a triplet. This coupling was also responsible for the larger 
coupling constant of the two values reported above. The adjacent equatorial proton on C6, would 
then further split the triplet to form the triplet of doublets observed in this spectrum. This occurred 
because coupling between two axial protons are bigger than the coupling between an axial proton 
and an equatorial proton. Another noteworthy peak observed in the 1H NMR spectrum, was a sharp 
singlet at 3.00 ppm which was due to the three protons of the methyl group introduced by the 
methane sulfonate functionality (H11). In the 13C NMR spectrum, a deshielded peak was seen at 
83.55 ppm, which represented the carbon next to the methane sulfonate group (C1). In addition, a 
peak was seen at 42.39 ppm which was assigned to the carbon of the methyl group introduced by 
the methane sulfonate functionality (C11). Also note the presence of two separate peaks for the two 
methyl groups (C8 an C9) of the isopropyl substituent. Due to free rotation only one peak would be 
expected for these carbons; however, literature also reported two distinct peaks for this specific 
compound.156 All other relevant nuclei were accounted for, and the NMR spectroscopic data was 
consistent with literature.156  
The next step was converting this methanesulfonate derivative 15 into the corresponding azide 16. 
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3.3.2. SYNTHESIS OF (1S,2S,4R)-2-AZIDO-1-ISOPROPYL-4-METHYLCYCLOHEXANE 16 
The methanesulfonate derivative 15 was subsequently subjected to a nucleophilic substitution 
reaction with sodium azide to obtain the axial azide 16, as can be seen in Scheme 3:32. During a 
nucleophilic substitution reaction on a carbon consisting of stereochemistry, the nucleophile will 
attack from the opposite side than the attached group. During this reaction, with the methane 
sulfonate group in the front, the azide nucleophile will attack from the back, thereby expelling the 
methane sulfonate group as the leaving group. As already mentioned, the inversion of 
stereochemistry observed under these specific conditions was confirmed by Sankararaman and co-
workers.156 Considering that the proton of the carbon adjacent to the methane sulfonate group is a 
diastereotopic proton, the stereochemistry of this proton will influence the chemical shift and 
multiplicity of this proton. By comparing the spectroscopic results with that published by 
Sankararaman and co-workers we confirmed that the inversion of stereochemistry did indeed occur. 
After standard work-up and purification by column chromatography the pure compound 16 was 
obtained in a yield of 41%.  
 
Scheme 3:32   Nucleophilic substitution reaction with sodium azide to obtain the axial azide 16. 
Product 16 was characterized by studying the NMR spectra 29 and 30 as seen in Appendix 1. In the 
1H NMR spectrum, a multiplet was seen at 3.99 – 3.96 ppm which represented the proton of the 
carbon adjacent to the nitrogen atom of the azide functionality. Contrary to the 1H spectrum of 15, 
this peak appeared less resolved and was therefore assigned as a multiplet. It is interesting to note 
that this proton moved slightly upfield in comparison to the methanesulfonate derivative 15. The 
disappearance of the singlet at 3.00 ppm, which corresponded to the three protons of the methyl of 
the methane sulfonate group in the spectrum of 15, was also a good indication that the conversion 
was successful. In the 13C NMR spectrum, a slightly deshielded peak was present at 60.69 ppm, 
which represented the carbon next to the nitrogen atom of the azide group. The chemical shift of this 
carbon shifted upfield by approximately 20 ppm during this azide substitution. Once again, note 
should be taken of the disappearance of the peak at 42.39 ppm, which corresponded to the carbon 
of the methyl of the methane sulfonate group in the spectrum of 15. Based on examination of the 
13C NMR spectrum only the one diastereomer was obtained during this reaction. All other proton and 
carbon peaks were accounted for, and the NMR spectroscopic data was in agreement with 
previously reported spectra.156  
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With the (1S,2S,4R)-axial azide 16 in hand, the synthesis of the (1S,2R,4R)-equatorial azide 18 was 
explored. The first step of this endeavour involved an Appel reaction to obtain the axial chloride 17. 
3.3.3. SYNTHESIS OF (1S,2S,4R)-2-CHLORO-1-ISOPROPYL-4-METHYLCYCLOHEXANE 17 
Treatment of ()-menthol with triphenylphosphine and carbon tetrachloride (which also acted as the 
solvent for this reaction) gave the corresponding axial chloride 17 (Scheme 3:33).  
This transformation once again involved an inversion of stereochemistry, as reported by 
Sankararaman and co-workers.156 Upon completion of this reaction, the reaction mixture was cooled 
and the precipitated triphenylphosphine oxide was filtered off. The solvent was then removed under 
reduced pressure and the residue was purified by flash chromatography to obtain the pure axial 
chloride 17 in a yield of 45%. 
 
Scheme 3:33 Appel reaction to obtain the axial chloride 17. 
The mechanism involved in this transformation as applied to this specific system is depicted in 
Scheme 3:34.157,158 This mechanism firstly involved the formation of a phosphonium cation by 
reacting triphenylphosphine with carbon tetrachloride. Subsequent deprotonation of the alcohol 
functionality of the starting material (()-menthol) led to the formation of an alkoxide. The resulting 
alkoxide then participated in a nucleophilic displacement with the phosphonium cation during which 
a chloride anion then acted as a leaving group. The resulting oxyphosphonium intermediate then 
took part in a nucleophilic substitution reaction (SN2) to produce the desired axial chloride 17. During 
this reaction, the previously expelled chloride anion acted as the nucleophile and triphenylphosphine 
oxide was formed as by-product. Note that an inversion of configuration occurred during the 
nucleophilic substitution reaction and that the formation of the strong P=O double bond was the 
driving force behind this reaction.157,158 
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Scheme 3:34   Mechanism for Appel reaction applied to this specific system.157,158 
NMR spectra 31 and 32, located in Appendix 1, were examined during the characterization of 
compound 17. In the 1H NMR spectrum, a multiplet was observed at 4.58 – 4.46 ppm which 
represented the proton of the carbon adjacent to the chloride atom. Furthermore, another multiplet 
was observed at 2.10 – 2.02 ppm which corresponded to the proton of the carbon attached to the 
isopropyl group. In the 13C NMR spectrum, a slightly deshielded peak was seen at 63.58 ppm, which 
represented the carbon next to the chloride atom. In addition, two peaks appeared at 49.12 and 
43.44 ppm, which corresponded to the carbon attached to the isopropyl group and the carbon in 
between the methyl substituent and the chloride substituent, respectively. As was the case for 
compound 15, two separate peaks were seen for the two methyl groups of the isopropyl substituent 
on compound 17. Literature did however also report two distinct peaks for this specific compound.156 
All other proton and carbon atoms were noted, and the NMR spectroscopic data was in accordance 
with literature.156 
The next step involved the attempted synthesis of the equatorial azide 18, through a similar 
nucleophilic substitution that was used to obtain the axial azide 16. 
3.3.4. ATTEMPTED SYNTHESIS OF (1S,2R,4R)-2-AZIDO-1-ISOPROPYL-4-
METHYLCYCLOHEXANE 18 
The axial chloride 17 was subsequently reacted with sodium azide in dimethyl sulfoxide, as seen in 
Scheme 3:35. Unfortunately, the formation of the desired equatorial azide 18 was not observed 
under these conditions.  
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Scheme 3:35   Attempted synthesis of the equatorial azide 18. 
The reaction conditions attempted for this conversion was identical to the conditions used during the 
SN2 reaction to obtain the axial azide 16. The only differences between this transformation and the 
successfully formed axial azide 16, was the conformation of the carbon involved in the substitution 
reaction and the specific leaving group attached to this carbon atom. Although a chloride is 
considered to be a good leaving group, the approach of this SN2 reaction might have been hindered 
by the specific conformation of compound 17. 
With these problems encountered during the synthesis of the equatorial azide 18, and the time 
allocated to this project, it was decided to rather focus our attention on obtaining one of the triazole 
CBD analogues aimed for during the synthesis of Scaffold C. With one of these analogues in hand, 
biological results could indicate whether these compounds show any potential, and if continued 
investigation on this route would be recommended. 
The final step for Scaffold C therefore involved a CuAAC reaction with the axial azide 16. 
3.3.5. SYNTHESIS OF 1-[(1S,2S,5R)-2-ISOPROPYL-5-METHYLCYCLOHEXYL]-4-PENTYL-
1H-1,2,3-TRIAZOLE 19 
The axial azide 16 was subsequently reacted with the chosen alkyne, 1-heptyne, under the optimized 
CuAAC reaction conditions as determined for Scaffold A (Scheme 3:36). As explained previously, it 
was assumed that the 1,4-regioisomer was obtained under the CuAAC reaction conditions due to 
overwhelming literature preference for this product; however, future two-dimensional NMR 
spectroscopy experiments are recommended for confirmation of this assumption. After standard 
work-up and purification by column chromatography, the pure 1,4-disubstituted triazole 19 was 
obtained in a rather disappointing yield of 21%.  
 
Scheme 3:36   CuAAC reaction to form the 1,4-disubstituted triazole 19. 
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This poor yield was once again due to incomplete consumption of both starting materials, which were 
successfully salvaged during the purification step. This low yield suggested that the optimised 
CuAAC reaction conditions, as based on the structures of Scaffold A, might not have been the ideal 
set of conditions for this system. Further optimization of the CuAAC reaction conditions for Scaffold 
C would therefore be recommended, but did not fall under the scope of this project due to a lack of 
time. 
NMR spectra 33 and 34, located in Appendix 1, were used to characterize product 19. In the 1H NMR 
spectrum, a sharp singlet was observed in the aromatic region at 7.33 ppm which represented the 
proton of the unsubstituted carbon atom in the triazole ring. When comparing this spectrum to that 
of compounds (±)-3 and 14, the 1,4-disubstituted triazoles of Scaffold A and B, the chemical shift of 
this triazole ring proton appeared in a similar region. Furthermore, a multiplet was seen at 5.02 – 
4.95 ppm which corresponded to the proton attached to the nitrogen atom (of the newly formed 
triazole ring). When comparing this spectrum to that of compound 16, the corresponding azide, this 
peak shifted more downfield due to the ring current provided by the adjacent triazole ring.  
In the 13C NMR spectrum, one peak was observed at a high chemical shift value of 121.68 ppm. This 
peak represented the unsubstituted carbon atom of the triazole ring. When once again comparing 
this peak to the spectrum of compounds (±)-3 and 14, the 1,4-disubstituted triazoles of Scaffold A 
and B, the chemical shift of this unsubstituted carbon atom of the triazole ring was very similar. In 
the 13C NMR spectrum, we would however expect to see another peak at an even higher chemical 
shift value corresponding to the substituted carbon atom of the triazole ring. The absence of this 
peak could once again be the result of an inadequate acquisition time during the NMR spectroscopy 
experiment based on the concentration of this specific NMR sample. A similar case was observed 
in the 13C NMR spectrum of 1,4,5-disubstituted triazole (±)-7 in Scaffold A, as this is a problem often 
encountered for quaternary carbons with no protons attached. Furthermore, in the 13C NMR 
spectrum, a peak was seen at 58.97 ppm, which represented the carbon adjacent to the nitrogen 
atom (of the newly formed triazole ring). When comparing this spectrum to that of compound 16, the 
corresponding azide, this peak shifted slightly downfield due to the ring current provided by the 
triazole ring. It was also interesting to note the two methyl groups of the isopropyl substituent of 
compound 19. As already mentioned, although only one peak would be expected for these carbon 
atoms, two separate peaks were observed for all the precursors of this scaffold. The chemical shift 
values for these two carbon atoms were however much closer together than observed for compound 
15 and 17.   
In addition, HRMS results also indicated the successful formation of this triazole CBD analogue 19, 
see Mass Spectrum 7 in Appendix 1. The spectroscopic result obtained, 278.2600 amu, correlated 
well with the calculated value of 278.2596 amu. Considering the chirality of product 19, further 
characterization will entail various optical measurements by way of spectroscopic methods such as 
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optical rotation and perhaps even circular dichroism spectroscopy; however, this was outside the 
scope of the current study.   
During the synthesis of the compounds based on Scaffold C, a readily available starting material, 
()-menthol, was converted to the enantiomerically pure 1,4-disubstituted triazole 19 in only three 
steps. In addition, the synthesis of the corresponding enantiomer, as well as the two 1,5-disubstituted 
triazoles were set up for future completion.  
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BIOLOGICAL EVALUATION 
Two sets of the synthesized triazole CBD analogues were sent for biological tests to determine 
whether these compounds exhibit anti-cancer activity. The first set was sent to the Council for 
Scientific and Industrial Research (CSIR) in Pretoria, South Africa; and the second set was sent to 
the New Mexico Institute of Mining and Technology (NMT) in Socorro, the United States of America. 
The test conducted at NMT was done by the research group of Dr Snezna Rogelj. Please note that 
these biological tests were independently conducted at the two institutes mentioned, and that we 
were not involved in the testing procedures. The method used for each set, as well as the results 
obtained will be discussed separately.  
4.1. BIOLOGICAL TEST CONDUCTED AT THE CSIR 
This set of evaluations were done by Dr Kabamba B. (Alex) Alexandre and Dr Asongwe Lionel 
Tantoh from the CSIR in Pretoria. In preparation for these biological tests, the samples were exposed 
to MCF-7 cells (a breast cancer cell line) for four days. The detailed method is discussed below.  
 TESTING METHOD USED AT THE CSIR 
The synthetic molecule array printing solution was prepared according to the method reported by 
Erfle and Pepperkok in 2005.159 This process began by dispensing 5 μL of each sample into a 96 
well plate, followed by the addition of 18 μL of the encapsulation mixture to the respective samples. 
The encapsulated compounds were then loaded from the 96 well plate, by capillary action using 
micro-fluidic filling plates, into 330 μm diameter elements. During this step, each encapsulated 
compound was loaded into a different element which was pre-mounted onto a printing plate.  
Microarray printing was subsequently performed with a custom-built printer. This was achieved by 
mounting the printing plates onto a custom-built Z axis movable head. An array of the individual 
compounds was then spotted from the printing plates onto a poly-L-Lysine (PLL) modified glass slip 
array using a 2.5 second contact time. This array printing process was done under a constant stream 
of humidified air. The printed array was then stored in an airtight desiccator in the absence of light. 
The next step involved the diffusion of the printed compounds into target cells. This was done by 
transferring the printed array glass slip from the desiccator into a tissue culture dish, followed by 
subsequent culture of MCF-7 breast cancer cells in the same dish. The MCF-7 cells were cultured 
in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum at a concentration 
of 1.5 × 106 cells / 10 mL. This was done over four days while keeping the temperature constant at 
37 °C; and under a 5% carbon dioxide concentration to maintain a constant pH. These conditions 
were chosen to mimic the cell’s natural environment. The printed array glass slip containing the 
MCF-7 cells was subsequently treated with immunofluorescence, mounted on a microtiter plate 
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dummy for imaging, and imaged under consecutive acquisitions with a point scanner confocal reader 
(Cytation 3 imaging reader) to provide the required microarray images. During the microarray 
acquisition with the imaging reader, three channels were used: the spots were imaged in the red 
channel (Sulforhodamine B, 568 nm), the actin cytoskeleton in the green channel (Phalloidin, 488 
nm) and the DNA in the blue channel (DAPI, 408 nm). 
 RESULTS OBTAINED AGAINST THE MCF-7 CELL LINE 
Two independent experiments were carried out according to the method described. Please note that 
the triazole CBD analogues of this project were tested with other samples sent from Stellenbosch 
University, along with various reference compounds. The figure below indicates the location on the 
compound array of the samples sent from Stellenbosch University, which were 24 in total. Out of the 
24 samples, 7 compounds, marked on position 16-22, were the CBD triazole analogues generated 
as a result of this project (Figure 4:1 A). This figure further depicts the images obtained from the two 
independent experiments conducted on these samples (Figure 4:1 B).  
 
 
 
 
 
 
 
 
 
A summary of the seven CBD analogues submitted for testing can be seen in Figure 4:2 below.  
 
Figure 4:2   Structures of the seven compounds sent for testing. 
 
A B 
Sample labels: 
16: (±)-2 (Scaffold A) 
17: (±)-3 (Scaffold A) 
18: (±)-4 (Scaffold A) 
19: 12 (Scaffold B) 
20: 14 (Scaffold B) 
21: 19 (Scaffold C) 
22: (±)-7 (Scaffold A) 
Figure 4:1   A: Location of compounds 16-22 on array; B: The two independent experiments.  
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The images (TIFF files) obtained from these two experiments were then processed using ImageJ 
v1.44 and Array-pro analyzer v6.3 software, and subsequently analyzed with Persomics and 
CellProfiler algorithms. In addition, data quantification was done using Microsoft Excel and the 
results are illustrated in Figure 4:3 below. The activity was measured relative to untreated MCF-7 
cells, and subsequently quantified in terms of the percentage cell count normalized against the 
untreated MCF-7 cells. The final values as seen below resulted from averaging the two independent 
experiments that were conducted.  The compounds pertaining to this project, are shown in blue, and 
some reference samples3 with anticancer activity are shown in grey. All irrelevant samples were 
removed for simplification. 
 
Figure 4:3   Graph representing the % cell count of the triazole CBD analogues and various reference samples. 
Unfortunately, most of these analogues did not show any significant activity against the MCF-7 cell 
line. For most of the triazole CBD analogues the percentage cell count obtained was more than 
100%. This indicates that these compounds did not inhibit the growth of the cancer cells, but 
promoted proliferation instead. Nevertheless, a speculative comparison was drawn between the 
structure of these analogues through interpretation of the graph illustrated in Figure 4:3. When 
comparing the triazole analogues associated with Scaffold A, the 1,4-disubstituted triazole analogue 
(±)-3 had a lower % cell count than the 1,5-disubstituted triazole analogue (±)-4. Disappointingly, the 
1,4,5-trisubstituted triazole analogue (±)-7 was not detected (see position 22 in Figure 4:1 A), which 
means that the cells on this spot could not be counted. When further comparing the compounds for 
Scaffold B and Scaffold C to the compounds of Scaffold A, the ketone functionalized 1,4-
disubstituted triazole analogue 12, of Scaffold B, had the highest % cell count of all the analogues 
tested against the MCF-7 cells. However, the hydroxyl functionalized 1,4-disubstituted triazole 
                                               
 
3 Structures of these reference samples with anticancer activity are illustrated in Appendix 1. 
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analogue 14 provided a slightly lower % cell count compared to 12 and also had a lower % cell count 
than the 1,5-disubstituted triazole analogue (±)-4. In addition, the analogue associated with Scaffold 
C (19) containing the additional functional group on the cyclohexyl ring, had a lower % cell count 
than the compounds of Scaffold B and had a similar % cell count than (±)-3.  
As previously mentioned, none of these results were particularly appealing, but to our surprise, the 
only compound which showed some potentially interesting activity against the MCF-7 cell line was 
the phenyl side chain triazole analogue (±)-2 of Scaffold A. Although this compound was initially 
synthesized as a test compound for the triazole formation, this was the only compound with a % cell 
count below 100 (91.6%). If we consider the reference compounds used during this evaluation, it is 
interesting to note that compound (±)-2 provided a better % cell count value than Gefitinib (a kinase 
inhibitor drug used in the treatment of certain breast cancers).160 After interpreting these results, we 
can conclude that the replacement of the fatty acid-inspired tails (pentyl side chain) of our 
compounds with aromatic groups should rather be investigated in future CBD analogues. 
This same set of compounds was then sent to NMT for additional biological tests. 
4.2. BIOLOGICAL TEST CONDUCTED AT NMT 
These evaluations were performed in Dr Snezna Rogelj’s group at NMT by the following students, 
Maximo Santarosa, Danielle Turner and Shishir Acharya. During these biological tests, the samples 
were exposed to HeLa cells, and the anti-bacterial, anti-trypanosomal and anti-fungal toxicity of 
these seven compounds were assessed.   
The anti-bacterial toxicity was determined through in-vitro screening of MRSA (Gram-positive), as 
well as A. baumannii (Gram-negative) bacterial cultures. The anti-fungal toxicity was also evaluated 
through in-vitro screening of a C. albicans yeast culture; and additionally, the anti-trypanosomal 
toxicity was investigated through in-vitro screening of a T.cruzi epimastigotes culture. The anti-
bacterial, anti-fungal and anti-trypanosomal activity of the triazole CBD analogues was then 
assessed by using a tetrazolium dye (MTT) colorimetric assay. Unfortunately, during all three of 
these screenings no activity was observed below a concentration of 100 μM of the triazole CBD 
analogues. An additional assay was also performed to determine whether these compounds induce 
shedding of L-selection from human polymorphonuclear leukocytes (PMNs), which would indicate if 
these compounds have potential as an immunosuppressive. Unfortunately, no induction was 
observed from human neutrophils and lymphocytes. 
The biological evaluation that was most of interest to us, was the anti-proliferative activity of these 
compounds against the HeLa cell line. 
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 TESTING METHOD USED AT THE NMT 
This process started with the trypsinization of the HeLa cell line. The resulting trypsinized cells were 
subsequently plated on a 96-well microtiter plate. Thereafter, the cells were cultured at 37 °C for 24 
hours. The triazole CBD analogues were subsequently diluted to 100 mM in DMSO and added to 
the cultured cells at concentrations ranging from 0.004 to 100 µM. The next step involved a 48-hour 
incubation period in 200 µL of media. This was followed by the addition of 20 µL MTT reagent in 
serum free medium and an additional 2-hour incubation period. After the stipulated period, the media 
was removed and the newly formed formazan crystals were dissolved in 100 µL of DMSO. A plate 
reader was then used to measure the absorbance at 490 nm. Experiments were done in quadruplets.  
 RESULTS OBTAINED AGAINST THE HELA CELL LINE 
Out of the seven compounds illustrated in Figure 4:2 that were sent for testing, only two had an IC50 
value below 100 µM. The structures of these two compounds along with their determined IC50 values 
are illustrated in Figure 4:4. 
 
Figure 4:4   The two compounds that showed moderate activity against the HeLa cell line. 
It was interesting to compare the results from the CSIR, during which these analogues where tested 
against MCF-7 cells, to the results obtained from NMT, where these analogues were tested against 
HeLa cells. The phenyl side chain triazole analogue (±)-2 of Scaffold A was the only compound that 
showed activity against MCF-7 cells, but did not show any activity against the HeLa cells. In addition, 
the ketone functionalized 1,4-disubstituted triazole analogue 12 gave the least favourable result 
against MCF-7 cells, but showed the best activity against the HeLa cells with an IC50 value of 74.6 
μM. Finally, the analogue of Scaffold C (19) provided moderate results against both cancer cell lines 
compared to the other analogues tested.  
The complete absence of toxicity of these analogues below a concentration of 100 μM, as 
determined through the anti-bacterial, anti-trypanosomal and anti-fungal assays, is an initial 
indication that these compounds could be safe to use as potential drugs. Apart from the limitations 
of using a very small set of compounds for testing, the two sets of results obtained on different cancer 
cell lines can now be used to design new analogues with increased anti-cancer activity against the 
two cell lines that were tested. As a first step, the generation of more compounds should be a high 
priority – this will be important if further structure-activity relationships (SAR) are to be determined.  
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CONCLUDING REMARKS 
5.1. CONCLUSION 
In conclusion, this research project focused on the synthesis of CBD analogues with potential 
anticancer activity, in which the core structure was modified with a triazole moiety. To this end, three 
different systems (Scaffold A, B, and C) were synthesized with the help of copper- and ruthenium-
mediated click chemistry.  
The general structure of these analogues was systematically altered, with each alteration bringing 
us closer to the structure of CBD. The three pharmacophoric groups of importance in the synthesis 
of Scaffold A, was the cyclohexyl ring, the cyclohexanol group and the fatty acid-inspired tail. Most 
analogues aimed for throughout this project were small molecules lacking any UV-active groups, 
making the tracking of reactions by TLC very difficult. For this reason, an initial 1,4-disubstituted 
1,2,3-triazole compound was synthesized as a test reaction under Scaffold A, which contained an 
aromatic group, instead of the chosen lipophilic side-chain as mentioned above. This test reaction 
was conducted to monitor the triazole formation and the starting material consumption. After 
optimization of the copper- and ruthenium-mediated click reactions, the 1,4-, 1,5-, as well as the 
1,4,5-polysubstituted 1,2,3-triazole analogues of Scaffold A containing the chosen lipophilic side-
chain was successfully synthesized. The desired 1,4,5-trisubstituted 1,2,3-triazole analogue (±)-7 
was unfortunately obtained in a very low yield, and the selectivity of this reaction was not satisfactory. 
In this study, we attempted this synthesis with an internal alkyne containing a propargyl alcohol. The 
presence of this functionality is thought to provide the product with the propargyl alcohol in the 5-
position on the triazole ring as major product, but in our hands, this was not the case. Although these 
two regioisomers were successfully separated from each other, the ruthenium-mediated click 
reaction with the chosen internal alkyne requires further investigation.  
During the design of Scaffold B, the same three pharmacophoric groups were used as in Scaffold A. 
The alteration that was made was the position of the cyclohexanol group which was placed one atom 
further away from the triazole ring, to mimic the one cyclohexyl ring substituent on the structure of 
CBD. The synthesis of this system did however prove somewhat problematic, as neither the desired 
azide 11, nor the 1,5-disubstituted 1,2,3-triazole CBD analogue 13, could be isolated in a pure form. 
Nevertheless, the ketone functionalized 1,4-disubstituted 1,2,3-triazole CBD analogue 12 was 
successfully obtained by using the inseparable azide mixture, and this product was subsequently 
reduced to the desired hydroxyl functionalized 1,4-disubstituted 1,2,3-triazole CBD analogue 14.  
The general analogues designed for Scaffold C included an additional functional group on the 
cyclohexyl ring to mimic the second cyclohexyl ring substituent on the structure of CBD. ()-Menthol 
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was chosen as a convenient starting material which inherently provided the desired functional groups 
while also introducing stereochemistry into the system. Two routes were set out which involved either 
a single or a double inversion of stereochemistry, thereby providing two diastereomeric triazole CBD 
analogues. Although the double inversion strategy was not successful in our hands, one 1,4-
disubstituted 1,2,3-triazole CBD analogue, 19, was successfully synthesized by making use of the 
optimised copper-mediated click reaction.  
The analogues obtained were subsequently subjected to independent biological evaluations. Two 
sets of analogues were prepared and the anticancer activity was assessed against the MCF-7 cell 
line, as well as the HeLa cell line. None of the CBD triazole analogues of this study showed 
particularly appealing activity against the MCF-7 cell line. The 1,4,5-trisubstituted 1,2,3-triazole 
analogue (±)-7 of Scaffold A did unfortunately not provide an anti-proliferation value, as it was not 
detected on the plate during this evaluation. The 1,5-disubstituted 1,2,3-triazole analogue of Scaffold 
A provided a higher % cell count than the 1,4-disubstituted 1,2,3-triazole analogue of Scaffold A, 
suggesting that the 1,5-regioisomers should not be further explored for these analogues. To our 
surprise, the only compound which showed some potentially interesting activity, with a cell count of 
91.6%, was the test compound (±)-2 which contained an aromatic group on the triazole ring. When 
considering the activity results obtained against the HeLa cell line, two compounds had an IC50 value 
below 100 μM. The compound which gave the most promising result, with an IC50 value of 74.3 μM, 
was the ketone functionalized analogue 12 of Scaffold B, the compound obtained before reduction 
to the final cyclohexanol analogue 14. In addition, the biological results showed that Scaffold C is 
worth exploring, as the first analogue synthesized in Scaffold C, compound 19, provided moderate 
activity against the Hela cell line. 
These results provide valuable insight for the future design of triazole CBD analogues, as will be 
discussed in the next section. 
5.2. FUTURE WORK 
This section will systematically address improvements needed based on the conclusion, followed by 
additional suggestions for the future design of CBD analogues.   
When first considering Scaffold A, the low yield and lack of selectivity obtained during the synthesis 
of the 1,4,5-trisubstituted 1,2,3-triazole analogue (±)-7 must be addressed. An improved synthetic 
method is essential due to the inability to determine the anticancer activity of this analogue against 
the MCF-7 cell line during the course of the study. Obtaining these biological results will enable us 
to conclude whether the incorporation of the additional hydroxyl group onto the triazole ring is worth 
exploring in future triazole CBD analogues. Suggestions on how to improve the yield and selectivity 
for this analogue was provided in section 3.1.6, but a brief summery will be given here. One 
possibility is to use an internal alkyne containing a propargyl amine, as this functionality is known to 
Stellenbosch University https://scholar.sun.ac.za
Chapter 5 – Triazole CBD analogues – Concluding Remarks 
81 
 
promote the formation of the regioisomer in which the propargyl group is in the 5-position on the 
triazole ring.130 This route will however require additional steps to convert the amine into the desired 
hydroxyl group after the cycloaddition reaction. This could be achieved through an initial conversion 
to the primary amine which could subsequently be converted into the primary alcohol.134,135 A second 
option would be to use an internal alkyne containing the desired propargyl alcohol, as well as an 
electron-withdrawing group, for instance a ketone, on the opposite side of the triple bond. Internal 
alkynes containing an electron-withdrawing group are known to promote the formation of the 
regioisomer with the electron-withdrawing group in the 4-position on the triazole ring.130 This route 
would however also require an additional step to remove the ketone functionality through either a 
Clemmensen or a Wolff-Kishner reduction.136 The general scheme for the processes which would 
be involved when using the proposed internal alkynes is re-illustrated in Scheme 5:1 below.  
 
Scheme 5:1   Two options for improving the selectivity for the synthesis of (±)-7, using internal alkynes with 
either a propargyl amine or an electron-withdrawing group and a propargyl alcohol. 
Upon writing-up, a more efficient route for the synthesis of the axial azide 16 of Scaffold C, obtained 
with a single inversion of stereochemistry, was revealed. By using this route, ()-menthol can be 
converted into the axial azide 16 in only one step by using a derivation of the Mitsunobu reaction as 
depicted in Scheme 5:2.161  
 
Scheme 5:2   Alternative route for the synthesis of the axial azide 16. 
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In order to obtain the diastereomer of analogue 19 synthesized in Scaffold C, the double inversion 
strategy must be revisited. As discussed in the results section, this approach might have been 
hindered by the specific chair conformation of the chlorinated ()-menthol compound 17. One could 
consider the incorporation of a better leaving group onto the structure of ()-menthol, for instance a 
bromine atom, which could be achieved with the help of an Appel reaction using carbon tetrabromide. 
Alternatively, the synthesis of the brominated ()-menthol compound with inversion of 
stereochemistry, could be obtained by subjecting ()-menthol to a mesylation reaction, followed by 
a nucleophilic substitution reaction with lithium bromide. After optimization of the single and double 
inversion strategy of Scaffold C, these conditions could be directly applied to a different starting 
material, namely (+)-menthol. This additional scaffold would provide two analogues which would be 
enantiomers of the two diastereomers discussed above.   
When considering the biological results, improved activity against the MCF-7 cell line could involve 
the replacement of the fatty acid-inspired tail with aromatic groups. For improved activity against the 
HeLa cell line, the intentional incorporation of a ketone functionality onto the cyclohexyl ring, without 
the additional reduction step should be considered. In addition, the results obtained from this project 
show that Scaffold C is worth exploring as the first analogue synthesized in Scaffold C showed 
moderate activity against the HeLa cell line. 
Besides the suggestions made above, the design of future CBD analogues could include different 
heterocycles, apart from the 1,2,3-triazole moiety found at the core of the present analogues. A 
possible option would be to explore the formation of 3,5-disubstituted isoxazoles via a copper(I)-
mediated cycloaddition of terminal alkynes with nitrile oxides. This step-wise cycloaddition sequence 
also proceeds via a copper(I) acetylides intermediate as seen in the CuAAC reactions.106 The 
required nitrile oxide moiety could be obtained from the corresponding chlorinated aldoxime, as 
shown in Scheme 5:3.162  
 
Scheme 5:3   General scheme that would be involved in the synthesis of 3,5-disubstituted isozoles. 
Finally, the pharmacophoric groups of CBD could further be explored by wisely choosing readily 
available monoterpenes, similar to menthol, to be used as starting materials for the synthesis of 
novel analogues with improved functionalities on the cyclohexyl ring portion of the final analogues. 
Examples of monoterpenes that could be used include limonene, carvone, pinene and thymol.163 
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Figure 5:1 shows the structure of these possible starting materials, as well as the structure of CBD 
for comparison.   
 
Figure 5:1   Comparison between the structure of CBD and suggested monoterpenes that can be used as 
starting materials when designing future CBD analogues. 
The basic structure of limonene is similar to that of menthol with the exception of an additional double 
bond on the cyclohexyl ring. By using this methylcyclohexylidene, all the pharmacophoric groups 
found on the cyclohexyl ring of CBD could be incorporated into future analogues. Carvone could 
subsequently be explored as this could incorporate an additional carbonyl functionality onto the 
cyclohexyl ring of these analogues. The structure of pinene also contains the additional double bond 
on the cyclohexyl ring as seen in CBD. It could be interesting to see what effect the carbon bridge 
found in this bicyclic monoterpene might have on the anticancer activity of future analogues. The 
use of thymol, could also provide valuable insight on whether additional aromaticity on the outer 
structure would have any effect on the activity of these analogues.   
In summary, this study produced a small series of CBD analogues by making use of the “click” 
approach. These compounds subsequently provided valuable information regarding the structure-
activity relationships (SARs) relative to the MCF-7 and HeLa cell lines, thereby providing a solid 
foundation for the design of future heterocycle CBD analogues. As a final remark, it is recommended 
that the synthesis of novel analogues, based on the suggestions presented above, should be of high 
priority as this will provide access to much needed further SARs information.    
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 EXPERIMENTAL 
6.1. GENERAL INFORMATION 
Reaction glassware was dried by heating under a positive nitrogen pressure, or in an oven at 110 
°C for two hours. Furthermore, standard Schlenk techniques were used when needed. Reaction 
mixtures were heated by placing the reaction flask in a paraffin oil bath, set to the correct temperature 
on a magnetic stirrer hot plate. Solvents were removed in vacuo, by using a rotary evaporator 
followed by the use of a high vacuum pump at ca. 0.08 mm Hg, to remove trace amounts of residual 
solvent. 
All chemicals used in these experiments were purchased from Sigma Aldrich (Merck). Reaction 
solvents were dried over the appropriate drying agents and distilled under a positive nitrogen 
pressure. Tetrahydrofuran was distilled under nitrogen from sodium metal flakes, with 
benzophenone as an indicator. Dichloromethane and acetonitrile were distilled under nitrogen from 
calcium hydride, and ethanol was distilled from magnesium turnings and iodine. In addition, 
triethylamine was distilled under potassium hydroxide. Other reagents which required purification 
was purified according to standard procedures.  
Solvents used for chromatography (ethyl acetate and hexane) were distilled by conventional 
distillation procedures. Thin layer chromatography (TLC) was performed using Macherey-Nagel™ 
Xtra SIL G Silica Layers on Alugram™ Aluminum Sheets. Visualization of the plates is usually 
achieved by using a 254 nm UV light; although during this project very few compounds proved to be 
UV-active. For this reason, various stains appropriate to the compounds, including iodine on silica 
or solutions of p-anisaldehyde, ninhydrin, potassium permanganate or cerium ammonium molybdate 
was used, followed by heating of the stained plate. Column chromatography was performed using 
Merck silica gel 60 (particle size 0.063-0.200 mm) and different combinations of ethyl acetate and 
hexane. 
Nuclear magnetic resonance (NMR) spectra (1H, 13C) were either recorded on a 300 MHz Varian 
VNMRS (75 MHz for 13C), a 400 MHz Varian Unity Inova (101 MHz for 13C), or a 600 MHz Varian 
Unity Inova (150 MHz for 13C). All spectra were obtained at 25 °C unless otherwise stated, and the 
NMR spectroscopy data was processed using MestReNova. Chemical shifts were recorded using 
the residual solvent peak or external reference (tetramethylsilane). Furthermore, chemical shifts (δ) 
are given in parts per million (ppm) and coupling constants (J-values) in Hertz (Hz). Mass 
spectrometry was performed on a Waters SYNAPT G2. Melting points were obtained using a 
Gallenkamp Melting Point Apparatus and are uncorrected. 
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6.2. SYNTHESIS OF SCAFFOLD A 
 SYNTHESIS OF (±)-TRANS-2-AZIDOCYCLOHEXAN-1-OL 1 
A 50 mL two-neck round-bottom flask charged with NaN3 (1.49 g, 22.9 mmol, 2.50 equiv.) was set 
up under reflux conditions. Distilled H2O (4.6 mL) was added through the septum, and the flask was 
left to stir for 5 min at RT to allow the complete dissolution of NaN3. Distilled acetone (4.6 mL) was 
subsequently added and the mixture was heated to 75 °C under reflux. Once heated, cyclohexene 
oxide (0.93 mL, 9.2 mmol, 1.0 equiv.) was slowly added by syringe and the reaction mixture was 
allowed to stir for 17 h at 75 °C. It is interesting to note that the reaction colour changed from 
colourless to a yellow-brown transparent solution during the course of the reaction. After complete 
consumption of the starting material (monitored by TLC), the acetone was removed under reduced 
pressure and the reaction residue was partitioned between distilled H2O and EtOAc. The aqueous 
layer was then extracted with successive portions of EtOAc (3 × 100 mL). The combined organic 
layers were washed with brine (40 mL), dried over MgSO4, filtered, and concentrated under reduced 
pressure. The resulting oily residue was purified by flash chromatography (Hexane: EtOAc, 95:5 – 
90:10) to afford the pure 1,2-azido alcohol (±)-1 as a light-yellow oil (1.23 g, 8.71 mmol, 95%).  
 
Rf = 0.31 (Hexane: EtOAc, 85:15). IR (ATR, cm-1): 3365 (O-H str, br), 2935 (C-H str), 2861, 2089 
(N=N=N str), 1451 (O-H bend), 1257 (C-N str), 1068, 991, 844. 1H NMR (400 MHz, CDCl3) δ 3.36 – 
3.30 (m, 1H, H1), 3.15 – 3.09 (m, 1H, H2), 2.48 (bs, 1H, OH7), 2.00 – 1.93 (m, 2H), 1.70 – 1.64 (m, 
2H), 1.31 – 1.17 (m). 13C NMR (101 MHz, CDCl3) δ 73.46 (C1), 66.98 (C2), 33.13, 29.82, 24.14, 
23.82.  
Analytical data was in accordance with literature.125  
 SYNTHESIS OF (±)-TRANS-2-(4-PHENYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-OL 
2  
A dry 50 mL two-neck round-bottom flask charged with copper(II) sulphate pentahydrate (42.4 mg, 
0.170 mmol, 0.100 equiv.), and sodium ascorbate (337 mg, 1.70 mmol, 1.00 equiv.) was evacuated 
under high vacuum and placed under a N2 atmosphere. Distilled H2O (1.0 mL) was subsequently 
added and the flask was allowed to stir for 10 min, allowing the reduction of the Cu(II) species to the 
active Cu(I) species. During the reduction, a colour change was observed from a dark brown to a 
yellow colour. Thereafter, MeOH (2.0 mL) was added to the flask followed by the alkyne, 
phenylacetylene (0.174 g, 1.70 mmol, 1.00 equiv.). The reaction mixture was stirred for 10 min, 
followed by the addition of the azide, (±)-trans-2-azidocyclohexan-1-ol (±)-1 (240 mg, 1.70 mmol, 
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1.00 equiv.), dissolved in MeOH (2 mL). The flask was then left to stir at 30 °C for 18 h. The MeOH 
was evaporated off under reduced pressure and the reaction residue was quenched with a saturated 
solution of NH4Cl (15 mL). The aqueous layer was then repeatedly extracted with EtOAc (3 × 50 
mL). The combined organic layers were washed with brine (20 mL), dried over MgSO4, filtered, and 
concentrated under reduced pressure. The crude residue was washed with Hexane (10 mL) and 
purified by crystallization from a minimum amount of hot EtOAc. The resulting crystals was filtered 
and redissolved in a minimum amount of hot EtOAc and left to recrystallize. This provided the pure 
product (±)-2 as a white solid (261 mg, 1.07 mmol, 63%). 
 
Rf = 0.19 (DCM: MeOH, 97:3). MP 160 – 162 °C. 1H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H, H7), 7.73 
– 7.68 (m, 2H, 2 × ArH), 7.40 – 7.35 (m, 2H, 2 × ArH), 7.33 – 7.27 (m, 1H, ArH), 4.21 – 4.03 (m, 2H, 
H1 and H2), 3.52 (bs, 1H, OH15), 2.27 – 1.35 (m, 8H, 2 × H3 and 2 × H4 and 2 × H5 and 2 × H6). 13C 
NMR (101 MHz, CDCl3) δ 147.18 (C8), 130.52, 128.91, 128.19, 125.68, 119.69 (C7), 72.77 (C1), 
67.21 (C2), 33.85, 31.73, 24.93, 24.18. HRMS-TOF MS ES+: m/z [M+H]+ calcd for C14H18N3O+: 
244.1450; found 244.1452. 
 SYNTHESIS OF (±)-TRANS-2-(4-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-OL 
3  
Optimization of the copper-catalyzed azide alkyne cycloaddition (CuAAC) reaction  
The experimental details regarding each method explored for the optimization of the CuAAC reaction 
will be discussed in the sections below, followed by the characterization of compound (±)-3.   
 CUAAC WITH COPPER(I) SULPHATE PENTAHYDRATE 
A dry 50 mL two-neck round-bottom flask containing copper(II) sulphate pentahydrate (106 mg, 
0.425 mmol, 0.300 equiv.), sodium ascorbate (281 mg, 1.42 mmol, 1.00 equiv.) and distilled H2O 
(1.0 mL) was evacuated under high vacuum and filled with N2. The flask was left to stir for 10 min, 
allowing the reduction of the Cu(II) species to the active Cu(I) species. During the reduction, a colour 
change was observed from a dark brown to a yellow colour. Thereafter, MeOH (2 mL) was added to 
the flask followed by the alkyne, 1-heptyne (0.20 mL, 1.6 mmol, 1.1 equiv.). The reaction mixture 
was stirred for 10 min, followed by the addition of the azide, (±)-trans-2-azidocyclohexan-1-ol (±)-1 
(200 mg, 1.42 mmol, 1.00 equiv.), dissolved in MeOH (2 mL). The flask was then left to stir at 30 °C 
for 18 h. The MeOH was evaporated off under reduced pressure and the reaction residue was 
Stellenbosch University https://scholar.sun.ac.za
Chapter 6 – Triazole CBD analogues – Experimental 
87 
 
quenched with saturated aqueous NH4Cl (40 mL). The aqueous layer was then extracted with 
successive portions of EtOAc (3 × 70 mL). The combined organic layers were washed with brine (30 
mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The crude product was 
purified by silica gel column chromatography (Hexane: EtOAc, 90:10 – 50:50) to obtain the pure 
product (±)-3 as a white solid (265 mg, 1.12 mmol, 79%). 
 CUAAC WITH COPPER(I) IODIDE 
 
A dry 50 mL two-neck round-bottom flask was covered with foil and charged with copper(I) iodide 
(80.9 mg, 0.425 mmol, 0.300 equiv.). The flask was then evacuated under high vacuum and placed 
under a N2 atmosphere. Anhydrous DCM (3.7 mL) was added by syringe, followed by DIPEA (0.81 
mL, 4.7 mmol, 3.3 equiv.), as well as the alkyne, 1-heptyne (0.20 mL, 1.6 mmol, 1.1 equiv.). The 
mixture was then left to stir at RT for 15 min, followed by the addition of the azide, (±)-trans-2-
azidocyclohexan-1-ol (±)-1 (200 mg, 1.42 mmol, 1.00 equiv.). The resulting solution was stirred in 
the dark at RT for 18 h. Thereafter, the solution was diluted with DCM (20 mL) and washed with a 
saturated NH4Cl solution (40 mL). The layers were then separated, and the aqueous layer was 
extracted with consecutive portions of DCM (3 × 50 mL). The combined organic layers were then 
washed with brine (20 mL), dried over MgSO4 and evaporated under reduced pressure. The crude 
product was purified by silica gel column chromatography (Hexane: EtOAc, 90:10 – 50:50) to obtain 
the pure product (±)-3 as a white solid (130 mg, 0.548 mmol, 39%).  
 
The copper(I) iodide-catalyzed click reaction, with DCM as the solvent, was then also attempted at 
a slightly elevated temperature of 40 °C, following the same procedure as above. The exact amounts 
used are as follows: Copper(I) iodide (74.8 mg, 0.393 mmol, 0.300 equiv.), DIPEA (0.75 mL, 4.3 
mmol, 3.3 equiv.), the alkyne, 1-heptyne (0.19 mL, 1.4 mmol, 1.1 equiv.), and the azide, (±)-trans-2-
azidocyclohexan-1-ol (±)-1 (185 mg, 1.31 mmol, 1.00 equiv.) in anhydrous DCM (3.5 mL) at 40 °C 
for 18 h, in the absence of light. After purification by flash chromatography (Hexane: EtOAc, 90:10 – 
50:50), the pure product (±)-3 was obtained as a white solid (260 mg, 1.09 mmol, 83%). 
 
In a final attend to optimize the copper(I)-iodide catalyzed click reaction, MeCN was used as the 
solvent, following the same procedure as above. The exact amounts used are as follows: Copper(I) 
iodide (80.9 mg, 0.425 mmol, 0.300 equiv.), DIPEA (0.81 mL, 4.7 mmol, 3.3 equiv.), the alkyne, 1-
heptyne (0.20 mL, 1.6 mmol, 1.1 equiv.), and the azide, (±)-trans-2-azidocyclohexan-1-ol (±)-1 (200 
mg, 1.42 mmol, 1.00 equiv.) in MeCN (3.7 mL) at 65 °C for 18 h, in the dark. Thereafter, the MeCN 
was removed under reduced pressure, and the reaction residue was diluted with EtOAc (30 mL). 
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This organic layer was washed with saturated aqueous NH4Cl (50 mL). The layers were separated 
and the aqueous layers was extracted with EtOAc (3 × 50 mL). The combined organic layers were 
washed with brine (40 mL), dried over MgSO4 and the solvent was removed in vacuo. After 
purification by flash column chromatography over silica gel (Hexane: EtOAc, 90:10 – 50:50), the 
pure product (±)-3 was obtained as a white solid (289 mg, 1.21 mmol, 86%). 
 CUAAC WITH COPPER(II) ACETATE  
Copper(II) acetate (772 mg, 0.425 mmol, 0.300 equiv.) and distilled H2O (1.5 mL) was added into a 
dry 50 mL two-neck round-bottom flask and placed under a N2 atmosphere. MeOH (3.0 mL) was 
added through the septum by syringe, followed by the alkyne, 1-heptyne (0.20 mL, 1.6 mmol, 1.1 
equiv.). The mixture was left to stir for 10 min, and the azide (±)-trans-2-azidocyclohexan-1-ol (±)-1 
(200 mg, 1.42 mmol, 1.00 equiv.) was subsequently added to the flask. The reaction was allowed to 
stir at 30 °C for 18 h. After complete consumption of the starting materials (monitored by TLC), the 
MeOH was removed under reduced pressure, diluted with EtOAc (20 mL) and washed with a 
saturated NH4Cl solution (50 mL). The aqueous layer was extracted with EtOAc (3 × 100 mL) and 
the combined organic layers were washed with brine (40 mL), dried over MgSO4, filtered, and 
concentrated in vacuo. The crude product was purified by column chromatography (Hexane: EtOAc, 
90:10 – 50:50) to obtain the pure product (±)-3 as a white solid (300 mg, 1.26 mmol, 89%). 
 
Rf = 0.33 (Hexane: EtOAc, 50:50). MP 54 – 56 °C. 1H NMR (300 MHz, CDCl3) δ 7.28 (s, 1H, H7), 
4.17 (bs, 1H, OH14), 4.09 – 3.95 (m, 2H, H2 and H1), 2.56 (t, 
3J = 7.4 Hz, 2H, 2 × H9), 2.18 – 1.36 (m, 
10H), 1.30 – 1.26 (m, 4H), 0.85 (t, 3J = 6.9 Hz, 3H, 3 × H13). 13C NMR (75 MHz, CDCl3) δ 147.48 
(C8), 120.55 (C7), 72.41 (C1), 66.80 (C2), 33.93, 31.78, 31.55, 29.06, 25.62, 24.86, 24.16, 22.46, 
14.04 (C13). HRMS-TOF MS ES+: m/z [M+H] calcd for C13H24N3O+: 238.1919; found 238.1920. 
Analytical data was in accordance with literature.121 
 
The CuAAC reaction with copper(II) acetate as the copper source gave the best result, and was the 
only method which did not require the addition of a reducing agent or stabilizing ligand, as was the 
case with the other two copper sources investigated. For this reason, this method was used 
throughout this project for all further CuAAC reactions. 
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6.2.4. SYNTHESIS OF (±)-TRANS-2-(5-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-
OL 4 
Optimized ruthenium-catalyzed azide alkyne cycloaddition (RuAAC) reaction  
A dry Schlenk tube was evacuated under high vacuum and placed under a N2 atmosphere. 
Anhydrous dioxane (8.0 mL) was subsequently added via syringe and the solvent was degassed by 
five cycles of the freeze-pump-thaw technique. One of these cycles involved the evacuation of the 
tube under high vacuum, after which the Schlenk tube containing dioxane was placed into a liquid 
nitrogen container until the solvent was completely frozen. The tube was subsequently placed under 
high vacuum for 5 min, while still immersed in liquid nitrogen. Thereafter, the tube was placed in a 
beaker with lukewarm water and the solvent was allowed to slowly thaw. The Schlenk tube was then 
purged with N2 gas for 5 min, followed by the addition of the catalyst Cp*RuCl(COD) (21.5 mg, 0.0567 
mmol, 4 mol%). The Schlenk tube was once again purged with N2 gas for 5 min before adding the 
alkyne, 1-heptyne (0.19 mL, 1.4 mmol, 1.0 equiv.) into the flask by syringe. After another round of 
N2 purging, the azide (±)-trans-2-azidocyclohexan-1-ol (±)-1 (200 mg, 1.42 mmol, 1.00 equiv.) was 
added under positive N2 pressure. After a final N2 purge, the reaction mixture was left to stir at 60 °C 
for 24 h. The reaction mixture was then wet loaded directly onto a silica gel column and purified by 
flash chromatography (Hexane: EtOAc, 90:10 – 50:50). This afforded the pure product (±)-4 as a 
white solid (0.212 mg, 0.893 mmol, 63%). 
 
Rf = 0.26 (Hexane: EtOAc, 50:50). MP 122 – 124 °C. 1H NMR (300 MHz, CDCl3) δ 7.39 (s, 1H, H8), 
4.33 (bs, 1H, OH14), 3.94 – 3.85 (m, 1H, H1), 2.72 – 2.54 (m, 3H, 2 × H9 and H2), 2.23 – 1.42 (m, 
10H, 2 × H3 and 2 × H4 and 2 × H5 and 2 × H6 and 2 × H10), 1.40 – 1.35 (m, 4H), 0.91 (t, 
3J = 7.1 Hz, 
3H, 3 × H13). 13C NMR (75 MHz, CDCl3) δ 138.24 (C7), 131.82 (C8), 72.47 (C1), 64.36 (C2), 33.95, 
32.25, 31.48, 27.93, 25.18, 24.35, 23.24, 22.45, 14.07 (C13). HRMS-TOF MS ES+: m/z [M+H] calcd 
for C13H24N3O+: 238.1919; found 238.1921. 
6.2.5. SYNTHESIS OF INTERNAL ALKYNE, OCT-2-YN-1-OL 5 
Dry THF (7.0 mL) was added into a 50 mL two-neck round-bottom flask under a constant N2 flow, 
followed by 1-heptyne (0.95 mL, 7.3 mmol, 1.0 equiv.). This solution was then cooled down to 78 °C 
(acetone/dry ice bath). n-Butyllithium (1.9 M in Hexane, 3.9 mL, 7.3 mmol, 1.0 equiv.) was then added 
drop-wise. This mixture was then stirred for 1 h at 78 °C, after which time paraformaldehyde (229 
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mg, 7.64 mmol, 1.05 equiv.) was added to the flask. During the addition of paraformaldehyde, a 
white suspension was formed. The mixture was then allowed to stir for another 2 h at 78 °C. 
Thereafter, the reaction mixture was warmed up slowly and allowed to stir for 20 h at RT. After this 
time, the flask contained a yellow-green transparent solution. The reaction was then quenched with 
a saturated solution of NH4Cl (40 mL) and the aqueous layer was repeatedly extracted with EtOAc 
(3 × 50 mL). The combined organic layers were washed with brine (30 mL), dried over MgSO4 and 
filtered. The solvent was removed in vacuo to afford a crude oily residue which was subsequently 
purified by flash chromatography. (Hexane: EtOAc, 98:2 – 90:10). This afforded the pure internal 
alkyne 5 as a yellow-green oil (623 mg, 4.86 mmol, 67%). 
 
Rf = 0.57 (Hexane: EtOAc, 70:30). 1H NMR (400 MHz, CDCl3) δ 4.24 (m, 2H, 2 × H1), 2.23 – 2.16 
(m, 2H, 2 × H4), 1.80 – 1.77 (m, 1H, OH9), 1.55 – 1.45 (m, 2H), 1.37 – 1.29 (m, 4H), 0.89 (t, 
3J = 7.1 
Hz, 3H, 3 × H8). 13C NMR (101 MHz, CDCl3) δ 86.73 (C2), 78.40 (C3), 51.49 (C1), 31.16 (C4), 28.42, 
22.32, 18.82 and 14.07 (C8). 
Analytical data was in accordance with literature.131  
6.2.6. SYNTHESIS OF (±)-TRANS-2-[4-(HYDROXYMETHYL)-5-PENTYL-1H-1,2,3-TRIAZOL-
1-YL]CYCLOHEXAN-1-OL 6 AND (±)-TRANS-2-[5-(HYDROXYMETHYL)-4-PENTYL-1H-
1,2,3-TRIAZOL-1-YL]CYCLOHEXAN-1-OL 7 
A dry Schlenk tube was evacuated and filled with N2 gas (3×). Anhydrous dioxane (8.0 mL) was then 
added by syringe and the solvent was degassed through five cycles of the freeze-pump-thaw 
technique, see section 6.4.2. The Schlenk tube was then purged with N2 gas for 5 min, followed 
by the addition of the catalyst Cp*RuCl(COD) (21.5 mg, 0.0567 mmol, 4 mol%). The Schlenk tube 
was once again purged with N2 gas for 5 min, before adding the alkyne, oct-2-yn-1-ol 5 (200 mg, 
1.56 mmol, 1.10 equiv.), followed by another 5 min of N2 purging. The azide, (±)-trans-2-
azidocyclohexan-1-ol (±)-1 (200 mg, 1.42 mmol, 1.00 equiv.) was then added under positive N2 
pressure and after a final N2 purge, the reaction mixture was left to stir at 60 °C for 24 h. The reaction 
mixture was then wet loaded directly onto a silica gel column and purified by flash chromatography 
(Hexane: EtOAc, 90:10 – 50:50) to obtain compound (±)-6 as a yellow-green solid (22.1 mg, 0.0827 
mmol, 6%) and compound (±)-7 as a yellow-green solid (20.9 mg, 0.0782 mmol, 6%). 
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Rf = 0.08 (Hexane: EtOAc, 50:50) and 0.17 (Hexane: EtOAc, 0:100). 1H NMR (300 MHz, CDCl3) δ 
5.82 (bs, 1H, OH16), 4.55 (s, 2H, 2 × H15), 4.43 (bs, 1H, OH14), 4.10 – 3.95 (m, 2H, H2 and H1), 2.59 
– 2.42 (m, 2H, 2 × H9), 2.37 – 1.39 (m,10H), 1.35 – 1.17 (m, 4H), 0.85 (t, 3J = 6.9 Hz, 3H, 3 × H13). 
13C NMR (75 MHz, CDCl3) δ 144.93 (C8), 133.37 (C7), 73.13 (C1), 64.59 (C2), 51.42 (C15), 34.49, 
31.54, 30.90, 29.72, 25.20, 24.57, 24.39, 22.50, 14.12 (C13). 
 
Rf = 0.19 (Hexane: EtOAc, 50:50) and 0.52 (Hexane: EtOAc, 0:100). 1H NMR (300 MHz, CDCl3) δ 
4.62 – 4.48 (m, 2H, 2 × H15), 4.30 (bs, 1H, OH14), 4.23 – 4.15 (m, 1H, H2), 3.88 – 3.80 (m, 1H, H1), 
3.56 (bs, 1H, OH16), 2.78 – 2.62 (m, 2H, 2 × H9), 2.19 – 1.42 (m,10H), 1.34 – 1.29 (m, 4H), 0.88 (t, 
3J = 6.8 Hz, 3H, 3 × H13). 13C NMR (75 MHz, CDCl3) δ 136.46 (C7 or C8), 72.61 (C1), 64.82 (C2), 
55.56 (C15), 34.06, 32.12, 31.47, 29.07, 25.27, 24.36, 22.40, 22.36, 14.03 (C13). HRMS-TOF MS 
ES+: m/z [M+H]+ calcd for C14H26N3O2+: 268.2025; found 268.2037. 
6.3. SYNTHESIS OF SCAFFOLD B 
6.3.1. ATTEMPTED SYNTHESIS OF AZIDE 11 IN FOUR STEPS 
The starting material used to obtain the desired azide 11, namely 2-cyclohexen-1-one is labeled as 
11SM.  
 SYNTHESIS OF 2,3-EPOXYCYCLOHEXANONE, (7-OXABICYCLO[4.1.0]HEPTAN-2-ONE) 8 
A dry 100 mL three-neck round-bottom flask was evacuated and placed under a N2 atmosphere. 
MeOH (9.0 mL) was added into the flask via syringe, followed by 2-cyclohexen-1-one 11SM (0.91 mL, 
9.4 mmol, 1.0 equiv.). This solution was then cooled to 0 °C by placing the flask in an ice bath. 
Thereafter, 30% hydrogen peroxide (4.8 mL, 47 mmol, 5.0 equiv.) was added through the septum 
by syringe, followed by 1 M NaOH (1.3 mL, 1.3 mmol, 0.14 equiv.). The reaction mixture was then 
allowed to stir under N2 for 6 h, while maintaining the 0 °C environment. After this time, the MeOH 
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was removed under reduced pressure and the reaction residue was partitioned between H2O (30 
mL) and DCM (30 mL). The aqueous layer was then extracted with successive portions of DCM (3 
× 100 mL). The combined organic layers were washed with 10% aqueous Na2SO3 and brine, dried 
over MgSO4, filtered, and concentrated under reduced pressure. The resulting oily residue was 
purified by flash chromatography (Hexane: EtOAc, 97:3 – 90:10). This afforded the pure epoxide 8 
as a colourless oil (0.691 g, 6.16 mmol, 66%).  
However, a yield of 77% was obtained when doing this reaction on a smaller scale (2-cyclohexen-1-
one = 0.200 g (0.22 mL)). 
 
Rf = 0.25 (Hexane: EtOAc, 90:10). 1H NMR (300 MHz, CDCl3) δ 3.53 – 3.50 (m, 1H, H3), 3.13 (d, 
3J 
= 3.9 Hz, 1H, H2), 2.45 (dt, 2J = 8.2, 3J = 4.4 Hz, 1H), 2.25 – 2.13 (m, 1H), 2.05 – 1.79 (m, 3H), 1.65 
– 1.54 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 205.85 (C1), 55.87, 55.04, 36.33, 22.80, 16.95. 
Analytical data was in accordance with literature.140   
 SYNTHESIS OF 3-HYDROXYCYCLOHEXAN-1-ONE 9 
A dry 50 mL two-neck round-bottom flask charged with diphenyl diselenide (1.80 g, 5.75 mmol, 1.50 
equiv.) was evacuated and placed under a constant N2 flow. EtOH (5.0 mL) was added through the 
septum by syringe and the flask was then left to stir for 5 min at 30 °C until the diphenyl diselenide 
was completely dissolved. At this point the solution had an orange colour. Sodium borohydride 
(0.435 g, 11.5 mmol, 3.00 equiv.) was then slowly added and the flask mixture was left to stir for 5 
min at 30 °C to allow for the reduction of diphenyl diselenide. After the reduction, the colour changed 
to a light-yellow colour, indicating the presence of the active species, BH3PhSeNa. Acetic acid (0.11 
mL, 1.9 mmol, 0.50 equiv.) was then added to this flask containing the BH3PhSeNa species and this 
mixture was stirred for 5 min. In a separate 100 mL three-neck round-bottom flask, the epoxide, 2,3-
epoxycyclohexanone (7-oxabicyclo[4.1.0]heptan-2-one) 8 (0.430 g, 3.84 mmol, 1.00 equiv.) was 
dissolved in EtOH (5.0 mL) and placed in an ice bath. The solution containing the BH3PhSeNa 
species was then slowly added to this cooled solution of the epoxide, 2,3-epoxycyclohexanone 8. 
The reaction mixture was then left to stir for 4 h at 30 °C. The solution was then diluted with EtOAc 
(40 mL) and distilled H2O (40 mL), the layers were separated and the aqueous layer was repeatedly 
extracted with EtOAc (3 × 100 mL). The combined organic layers were then washed with brine (40 
mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The resulting oily residue 
was purified by flash chromatography (first eluted with Hexane: EtOAc, 95:5 to recover the diphenyl 
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diselenide (1.62 g, 5.19 mmol, 90% recovered), followed by a gradient elution of Hexane: EtOAc, 
80:20 – 50:50). This afforded the pure β-hydroxy ketone 9 as a colourless oil (0.274 g, 2.40 mmol, 
63%).  
 
Rf = 0.25 (Hexane: EtOAc, 50:50). 1H NMR (300 MHz, CDCl3) δ 4.18 – 4.10 (m, 1H, H3), 3.09 (bs, 
1H, OH7), 2.59 (dd, 
2J = 14.0, 3J = 4.2 Hz, 1H), 2.36 (dd, 2J = 14.0, 3J = 7.4 Hz, 1H), 2.27 (t, 3J = 6.7 
Hz, 2H), 2.09 – 1.90 (m, 2H), 1.79 – 1.60 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 210.75 (C1), 69.68 
(C3), 50.39, 40.98, 32.67, 20.72. 
Analytical data was in accordance with literature.140,146  
 ATTEMPTED SYNTHESIS OF 3-OXOCYCLOHEXYL METHANESULFONATE 10 
A solution of 3-hydroxycyclohexan-1-one 9 (0.210 g, 1.84 mmol 1.00 equiv.) in anhydrous DCM (7 
mL) was added into a 50 mL two-neck round-bottom flask set up under inert conditions. Thereafter, 
Et3N (0.51 mL, 3.7 mmol, 2.0 equiv.) was added by syringe and the solution was left to stir for 5 min. 
Methanesulfonyl chloride (0.27 mL, 3.5 mmol, 1.9 equiv.) was subsequently added through the 
septum and the mixture was left to stir for 2 h at RT. Although literature suggests full consumption 
of the starting material after 1 h, in our hands this was not the case. When monitoring the reaction 
by TLC, some starting material was still detected after stirring for 2 h at RT. As a result, the reaction 
mixture was then heated to 30 °C and stirred for another 2 h, after which time, TLC showed complete 
conversion to the product. Thereafter, distilled H2O (20 mL) was added, the layers were separated 
and the aqueous layer was extracted with successive portions of DCM (3 × 50 mL). The combined 
organic layers were then washed with brine (30 mL), dried over MgSO4, filtered, and concentrated 
in vacuo. However, we were surprised to find the reaction flask practically empty after concentration 
of the crude residue.  
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6.3.2. SYNTHESIS OF AZIDE 11 IN ONE STEP 
 SYNTHESIS OF 3-AZIDOCYCLOHEXAN-1-ONE 11 
Three different methods were explored for this conversion. In the next section, the experimental 
procedure for each method will be discussed separately and the characterization of 11 will follow. 
 
A two-neck round-bottom flask charged with NaN3 (0.812 g, 12.5 mmol, 4.00 equiv.) was evacuated 
and filled with N2 gas. Distilled H2O (2.0 mL) was then added to the flask via syringe and the flask 
was stirred for 10 min to allow the complete dissolution of NaN3. Glacial acetic acid (0.71 mL, 13 
mmol, 4.0 equiv.) was subsequently added and the mixture was stirred for 30 min at RT. After this 
time, the mixture became a light transparent orange-brown colour. Thereafter, Et3N (0.087 mL, 0.62 
mmol, 0.20 equiv.) was added through the septum, followed by cyclohex-2-en-1-one (11SM) (0.30 
mL, 3.1 mmol, 1.0 equiv.). After the addition of cyclohex-2-en-1-one (11SM) the mixture changed into 
a light-orange milky colour. The reaction mixture was left to stir at 30 °C for 24 h. After this time, the 
reaction mixture was a brown suspension.  
The Rf values of the starting material, cyclohex-2-en-1-one (11SM) and the desired product, 3-
azidocyclohexan-1-one 11 was extremely similar, irrespective of the mobile phase used. This made 
it very difficult to say for certain whether all the starting material was consumed during the course of 
the reaction. To compensate for this, the reaction time was significantly increased compared to the 
prescribed time in literature, but it could still not be said with certainty that the reaction was complete. 
In literature, the pure azido ketone was obtained within 6 h, without any further purification; but in 
our hands, some starting material was still present even after running the reaction for 24 h. After 
experimenting with different TLC stains, as well as various combinations of stains, we found that by 
staining the TLC plate with 10% PPh3 in DCM, followed by immediate staining with Ninhidrin, the 
formation of an azide functionality could selectively be detected on the TLC plate.  
The reaction was then worked up after 24 h by adding saturated NaHCO3 (20 mL) to the flask, 
followed by repeated extraction with EtOAc (3 × 50 mL). The combined organic layers were then 
washed with brine (30 mL), dried over MgSO4, filtered, and concentrated under reduced pressure. 
After various purification attempts, the pure product, 3-azidocyclohexan-1-one 11, could 
unfortunately not be separated from the unreacted starting material, cyclohex-2-en-1-one (11SM). 
The same reaction was also attempted with pyridine as a base instead of Et3N, but the same problem 
was encountered.  
A second procedure which required TMSN3, along with a polystyrene-supported ammonium fluoride 
catalyst, namely Amberlite IRA900F, under solvent free conditions, was then investigated. 
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A 50 mL two-neck round-bottom flask charged with Amberlite IRA900F (88.0 mg, 0.263 mmol, 0.250 
equiv.) was evacuated and set up under inert conditions. By using a syringe, cyclohex-2-en-1-one 
(11SM) (0.11 mL, 1.1 mmol, 1.0 equiv.) was added to the flask, followed by TMSN3 (0.21 mL, 1.6 
mmol, 1.5 equiv.). The reaction mixture was left to stir at 30 °C for 18 h. Thereafter, the flask was 
diluted with EtOAc (20 mL), and the catalyst was recovered by filtration. The organic solvent was 
then evaporated under vacuum. 
This procedure gave the same problem as explained in the first attempted synthesis of 3-
azidocyclohexan-1-one 11, in which residual starting material, cyclohex-2-en-1-one (11SM) remained 
present even after a prolonged reaction time. When taking in to account the conversion and 
purification problems already explained, as well as the cost associated with the Amberlite IRA900F 
catalyst, a third procedure for this conversion was explored. 
 
Anhydrous DCM (2.1 mL) was added into a dry two-neck round-bottom flask set up under a N2 
atmosphere. By making use of a syringe, TMSN3 (1.4 mL, 10 mmol, 5.0 equiv.) was then added 
through the septum, followed by glacial acetic acid (0.60 mL, 10 mmol, 5.0 equiv.). The mixture was 
left to stir for 20 min, during which the colour of the solution changed from colourless to a milky white 
colour. Thereafter, cyclohex-2-en-1-one (11SM) (0.21 mL, 2.1 mmol, 1.0 equiv.) was added by 
syringe, followed by Et3N (0.058 mL, 0.42 mmol, 0.20 equiv.). The reaction mixture was left to stir 
over the weekend at RT and after this time the flask contained a dark brown solution.  
In the literature procedure, the crude reaction mixture was directly applied to a silica plug and eluted 
with a solution of Hexane: EtOAc, 55:45. During various attempts to obtain the pure product, the 
DCM was removed by evaporation and the crude mixture was dry loaded onto the column. 
Purification was attempted with varying gradients of Hexane: EtOAc, 95:5 – 50:50. Even under these 
varied purification conditions, it was still not possible to separate the desired product, 
azidocyclohexan-1-one 11 from the unreacted starting material, cyclohex-2-en-1-one (11SM). 
Evaluation by way of NMR spectroscopy showed a 5:1 ratio of product, 3-azidocyclohexan-1-one 11 
to residual starting material, cyclohex-2-en-1-one (11SM) under these conditions.  
Please note that the following NMR assignment has a slightly different style compared to the 
previous assignments in this document. This is due to the residual inseparable starting material 
present in this sample. It is important to keep in mind that the desired product is in a 5 to 1 ratio with 
the residual starting material. This means that while one proton of 11 will accurately integrate for 1H, 
one proton of 11SM will only integrate for 0.2H. 
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To explain the style used, the first assignment of the 1H NMR assignment will act as an example. 
The first different seen in the assignment is the style in which the integration is given. The ‘1H’ refers 
to the number of protons responsible for this peak, while the integration given in brackets as ‘=0.2H’ 
refers to the accurate integration obtained from the NMR spectrum due to the product to starting 
material ratio, as explained above. 
The second difference seen in this style is the compound number given after the atom assignment. 
For example, H3(11SM) means this peak resulted from the proton atom number 3 of the residual starting 
material, compound 11SM. 
 
Rf (11) = 0.44 (Hexane: EtOAc, 80:20), Rf (11SM) = 0.44 (Hexane: EtOAc, 80:20).  
Rf (11) = 0.68 (Hexane: EtOAc, 50:50). Rf (11SM) = 0.70 (Hexane: EtOAc, 50:50).  
Rf (11) = 0.61 (Hexane: EtOAc, 25:75). Rf (11SM) = 0.68 (Hexane: EtOAc, 25:75). 
1H NMR (400 MHz, CDCl3) δ 6.99 – 6.95 (m, 1H(=0.2H), H3(11SM)), 6.01 – 5.97 (m, 1H(=0.2H), 
H2(11SM)), 3.90 – 3.84 (m, 1H, H3(11)), 2.62 (dd, 
3J = 14.3, 4J = 4.6 Hz, 1H, H2a(11)), 2.43 – 2.30 (m, 
7H(=3.8H), 2 × H6(11SM) and 2 × H6(11) and 2 × H4(11SM) and H2b(11)), 2.10 – 2.01 (m, 4H(=2.4H), 2 × 
H5(11SM) and H5b(11) and H4a(11)), 1.84 – 1.66 (m, 2H, H5a(11) and H4b(11)). 13C NMR (101 MHz, CDCl3) δ 
207.55 (C1(11)), 199.78 (C1(11SM)), 150.74 (C3(11SM)), 129.97 (C2(11SM)), 59.61 (C3(11)), 46.66 (C2(11)), 
40.75 (C6(11)), 38.17 (C6(11SM)), 29.87 (C4(11)), 25.74 (C4(11SM)), 22.80 (C5(11SM)), 21.47 (C5(11)). 
Analytical data was in accordance with literature.151,152 
Because the conversion from cyclohex-2-en-1-one (11SM) into 3-azidocyclohexan-1-one 11 could 
not be quantified due to the purification problems encountered; it was decided that the inseparable 
3-azidocyclohexan-1-one 11 mixture would be would be used directly in the next step. This is 
possible because the residual 2-cyclohexen-1-one would not interfere with the following step, as it 
has no functionalities that could be utilized in the click reaction.  
6.3.3. SYNTHESIS OF 3-(4-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-ONE 12 
Due to the problems encountered during the purification of the desired azide 11, the inseparable 
azide mixture from two of the azidation methods discussed above was directly used for the copper-
mediated click reaction using the optimized conditions.  
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 FIRST SYNTHESIS OF 3-(4-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-ONE 12 
A two-neck round-bottom flask charged with NaN3 (0.812 g, 12.5 mmol, 4.00 equiv.) was evacuated 
and filled with N2 gas. Distilled H2O (2.0 mL) was then added to the flask via syringe and the flask 
was stirred to allow all NaN3 to dissolve. Glacial acetic acid (0.71 mL, 13 mmol, 4.0 equiv.) was 
subsequently added and the mixture was stirred for 30 min. After this time, the mixture became a 
light transparent orange-brown colour. Thereafter, Et3N (0.22 mL, 1.6 mmol, 0.50 equiv.) was added 
through the septum, followed by cyclohex-2-en-1-one (0.30 mL, 3.1 mmol, 1.0 equiv.). After the 
addition of cyclohex-2-en-1-one, the mixture changed into a light-orange milky colour. The reaction 
mixture was left to stir for 24 h at 30 °C. After this time, the reaction mixture was a brown suspension. 
The mixture was quenched with NaHCO3 (25 mL) and repeatedly extracted with EtOAc (3 × 70 mL). 
The combined organic layers were then washed with NH4Cl (20 mL) and brine (20 mL), dried over 
MgSO4, filtered, and concentrated under reduced pressure, to obtain the crude intermediate, 3-
azidocyclohexan-1-one 11 as a brown oil. The inseparable mixture was then directly used in the 
copper-mediated click reaction. Copper(II) acetate (170 mg, 0.936 mmol, 0.300 equiv.) was added 
into a two-neck round-bottom flask, followed by distilled H2O (2.0 mL). The flask was then evacuated 
under high vacuum, and placed under a N2 atmosphere. MeOH (2.0 mL) was then added into the 
flask, followed by the alkyne 1-heptyne (0.41 mL, 3.1 mmol, 1.0 equiv.). The flask was allowed to stir 
for 10 min. The crude azide, 3-azidocyclohexan-1-one 11, dissolved in MeOH (2.0 mL) was 
subsequently added into the flask via syringe and the reaction mixture was left to stir for 24 h at 30 
°C. Upon completion (monitored by TLC), the MeOH was removed under reduced pressure, diluted 
with EtOAc (20 mL) and washed with a saturated NH4Cl solution (50 mL). The aqueous layer was 
extracted with EtOAc (3 × 100 mL) and the combined organic layers were washed with brine, dried 
over MgSO4, filtered, and concentrated in vacuo. The crude product was purified by column 
chromatography (Hexane: EtOAc, 90:10 – 50:50) to obtain the pure product 12 as a white solid 
(0.260 mg, 1.10 mmol, 35%, yield over two steps, based on cyclohex-2-en-1-one). 
 SECOND SYNTHESIS OF 3-(4-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-ONE 
12 
Anhydrous DCM (3.2 mL) was added into a dry two-neck round-bottom flask set up under a N2 
atmosphere. By making use of a syringe, TMSN3 (2.1 mL, 16 mmol, 5.0 equiv.) was then added 
through the septum followed by glacial acetic acid (0.90 mL, 16 mmol, 5.0 equiv.). The mixture was 
left to stir for 20 min, during which time the colour of the solution changed from colourless to a milky 
white colour. Thereafter, cyclohex-2-en-1-one (0.30 mL, 3.1 mmol, 1.0 equiv.) was added by syringe 
followed by Et3N (0.087 mL, 0.62 mmol, 0.20 equiv.), and the reaction mixture was left to stir for 24 
h at RT. After this time, the flask contained a dark brown solution. The reaction mixture was 
concentrated under reduced pressure to obtain the crude intermediate 3-azidocyclohexan-1-one 11 
as a brown oil. The crude azide, 3-azidocyclohexan-1-one 11 was then directly used in the CuAAC 
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reaction. Copper(II) acetate (170 mg, 0.936 mmol, 0.300 equiv.) was added into a two-neck round-
bottom flask, followed by distilled H2O (2.0 mL). The flask was then evacuated under high vacuum, 
and placed under a nitrogen atmosphere. MeOH (2.0 mL) was then added into the flask, followed by 
the alkyne, 1-heptyne (0.41 mL, 3.1 mmol, 1.0 equiv.). The flask was then allowed to stir for 10 min 
allowing coordination of the alkyne to the copper catalyst. The crude azide, 3-azidocyclohexan-1-
one 11, dissolved in MeOH (2.0 mL), was subsequently added into the flask via syringe and the 
reaction mixture was then left to stir for 24 h at 30 °C. Upon completion, the MeOH was removed 
under reduced pressure, diluted with EtOAc (20 mL) and washed with a saturated NH4Cl solution 
(50 mL). The aqueous layer was extracted with EtOAc (3 × 100 mL) and the combined organic layers 
were washed with brine (50 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude 
product was purified by column chromatography (Hexane: EtOAc, 90:10 – 50:50) to obtain the pure 
product 12 as a white solid (0.280 mg, 1.19 mmol, 38%, yield over two steps, based on cyclohex-2-
en-1-one). 
 
Rf = 0.39 (Hexane: EtOAc, 50:50). MP 51 – 53 °C. 1H NMR (300 MHz, CDCl3) δ 7.27 (s, 1H, H7), 
4.83 – 4.73 (m, 1H, H3), 3.03 – 2.65 (m, 4H, 2 × H2 and 2 × H6), 2.55 – 1.61 (m, 8H), 1.42 – 1.27 (m, 
4H), 0.89 (t, 3J = 7.0 Hz, 3H, 3 × H13). 13C NMR (75 MHz, CDCl3) δ 206.82 (C1), 148.58 (C8), 119.12 
(C7), 58.74 (C3), 47.59 (C2), 40.69 (C6), 31.90, 31.61, 29.26 (C4), 25.81, 22.55, 21.88 (C5), 14.14 
(C13). HRMS-TOF MS ES+: m/z [M+H] calcd for C13H22N3O+: 236.1763; found 236.1768. 
6.3.4. SYNTHESIS OF 3-(5-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-ONE 13 
A two-neck round-bottom flask charged with NaN3 (0.812 g, 12.5 mmol, 4.00 equiv.) was evacuated 
and filled with N2. Distilled H2O (2.0 mL) was then added to the flask via syringe and the flask was 
stirred for 10 min to allow all NaN3 to dissolve. Glacial acetic acid (0.71 mL, 13 mmol, 4.0 equiv.) was 
subsequently added and the mixture was stirred for 30 min. After this time, the mixture became a 
light transparent orange-brown colour. Next, by Et3N (0.22 mL, 1.6 mmol, 0.50 equiv.) was added 
through the septum, followed by 2-cyclohexen-1-one (0.30 mL, 3.1 mmol, 1.0 equiv.). After the 
addition of 2-cyclohexen-1-one, the mixture changed into a light-orange milky colour. The reaction 
mixture was left to stir for 24 h at 30 °C. After this time, the reaction mixture was a brown suspension. 
The reaction mixture was quenched with NaHCO3 (50 mL) and extracted with EtOAc (3 × 100 mL). 
The combined organic layers were then washed with NH4Cl (40 mL) and brine (40 mL), dried over 
MgSO4, filtered, and concentrated under reduced pressure to obtain the crude azidocyclohexan-1-
one 11 as a brown oil. The crude product 11 was then directly used in the RuAAC reaction. A dry 
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Schlenk tube was evacuated under high vacuum and placed under a nitrogen atmosphere. 
Anhydrous dioxane (8.0 mL) was then added to this Schlenk tube by syringe. The solvent was then 
degassed by 5 cycles of the freeze-pump-thaw technique. The Schlenk tube was then purged 
with N2 gas for 5 min, followed by the addition of the catalyst Cp*RuCl(COD) (47.4 mg, 0.125 mmol, 
4 mol%) under inert conditions. The tube was once again purged with N2 gas for 5 min before adding 
the alkyne, 1-heptyne (0.41 mL, 3.1 mmol, 1.0 equiv.) into the flask by syringe. After another round 
of N2 purging, the crude azide, azidocyclohexan-1-one 11 was added under positive N2 pressure. 
After a final N2 purge, the reaction mixture was left to stir at 60 °C for 24 h. The reaction mixture was 
then wet loaded directly onto a silica gel column and purified by flash column chromatography over 
silica gel (Hexane: EtOAc, 90:10 – 50:50). Under these conditions, we recovered a substantial 
amount of the crude azide, azidocyclohexan-1-one 11 (0.164 g, 1.18 mmol, 38%, based on the 
theoretical yield of 11 before the click reaction) and obtained the desired 1,5-disubstituted product 
13 in a 2 to 1 ratio with the 1,4-disubstituted product 12, as determined by way of NMR evaluation, 
(0.0383 g, 0.163 mmol, 5%, combined yield of 13 and 12 in a 2:1 ratio). 
NMR spectra 23 and 24, found in Appendix 1, were used to characterize these two products 12 and 
13. The numbered structures of 12 and 13 are depicted in Figure 3:4. These atom numbers will be 
referred to during the NMR spectroscopy discussion below. 
Please note that the NMR assignment below is once again given in a different style. The style used 
is the same as explained in section 6.3.2.1.3. The desired product 13 is present in a 2 to 1 ratio with 
the regioisomer 12, meaning that while one proton of 13 will accurately integrate for 1H, one proton 
of 12 will only integrate for 0.5H. Although this style was already explained, a brief explanation will 
be given here: 
The second peak (7.27 ppm) of the 1H NMR assignment will act as an example. The ‘1H’ refers to 
the number of protons responsible for this peak, while the integration given in brackets as ‘=0.5H’ 
refers to the accurate integration obtained from the NMR spectrum due to the ratio of the two 
products, as explained above. In addition, the compound number is given after the atom assignment, 
in this case, H7(12) means this peak resulted from the proton atom number 7 of compound 12. 
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Rf = 0.37 (Hexane: EtOAc, 50:50). 1H NMR (400 MHz, CDCl3) δ 7.45 (s, 1H, H8(13)), 7.27 (s, 
1H(=0.5H), H7(12)), 4.83 – 4.73 (m, 1H(=0.5H), H3(12)), 4.52 – 4.42 (m, 1H, H3(13)), 3.24 – 2.67 (m, 
6H(=4H), 2 × H6(13) and 2 × H2(12) and 2 × H6(12)), 2.61 – 2.56 (m, 2H, 2 × H2(13)), 2.51 – 1.61 
(m,16H(=12H)), 1.38 – 1.31 (m, 8H(=6H)), 0.90 (m, 6H(=4.5H), 3 × H13(12) and 3 × H13(13)). 13C NMR 
(101 MHz, CDCl3) δ 207.16 (C1(13)), 206.85 (C1(12)), 148.56 (C8(12)), 136.46 (C7(13)), 132.12 (C8(13)), 
119.13 (C7(12)), 58.74 (C3(12)), 55.99 (C3(13)), 47.85 (C2(13)), 47.56 (C2(12)), 40.68 (C6(12)), 40.58 (C6(13)), 
31.87, 31.71, 31.60, 31.41, 29.24 (C4(12)), 28.05 (C4(13)), 25.78, 23.14, 22.54, 22.41, 22.13 (C5(13)), 
21.86 (C5(12)), 14.13 (C13(12)), 14.02 (C13(13)). HRMS-TOF MS ES+: m/z [M+H] calcd for C13H22N3O+: 
236.1763; found 236.1770. 
6.3.5. SYNTHESIS OF 3-(4-PENTYL-1H-1,2,3-TRIAZOL-1-YL)CYCLOHEXAN-1-OL 14 
Anhydrous THF (4.0 mL) was added into a 50 mL two-neck round-bottom flask charged with LiAlH4 
(0.100 g, 2.64 mmol, 3.00 equiv.) under a constant N2 flow. The click product 12 (0.207 g, 0.879 
mmol, 1.00 equiv.) dissolved in an additional amount of THF (6.0 mL) was added to the flask 
containing the LiAlH4 solution. The reaction mixture was heated to 60 °C (oil-bath) under reflux for 1 
h. Thereafter the oil bath was removed and the flask was allowed to cool while stirring for an 
additional 1 h. At this point, the reaction mixture was grey in colour. Upon completion, the mixture 
was quenched with distilled H2O (15 mL). The H2O was added drop-wise to dampen the resulting 
vigorous reaction. During the quenching process, the colour of the reaction mixture changed from 
grey to white. The aqueous solution was subsequently extracted with successive portions of EtOAc 
(3 × 60 mL). The combined organic layers were washed with brine (30 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The crude mixture was then purified by silica gel column 
chromatography (Hexane: DCM, 90:10 – 50:50) to obtain the pure product 14 as a white solid (0.183 
g, 0.771 mmol, 88%). 
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Rf = 0.27 (Hexane: EtOAc, 50:50). 1H NMR (300 MHz, cdcl3) δ 7.27 (s, 1H, H7), 4.52 – 4.40 (m, 1H, 
H3), 3.86 – 3.73 (m, 1H, H1), 2.75 – 2.41 (m, 4H, incl. OH14), 2.20 – 2.06 (m, 2H), 1.98 – 1.90 (m, 
1H), 1.82 – 1.29 (m, 10H), 0.88 (t, 3J = 7.0 Hz, 3H, 3 × H13).13C NMR (75 MHz, CDCl3) δ 148.32 (C8), 
118.39 (C7), 68.97 (C1), 58.11 (C3), 42.17 (C2), 34.56 (C6), 32.75, 31.60, 29.26 (C4), 25.82, 22.54, 
21.88 (C5), 14.12 (C13). 
6.4. SYNTHESIS OF SCAFFOLD C 
6.4.1. SYNTHESIS OF (1R,2S,5R)-2-ISOPROPYL-5-METHYLCYCLOHEXYL 
METHANESULFONATE 15 
A 50 mL two-neck round-bottom flask loaded with (1R,2S,5R)-2-Isopropyl-5-methylcyclohexanol, 
()-menthol (0.562 g, 3.60 mmol, 1.00 equiv.) was evacuated and set up under inert conditions. 
Anhydrous DCM (8.0 mL) was added by syringe, followed by triethylamine (0.60 mL, 4.3 mmol, 1.2 
equiv.) and the flask was cooled to 0 °C (ice-bath). While maintaining the temperature at 0 °C, 
methanesulfonyl chloride (0.34 mL, 4.3 mmol, 1.2 equiv.) was added slowly through the septum. The 
flask was then removed from the ice-bath and allowed to warm up to RT, and stirred for 3 h. During 
the addition of methanesulfonyl chloride, the reaction mixture formed a white precipitate and upon 
completion the flask contained a yellow precipitate. After the specified reaction time, the reaction 
residue was partitioned between distilled H2O (30 mL) and DCM (30 mL). The layers were separated 
and the aqueous layer was extracted with consecutive portions of DCM (3 × 100 mL). The combined 
organic layers were washed with brine, dried over MgSO4, filtered and concentrated under reduced 
pressure. After purification by silica gel column chromatography (Hexane: DCM, 90:10 – 50:50), the 
pure product 15 was obtained as a colourless oil (0.754 g, 3.22 mmol, 89%). 
 
Rf = 0.46 (Hexane: EtOAc, 90:10). 1H NMR (300 MHz, CDCl3) δ 4.55 (td, 
3J = 10.9, 4.6 Hz, 1H, H1), 
3.00 (s, 3H, 3 × H11), 2.30 – 2.23 (m, 1H), 2.14 – 2.00 (m, 1H), 1.76 – 1.64 (m, 2H), 1.47 – 1.37 (m, 
2H), 1.32 – 1.21 (m, 1H), 1.13 – 0.99 (m, 1H), 0.93 (dd at 0.93, 3J = 6.7, 4J =2.5 Hz, 6H, 3 × H8 and 
3 × H9), 0.91 – 0.85 (m, 1H, H3a), 0.83 (d, 
3J = 7.0 Hz, 3H, 3 × H10). 13C NMR (75 MHz, CDCl3) δ 
83.55 (C1), 47.59, 42.39, 39.26, 33.92, 31.80, 25.96, 23.26, 22.00, 20.96, 15.84. 
Analytical data was in accordance with literature.156 
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6.4.2. SYNTHESIS OF (1S,2S,4R)-2-AZIDO-1-ISOPROPYL-4-METHYLCYCLOHEXANE 16 
A 50 mL two-necked round-bottom flask charged with (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 
methanesulfonate 15 (0.204 g, 0.871 mmol, 1.00 equiv.) was evacuated and filled with N2. 
Anhydrous DMSO (4.0 mL) was then added through the septum, followed by sodium azide (0.283 
g, 4.35 mmol, 5.00 equiv.). The reaction mixture was then heated to 80 °C (oil-bath) and the flask 
was allowed to stir for 24 h under inert conditions. Upon complete consumption of the starting 
material (monitored by TLC), the reaction residue was decanted into a beaker of cold water (30 mL), 
and the aqueous layer was extracted with successive portions of EtOAc (3 x 70 mL). The combined 
organic layers were washed with cold water (3 x) and then with brine, dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash chromatography (Hexane: EtOAc, 90:10). 
This afforded the pure product 16 as a light-yellow oil (0.0642 g, 0.354 mmol, 41%). 
 
Rf = 0.85 (Hexane: EtOAc, 90:10). 1H NMR (300 MHz, CDCl3) δ 3.99 – 3.96 (m, 1H, H1), 2.05 – 1.97 
(m, 1H, H2), 1.77 – 1.10 (m, 7H), 1.01 – 0.80 (m, 4H), 0.89 (d, 
3J = 6.7 Hz, 6H, 3 × H8 and 3 × H9). 
13C NMR (75 MHz, CDCl3) δ 60.69 (C1), 47.51 (C2), 39.08, 34.99, 29.64, 26.67, 25.04, 22.32, 21.05, 
20.82. 
Analytical data was in accordance with literature.156  
6.4.3. SYNTHESIS OF (1S,2S,4R)-2-CHLORO-1-ISOPROPYL-4-METHYLCYCLOHEXANE 17 
A two-neck 50 mL round-bottom flask was setup under inert conditions and (1R,2S,5R)-2-Isopropyl-
5-methylcyclohexanol, (-)-menthol (0.316 g, 2.02 mmol, 1.00 equiv.), as well as triphenylphosphine 
(1.06 g, 4.04 mmol, 2.00 equiv.) was added under constant N2 flow. CCl4 (2.5 mL) was then added 
through the septum and the reaction flask was heated to 80 °C under reflux for 16 h. After cooling to 
RT, hexane (100 mL) was added, and the white precipitate of triphenylphosphine oxide was removed 
by filtration. The filtrate was then cooled and the newly precipitated triphenylphosphine oxide was 
removed by filtration. The solvent was removed under reduced pressure, and purified by flash 
column chromatography (Hexane: EtOAc, 90:10). This afforded the pure product 17 as a colourless 
oil (0.160 g, 0.916 mmol, 45%). 
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Rf = 0.87 (Hexane: EtOAc, 95:5). 1H NMR (300 MHz, CDCl3) δ 4.58 – 4.46 (m, 1H, H1), 2.10 – 2.02 
(m, 1H, H2), 2.00 – 0.99 (m, 7H), 0.96 – 0.90 (m, 7H), 0.88 (d, 
3J = 7.0 Hz, 3H, 3 × H10). 13C NMR 
(75 MHz, CDCl3) δ 63.58 (C1), 49.12 (C2), 43.44, 34.99, 30.21, 26.03, 24.42, 22.03, 20.94, 20.33. 
Analytical data was in accordance with literature.156  
6.4.4. ATTEMPTED SYNTHESIS OF (1S,2R,4R)-2-AZIDO-1-ISOPROPYL-4-
METHYLCYCLOHEXANE 18 
A 50 mL two-necked round-bottom flask was charged with (1S,2S,4R)-2-chloro-1-isopropyl-4-
methylcyclohexane 17 (0.150 g, 0.859 mmol, 1.00 equiv.) and placed under an inert atmosphere. 
Anhydrous DMSO (4.0 mL) was then added by syringe, followed by sodium azide (0.279 g, 4.29 
mmol, 5.00 equiv.). The reaction mixture was then heated to 80 °C (oil-bath) and the flask was 
allowed to stir for 24 h under inert conditions. Unfortunately, under these conditions, no conversion 
was observed by TLC. The reaction residue was decanted into a beaker of cold water (30 mL), and 
the aqueous layer was extracted with DCM (3 x 70 mL). The combined organic layers were washed 
with brine, dried over MgSO4, filtered and concentrated in vacuo to recover the starting material 17. 
 
6.4.5. SYNTHESIS OF 1-[(1S,2S,5R)-2-ISOPROPYL-5-METHYLCYCLOHEXYL]-4-PENTYL-
1H-1,2,3-TRIAZOLE 19 
Copper(II) acetate (19.3 mg, 0.106 mmol, 0.300 equiv.) was added into a two-neck round-bottom 
flask, followed by distilled H2O (1.0 mL). The flask was then evacuated under high vacuum, and 
placed under a N2 atmosphere. MeOH (1.0 mL) was then added to the flask via syringe, followed by 
the alkyne, 1-heptyne (0.047 mL, 0.35 mmol, 1.0 equiv.). The flask was then allowed to stir for 10 
min. The azide, (1S,2S,4R)-2-azido-1-isopropyl-4-methylcyclohexane 16 (64.2 mg, 0.354 mmol, 
1.00 equiv.), dissolved in MeOH (1 mL) was subsequently added into the flask via syringe and the 
reaction mixture was then left to stir for 24 h at 30 °C. Upon completion (monitored by TLC), the 
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MeOH was removed under reduced pressure, diluted with EtOAc (20 mL) and washed with a 
saturated NH4Cl solution (50 mL). The aqueous layer was extracted with EtOAc (3 × 100 mL) and 
the combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated 
in vacuo. The crude product was purified by column chromatography (Hexane: EtOAc, 90:10 – 
50:50) to obtain the pure product 19 as a white solid (20.9 mg, 0.0753 mmol, 21%) 
 
Rf = 0.25 (Hexane: EtOAc, 50:50). MP 85 – 87 °C. 1H NMR (300 MHz, CDCl3) δ 7.33 (s, 1H, H11), 
5.02 – 4.95 (m, 1H, H1), 2.70 (t, 
3J = 7.8, 2H, 2 × H13), 1.97 – 1.30 (m, 14H), 0.93 – 0.81 (m, 10H), 
0.77 (d, 3J = 6.6 Hz, 3H, 3 × H17). 13C NMR (75 MHz, CDCl3) δ 121.68 (C11), 58.97 (C1), 46.88 (C2), 
41.02, 34.83, 31.69, 29.31, 29.28, 26.61, 25.83, 25.17, 22.57, 22.46, 21.29, 20.66, 14.19 (C17). 
HRMS-TOF MS ES+: m/z [M+H] calcd for C17H32N3+: 278.2596; found 278.2600. 
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APPENDIX 1 
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY RESULTS 
 
CBD NMR Spectrum 1   1H NMR spectrum of (±)-trans-2-azidocyclohexan-1-ol 1. 
 
CBD NMR Spectrum 2   13C NMR spectrum of (±)-trans-2-azidocyclohexan-1-ol 1. 
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CBD NMR Spectrum 3   1H NMR spectrum of (±)-trans-2-(4-phenyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 2. 
 
CBD NMR Spectrum 4   13C NMR spectrum of (±)-trans-2-(4-phenyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 2. 
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CBD NMR Spectrum 5   1H NMR spectrum of (±)-trans-2-(4-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 3. 
 
CBD NMR Spectrum 6   13C NMR spectrum of (±)-trans-2-(4-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 3. 
Stellenbosch University https://scholar.sun.ac.za
Appendix 1 – Triazole CBD analogues 
108 
 
 
CBD NMR Spectrum 7   1H NMR spectrum of (±)-trans-2-(5-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 4. 
 
CBD NMR Spectrum 8   13C NMR spectrum of (±)-trans-2-(5-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 4. 
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CBD NMR Spectrum 9   1H NMR spectrum of internal alkyne, oct-2-yn-1-ol 5. 
 
CBD NMR Spectrum 10   13C NMR spectrum of internal alkyne, oct-2-yn-1-ol 5. 
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CBD NMR Spectrum 11   1H NMR spectrum of (±)-trans-2-[4-(hydroxymethyl)-5-pentyl-1H-1,2,3-triazol-1-
yl]cyclohexan-1-ol 6. 
 
CBD NMR Spectrum 12   13C NMR spectrum of (±)-trans-2-[4-(hydroxymethyl)-5-pentyl-1H-1,2,3-triazol-1-
yl]cyclohexan-1-ol 6. 
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CBD NMR Spectrum 13   1H NMR spectrum of (±)-trans-2-[5-(hydroxymethyl)-4-pentyl-1H-1,2,3-triazol-1-
yl]cyclohexan-1-ol 7. 
 
CBD NMR Spectrum 14   13C NMR spectrum of (±)-trans-2-[5-(hydroxymethyl)-4-pentyl-1H-1,2,3-triazol-1-
yl]cyclohexan-1-ol 7. 
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CBD NMR Spectrum 15   1H NMR spectrum of 2,3-epoxycyclohexanone, (7-oxabicyclo[4.1.0]heptan-2-one) 8. 
 
CBD NMR Spectrum 16   13C NMR spectrum of 2,3-epoxycyclohexanone, (7-oxabicyclo[4.1.0]heptan-2-one) 8. 
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NMR Spectrum 17   1H NMR spectrum of 3-hydroxycyclohexan-1-one 9. 
 
CBD NMR Spectrum 18   13C NMR spectrum of 3-hydroxycyclohexan-1-one 9. 
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CBD NMR Spectrum 19   Crude 1H NMR spectrum of 3-azidocyclohexan-1-one 11 with residual cyclohex-2-en-1-
one (11SM) in a 5:1 ratio. 
 
CBD NMR Spectrum 20   Crude 13C NMR spectrum of 3-azidocyclohexan-1-one 11 with residual cyclohex-2-en-1-
one (11SM) in a 5:1 ratio. 
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CBD NMR Spectrum 21   1H NMR spectrum of 3-(4-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-one 12. 
 
CBD NMR Spectrum 22   13C NMR spectrum of spectrum of 3-(4-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-one 12. 
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CBD NMR Spectrum 23   1H NMR spectrum of 3-(5-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-one 13 in a 2:1 
mixture with 3-(4-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-one 12. 
 
CBD NMR Spectrum 24   13C NMR spectrum of 3-(5-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-one 13 in a 2:1 
mixture with 3-(4-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-one 12. 
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CBD NMR Spectrum 25   1H NMR spectrum of 3-(4-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 14. 
 
CBD NMR Spectrum 26   13C NMR spectrum of 3-(4-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 14. 
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CBD NMR Spectrum 27   1H NMR spectrum of (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl methanesulfonate 15.    
 
CBD NMR Spectrum 28   13C NMR spectrum of (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl methanesulfonate 15. 
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CBD NMR Spectrum 29   1H NMR spectrum of (1S,2S,4R)-2-azido-1-isopropyl-4-methylcyclohexane 16. 
 
CBD NMR Spectrum 30   13C NMR spectrum of (1S,2S,4R)-2-azido-1-isopropyl-4-methylcyclohexane 16. 
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CBD NMR Spectrum 31   1H NMR spectrum of (1S,2S,4R)-2-chloro-1-isopropyl-4-methylcyclohexane 17.    
 
CBD NMR Spectrum 32   13C NMR spectrum of (1S,2S,4R)-2-chloro-1-isopropyl-4-methylcyclohexane 17. 
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CBD NMR Spectrum 33   1H NMR spectrum of 1-[(1S,2S,5R)-2-isopropyl-5-methylcyclohexyl]-4-pentyl-1H-1,2,3-
triazole 19. 
 
CBD NMR Spectrum 34   13C NMR spectrum of 1-[(1S,2S,5R)-2-isopropyl-5-methylcyclohexyl]-4-pentyl-1H-1,2,3-
triazole 19. 
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HIGH-RESOLUTION MASS SPECTROMETRY RESULTS 
 
CBD Mass Spectrum 1   HRMS of (±)-trans-2-(4-phenyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 2. 
 
 
CBD Mass Spectrum 2   HRMS of (±)-trans-2-(4-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 3.   
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MS_Direct_181221_MJ47 53 (0.312) 1: TOF MS ES+ 
2.13e5238.1920
239.1958
497.3571
276.1485
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CBD Mass Spectrum 3   HRMS of (±)-trans-2-(5-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-ol 4. 
 
 
CBD Mass Spectrum 4   HRMS of (±)-trans-2-[5-(hydroxymethyl)-4-pentyl-1H-1,2,3-triazol-1-yl]cyclohexan-1-ol 7. 
 
 
m/z
100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 580 600 620 640 660 680
%
0
100
MS_Direct_181221_MJ55 20 (0.130) 1: TOF MS ES+ 
5.85e5238.1921
140.1189
238.1388
239.1955
475.3769240.1981
276.1468
350.2796
328.1674
382.3104
497.3583
622.4296537.2955 555.3077
m/z
100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 580 600 620 640 660 680
%
0
100
MS_Direct_181221_MJ91b 14 (0.107) Cm (13:24) 1: TOF MS ES+ 
5.70e6268.2037
222.1863170.1295124.1127
238.1923
269.2061
557.3798
503.3713
310.2137270.2086
362.2813311.2171 398.2524
412.2615 501.3580472.2546 504.3745
558.3824
599.3895 640.2565 651.4568
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CBD Mass Spectrum 5   HRMS of 3-(4-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-one 12. 
 
 
 
CBD Mass Spectrum 6   HRMS of 3-(5-pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-one 13 in a 2:1 mixture with 3-(4-
pentyl-1H-1,2,3-triazol-1-yl)cyclohexan-1-one 12. 
m/z
100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 580 600 620 640 660 680
%
0
100
MS_Direct_181221_MJ66 15 (0.111) Cm (15:30) 1: TOF MS ES+ 
4.28e6236.1768
140.1189
124.0874 141.1215
234.1608
165.1135
237.1795
254.1873 268.2028
274.1326
471.3441
275.1356
352.2599326.1462 469.3284
366.2155 395.2524
493.3260
525.3514 557.3759 583.3058
m/z
195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375
%
0
100
MS_Direct_181221_MJ92 14 (0.107) Cm (13:26) 1: TOF MS ES+ 
3.37e6236.1770
229.1413207.1583
192.1401 222.1625
237.1797
268.2029
254.1875
238.1852
258.1584
259.1616
274.1327
275.1355
295.2265290.1850 326.1444316.1171304.3005 339.1246 365.1083348.2579
353.2755 371.1532
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CBD Mass Spectrum   HRMS of 7 1-[(1S,2S,5R)-2-isopropyl-5-methylcyclohexyl]-4-pentyl-1H-1,2,3-triazole 19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
m/z
100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 580 600 620 640 660 680
%
0
100
MS_Direct_181221_MJ83 14 (0.107) Cm (13:28) 1: TOF MS ES+ 
5.07e6278.2600
140.1191
102.1285 238.1923
141.1219 165.1150 217.1045 247.1677
279.2629
555.5120
280.2667 314.2213
337.3081 515.4446376.3341
392.3315
483.4153414.3127
553.4943
556.5148
557.5176
617.4327
651.5919
669.5756
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STRUCTURES OF REFERENCE COMPOUNDS WITH ANTICANCER ACTIVITY 
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TRANSITION BETWEEN THE TRIAZOLE CBD ANALOGUES PROJECT AND 
THE SUBSTITUTED CPP PROJECT 
 
The focus of the next four chapters of this dissertation, as well as the Appendix (labeled as Appendix 
2) following these chapters, is on a second research project completely separate from the triazole 
CBD analogue project discussed above. The research of this project was conducted at the Justus 
Liebig University in Giessen, Germany, in the research group of Prof. Dr Hermann A. Wegner. 
Compound numbering and NMR spectra4 numbering was restarted at 1 - to illustrate the complete 
division between these two projects.5 
 
 
 
 
 
 
 
                                               
 
4 For this project, 13C NMR spectra were not obtained for compounds previously reported in literature.  
5 The room temperature in the laboratory in which this project was conducted was regulated and kept constant 
at 20 °C.  
 
Stellenbosch University https://scholar.sun.ac.za
Chapter 7 – Substituted CPPs – Introduction and Project Aim 
128 
 
SYNTHESIS OF SUBSTITUTED CYCLOPARAPHENYLENES (CPPS) 
  
INTRODUCTION AND AIM OF CPP PROJECT 
7.1. MACROCYCLES AND THEIR APPLICATIONS 
Macrocycles have been defined by Marsault et al. as compounds that contain one or more cyclic 
units and consists of at least 12 atoms.164 These molecules have interesting structures and 
properties which is why the synthesis of macrocycles is considered as a fascinating field of research. 
There are four general strategies available for macrocyclization, namely, cyclo-oligomerization, 
intramolecular cyclization, bimolecular coupling (dimerization), and template synthesis; however, all 
of these methods have certain drawbacks.  
One field in which macrocycles are widely used is pharmaceutical drug therapy. When comparing 
macrocycles with their acyclic analogues, it is clear that the conformation of macrocycles is 
significantly more restricted. This structural characteristic gives macrocycles the benefit of being 
more soluble, having better oral bioavailability, possessing improved target binding, while also being 
more biologically stable than their acyclic analogues.165 One macrocyclic compound which is 
currently being used in targeted drug therapy, is called Telomestatin (Figure 7:1) - this molecule acts 
as an inhibitor for the telomerase activity of cancer cells.166  
 
Figure 7:1   Structure of Telomestatin.166  
Another field in which macrocycles have attracted significant attention is in supramolecular 
chemistry, due to their catalytic and redox properties, as well as the host-guest interactions of these 
macrocycles. The host-guest interactions of certain macrocycles, such as calixarenes and crown 
ethers have already been investigated.167 Some unique macrocycles have also been investigated 
for their potential as building blocks for carbon nanotubes. 
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7.2. CARBON NANOTUBES 
Carbon nanotubes (CNTs) are an allotrope of carbon with unique hollow cylindrical nanostructures. 
The study and synthesis of carbon nanotubes is still a developing field as the first reported 
observation of CNTs only occurred in 1991 by Iijima.168 
These molecules have unique electrical transport properties, unusual mechanical properties, 
extraordinary strength and act as efficient heat conductors. When considering all these properties, 
CNTs can be used in many different applications including energy storage, electronics and in drug 
delivery systems. Many different methods have been reported for the synthesis of CNTs but the 
chiral-selective synthesis of CNTs is still under investigation. 
One strategy for synthesizing CNTs with a specific chirality is to focus on the organic synthesis of 
CNT segments and using these molecules as building blocks for CNTs (Figure 7:2).169  
 
Figure 7:2   CNT “sidewall segment” as building block for CNTs.169 
 CNT SEGMENTS 
“Carbon nanorings” are macrocycles that can be obtained from “slicing” CNTs perpendicular to the 
main axis. These macrocycles represent the sidewall segment of CNTs with a specific chirality.170 
Macrocycles that can now be identified as CNT armchair segments have attracted the attention of 
several chemists long before the discovery of CNTs, due to their remarkable symmetry and 
interesting properties. Thus far, a wide variety of armchair CNT segments have been synthesized 
including cycloparaphenylenes (CPPs), all-Z-benzannulenes and tetradehydrodianthracenes 
(TDDAs) (Figure 7:3).170 For the purpose of this project, only the CPPs will be discussed in more 
detail. 
 
Figure 7:3   Selected armchair CNT segments (A: CPP; B: Benzannulenes; C: TDDA).170 
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 CYCLOPARAPHENYLENES 
Cycloparaphenylenes (CPPs) are macrocycles which consist of benzene rings connected through 
para-linkages, and these macrocycles represent the shortest sidewall segment of carbon nanotube 
structures. The long-awaited selective synthesis of single-walled carbon nanotubes (SWNTs) could 
therefore be achieved by using CPPs as a building block.171  
Although the synthesis of CPPs have been investigated since the early 1930s, the first successful 
synthesis was only achieved in 2008 by Jasti et al.172 The reason for this long struggle is due to the 
high strain energy that must be overcome to form these macrocycles. Jasti et al. addressed this 
problem by designing a route which involved an unstrained macrocyclic precursor, which meant that 
full conjugation would only be introduced in the final step (Scheme 7:1). In this synthesis, a curved 
diodo-building block was prepared from 1,4-benzoquinone and 1,4-diiodobenzene, followed by a 
borylation reaction to provide the curved borylated building block. The next step involved a Suzuki 
cross-coupling reaction between these two curved building blocks to obtain three macrocycles of 
different sizes. As mentioned above, the final step introduced full conjugation into the system through 
a reductive aromatization of these three macrocycles with lithium naphthalenide (LiNaph) to obtain 
three different CPP macrocycles, [9]CPP, [12]CPP, and [18]CPP.  
 
Scheme 7:1   The first successful synthesis of CPPs.170 
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A few months later, Itami and co-workers reported the first size-selective synthesis of CPP (Scheme 
7:2).173 In this synthesis, a L-shaped diodo-building block was prepared from 1,4-cyclohexanedione  
and 1,4-diiodobenzene. This L-shaped diodo-building block was then transformed into a MOM-
protected L-shaped diodo-compound and an L-shaped borylated compound, respectively. These 
two compounds were then subjected to a palladium-catalyzed cross-coupling reaction to provide the 
C-shaped non-macrocyclic compound with two iodine’s at the ends of the chain. This C-shaped 
molecule was then coupled to the original L-shaped borylated compound to obtain the non-
conjugated macrocycle and the final step involved an aromatization reaction to finally get access to 
[12]CPP. 
 
Scheme 7:2   First successful size selective synthesis of CPP.173 
Although this route provided the desired CPP macrocycle size selectively, several steps were 
required to obtain the final compound. Itami and co-workers therefore focused on producing [7] – 
[16]CPPs in less steps. The success of this endeavor provided access to size dependent properties 
of specific CPPs, as well as their host–guest behaviour.169  
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After the successful synthesis of classical CPP macrocycles, the search for novel CPPs with different 
substituents began, as it became clear that this would lead to novel complex macrocycles with 
interesting properties and applications.  
 SUBSTITUTED CPPS 
By incorporating functionalities onto the CPP structure, their applications can be significantly 
expanded. These expanded applications include new host−guest possibilities, possible use in 
chemosensors and nanoporous materials, as well as the option of connecting these CPP 
macrocycles to various surfaces. Nevertheless, the synthesis of substituted CPPs is notably more 
challenging then the unsubstituted CPP macrocycles. 
A number of substituted CPPs have been successfully synthesized, including heteroatomic, acene-
containing, polycyclic, as well as phenyl- and aryl-substituted CPPs (Figure 7:4).174  
 
Figure 7:4   Examples of substituted CPPs.174 
A previous study conducted in the research group of Prof. Dr Hermann A. Wegner, focused on the 
development of a strategy to obtain novel heteroatomic aryl-substituted [8]CPPs (Scheme 7:3).175 
These CPP molecules were synthesized from the same MOM-protected L-shaped diodo-compound 
as used by Itami and co-workers in their first size selective synthesis as illustrated in Scheme 7:2.173 
This L-shaped building block was coupled with a protected diyne, followed by the removal of the 
protecting group. The resulting product was subsequently subjected to a macrocyclization reaction. 
The final two steps of this synthesis involved a [2+2+2] cycloaddition reaction, followed by an 
aromatization reaction.  
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Scheme 7:3   Previous strategy for substituted [8]CPPs in the research group of Prof. Dr Wegner.175 
The drawback of the method illustrated in Scheme 7:3, is that the protected diyne, as well as the L-
shaped unit, must be synthesized separately, which means that the “X“ atom in the protected diyne 
unit cannot be transformed into a different functional group during the synthesis. Incorporating 
different heteroatoms or halogens into the CPP structure is therefore not possible when using this 
strategy. 
7.3. AIM AND OBJECTIVES 
 CPP LINKER SYSTEM 
In this project, a unique strategy will be explored for the synthesis of substituted [8]CPPs, in which 
the substituents can easily be transformed into other functional group such as alcohols, thiols, or 
halogens throughout the synthesis. The envisioned synthetic route towards these substituted 
[8]CPPs is depicted in Scheme 7:4. The same MOM-protected L-shaped building block, containing 
two iodobenzenes, will be subjected to a series of reactions which include a Sonogashira coupling 
reaction, a macrocyclization reaction, a [2+2+2] cycloaddition reaction and finally an aromatization 
reaction, of which the final two steps are established reactions for this system. The aim is thus to 
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transform the “X” atom from an alcohol into a bromine atom and subsequently into a sulfur atom, 
before the macrocyclization step, which will give the option to either produce the oxygen- or sulfur-
containing CPP macrocycle at will. 
 
Scheme 7:4   Envisioned strategy for the synthesis of new substituted CPPs. 
 LINEAR TEST SYSTEM 
A linear test system with a similar backbone structure to the substituted CPPs (Scheme 7:5), will first 
be explored in this study. The aim is to use this linear test system to investigate the synthetic route 
for the formation of the thioether functionality starting from iodobenzene. With the thioether 5 in hand, 
the [2+2+2] cycloaddition reaction could also be explored on this test system; however, this step has 
previously been optimized in the research group of Prof. Dr Wegner.176 The most important aspect 
of the synthesis of the linear test system is to find the optimum route for the formation of the thioether 
functionality. This synthesis will include a Sonogashira coupling reaction, an Appel reaction or similar 
reactions leading to the same transformation, as well as a nucleophilic substitution reaction. After 
optimization of this route, the applicable reactions will directly be applied to the CPP linker system 
to gain access to the sulfur-containing CPP macrocycle.  
 
Scheme 7:5   Envisioned strategy for the linear test system. 
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RESULTS AND DISCUSSION 
8.1. SYNTHESIS OF THE LINEAR TEST SYSTEM 
 SYNTHESIS OF 3-PHENYLPROP-2-YN-1-OL 1 
The synthesis of the linear test system started with a Sonogashira cross-coupling reaction  as 
illustrated in Scheme 8:1.177 Only catalytic amounts of bis(triphenylphosphine)palladium(II)dichloride 
and copper(I)iodide were needed to successfully couple iodobenzene and propargyl alcohol to obtain 
the resulting propargylic alcohol 1 in a high yield of 90%.  
 
Scheme 8:1   Sonogashira coupling reaction for 1 in the linear test system. 
NMR spectra 1 and 2 in Appendix 2 were used to characterize this compound. In the 1H NMR 
spectrum, a peak was seen at 4.48 ppm which represented the protons attached to the carbon 
adjacent to the hydroxyl group. In addition, a broad singlet was observed at 2.81 ppm which 
corresponded to the proton of the hydroxyl group. In the 13C NMR spectrum, two peaks were seen 
at around 86 ppm which corresponded to the two carbon atoms of the triple bond. Another 
noteworthy peak appeared at 51.47 ppm which was assigned to the carbon adjacent to the hydroxyl 
group. This carbon appeared at a higher chemical shift value than normally expected for methylene 
groups, due to the magnetic anisotropy caused by the adjacent triple bond, as well as the 
electronegativity of the nearby hydroxyl group. All other proton and carbon atoms were accounted 
for and the chemical shift values were in accordance with literature.177 
The currently accepted mechanism for the co-catalyzed Sonogashira cross-coupling reaction 
applied to this specific system is illustrated in Scheme 8:2.178 This mechanism is thought to involve 
two independent catalytic cycles. The palladium cycle started with an oxidative addition of 
iodobenzene to the palladium catalyst, while the next step in the palladium cycle linked up with the 
copper cycle. This rate determining step is a transmetalation from the copper acetylide formed via 
the copper cycle employing triethylamine. The final step involves a reductive elimination which 
regenerated the palladium catalyst and produced the desired product 1.178  
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Scheme 8:2   Mechanism for the co-catalyzed Sonogashira cross-coupling reaction.178  
This reaction proceeded smoothly at room temperature, and in a subsequent attempt the reaction 
time was shortened without having any effect on the yield. With an optimized procedure in hand, this 
Sonogashira coupling reaction could be directly applied to the synthesis of the strained CPP linker 
system. 
The subsequent reaction focused on converting this alcohol group into a functionality that could act 
as a good leaving group.  
 SYNTHESIS OF (3-BROMOPROP-1-YN-1-YL)BENZENE 2 
In the next step, the propargylic alcohol 1 was transformed into the corresponding propargylic 
bromide 2 by means of an Appel reaction (Scheme 8:3).177 This transformation involved reacting the 
alcohol 1 with carbon tetrabromide in the presence of triphenylphosphine. Please note that the 
mechanism for the Appel reaction was already provided in Section 3.3.3. during the discussion of 
the main project of this dissertation. The only difference between these two examples is the carbon 
tetrahalide reagent used for this transformation. The same mechanism as seen in Scheme 3:34 
could therefore be consulted for the mechanistic aspects of this reaction. Although the desired 
product was successfully isolated after purification by column chromatography, the yield was not 
satisfactory as it did not exceed 60%, even after several attempts.  
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Scheme 8:3   Appel reaction for 2 in the linear test system. 
Keeping in mind that these reactions need to be applied to the synthesis of the more strained CPP 
linker system, a different set of reaction conditions were then investigated for this transformation due 
to the moderate yield obtained with the Appel reaction. The characterization of compound 2 will 
follow after the discussion of the second method used for this conversion. 
 ALTERNATIVE SYNTHESIS OF (3-BROMOPROP-1-YN-1-YL)BENZENE 2 
An alternative method for this functional group manipulation was then explored in which the alcohol 
1 was initially transformed into a mesylate, which subsequently underwent a nucleophilic substitution 
reaction with lithium bromide (Scheme 8:4).179 After standard work-up and purification, product 2 was 
obtained in a good yield of 78%, which was a significant improvement compared to the yield obtained 
when using the Appel reaction conditions.    
 
Scheme 8:4   Alternative method for 2 via mesylate intermediate in the linear test system. 
NMR spectrum 3 in Appendix 2 was used to characterize this compound. A peak was observed at 
4.17 ppm which represented the protons attached to the carbon next to the bromine atom. This peak 
moved more upfield in comparison to the corresponding peak for the propargylic alcohol 1. This 
could be explained by the less electronegative nature of the bromine atom compared to the oxygen 
atom, which caused this proton to appear more shielded in the spectrum of compound 2. The 
disappearance of the broad singlet at 2.81 ppm which corresponded to the proton of the hydroxyl 
group of 1 further confirmed the successful formation of the desired product 2. All other proton atoms 
were accounted for, and the NMR spectroscopic data was consistent with values provided in 
literature.177 
This optimized procedure could also be directly applied to the synthesis of the strained CPP linker 
system. The synthetic route set out for the thioether functionality 5 required the formation of the 
corresponding propargylic thiol 4.  
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 ATTEMPTED SYNTHESIS OF 3-PHENYLPROP-2-YNE-1-THIOL 4 
The next transformation therefore involved the conversion of a halide (in this case the propargylic 
bromide) into the deprotected thiol in one step. This transformation required both the formation of 
the thioacetate 3 followed by a deacetylation to obtained the desired product 4. It was reported that 
the deprotected thiol 4 should be obtained under the reaction conditions depicted in Scheme 8:5, 
but in our hands only the thioacetate 3 was observed.180  
 
Scheme 8:5   Attempted synthesis of 4 in the linear test system. 
With the difficulties encountered with the direct conversion of the propargylic bromide 2 into the 
deprotected thiol 4, the synthetic strategy was slightly altered to a route which included the intentional 
synthesis of compound 3. With the reaction conditions illustrated in Scheme 8:5, two compounds 
were observed as determined by TLC, and subsequent onsite GC-MS analysis confirmed the 
presence of the thioacetate 3 along with an unidentified by-product. Due to the formation of this 
unwanted side-product under these conditions, an additional set of reaction conditions were 
investigated for the synthesis of the thioacetate 3. The characterization of product 3 will follow after 
the discussion of the second method used for this conversion.  
 SYNTHESIS OF S-(3-PHENYLPROP-2-YN-1-YL) ETHANETHIOATE 3 
The propargylic thioacetate 3 could also be obtained from the alcohol 1 by using a Mitsunobu 
reaction with thioacetic acid in the presence of triphenylphosphine and diethyl azodicarboxylate 
(DEAD) as can be seen in Scheme 8:6.181 Unfortunately, this method also led to a variety of side 
products, as determined by TLC. After removal of the solvent and a challenging purification process 
by means of column chromatography, the pure thioacetate 3 was obtained in a low yield of 34%.  
 
Scheme 8:6   Intentional synthesis of 3 in the linear test system (Mitsunobu reaction). 
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The proposed mechanism for the Mitsunobu reaction as applied to this specific system is depicted 
in Scheme 8:7.182 This process started with the nucleophilic attack of triphenylphosphine onto the 
nitrogen-nitrogen double bond of DEAD and the resulting betaine intermediate was then protonated 
through an interaction with thioacetic acid. Subsequent addition of the propargylic alcohol 1 led to 
the formation of a hydrazide compound along with an oxyphosphonium intermediate. A final 
nucleophilic substitution reaction with the deprotonated thioacetic acid provided the thioacetate 3 
along with triphenylphosphine oxide as by-product.182  
 
Scheme 8:7   Proposed mechanism for the Mitsunobu reaction.182 
NMR spectrum 4 located in Appendix 2 was used to characterize this compound. A peak was seen 
at 3.90 ppm which represented the protons attached to the carbon next to the sulfur atom. This peak 
moved even more upfield in comparison to the corresponding peak for the propargylic bromide 2, 
and this could once again be explained by the electronegativity difference of the adjacent atom as 
the electronegativity of bromine is slightly larger than that of sulfur. An additional peak also appeared 
at 2.39 ppm which represented the protons of the methyl carbon introduced by the acetate group. 
The next step involved the transformation of the thioacetate 3 into the desired thioether functionality 
5. The crude thioacetate 3 obtained during the attempted synthesis of the free thiol 4 was used in 
the initial attempt to determine whether this would be a viable route to explore before using the 
thioacetate 3 isolated after the Mitsunobu procedure.  
 FIRST ATTEMPTED SYNTHESIS OF BIS(3-PHENYLPROP-2-YN-1-YL)SULFANE 5 
A procedure was then attempted which involved the in situ cleavage of the acetal moiety of the 
thioacetate 3 with potassium hydroxide in methanol, followed by an alkylation of the resulting 
propargylic thiol 4 with the propargylic bromide 2 to potentially form the linear sulfide 5 (Scheme 
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8:8).181 GC-MS analysis confirmed the presence of the propargylic thiol 4, but unfortunately no 
alkylation reaction took place with the bromide 2. 
 
Scheme 8:8   Deacetylation and first attempted formation of the linear sulfide 5 in the linear test system. 
Due to the problems encountered in obtaining the free thiol 4 and the subsequent low yield obtained 
for the thioacetate 3, as well as the unsuccessful formation of the sulfide 5, three alternative routes 
were investigated. The three additional routes explored for the synthesis of the linear sulfide 5, did 
not involve the formation of the propargylic thiol 4, which meant that two steps would be eliminated 
from the synthesis of the linear sulfide 5. 
 SECOND ATTEMPTED SYNTHESIS OF BIS(3-PHENYLPROP-2-YN-1-YL)SULFANE 5 
The second attempt at synthesizing the linear sulfide 5 was a coupling reaction in which the 
propargylic bromide 2 was reacted with sodium sulfide in methanol. Unfortunately, this route was 
also unsuccessful and only starting material was recovered (Scheme 8:9).181 
 
Scheme 8:9   Second attempted formation of linear sulfide 5 in the linear test system. 
 SUCCESSFUL SYNTHESIS OF BIS(3-PHENYLPROP-2-YN-1-YL)SULFANE 5 
For the third attempt at synthesizing the linear sulfide 5 two different methods were combined. The 
alcohol 1 was initially transformed into a mesylate, which was subsequently reacted with sodium 
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sulfide (Scheme 8:10).179,181 This method finally provided the linear sulfide 5, but unfortunately a 
variety of side products were also formed which led to a very low yield of 28%. 
 
Scheme 8:10   First successful formation of linear sulfide 5 in the linear test system. 
Characterization of compound 5 was achieved by studying NMR spectrum 5 in Appendix 2. A peak 
was observed at 3.72 ppm which represented the protons attached to the two carbon atoms adjacent 
to the sulfur atom. A significant difference was seen in the chemical shift values of these protons to 
the alcohol 1. Due to the less electronegative nature of the sulfur atom, these protons appeared 
more shielded for 5 than in the corresponding alcohol. Also note the absence of a peak representing 
a methyl group which confirmed that this product was not the mesylate intermediate formed during 
this reaction. The calculated molar mass also corresponded with the molar mass determined by GC-
MS. All other proton atoms were accounted for, and were in accordance with previously reported 
spectral data.179 
 ALTERNATIVE SYNTHESIS OF BIS(3-PHENYLPROP-2-YN-1-YL)SULFANE 5 
An alternative method for the synthesis of the linear sulfide 5 was then explored in which the 
propargylic bromide 2 underwent treatment with sodium sulfide in a solvent mixture of 
tetrahydrofuran and water, under phase transfer conditions (Scheme 8:11).179 After standard work-
up and purification by column chromatography, product 5 was obtained in a yield of 58%. Although 
the yield of this reaction was still not ideal, it was a significant improvement based on the yield 
obtained with the method shown in Scheme 8:10. When considering all the problems encountered 
while trying to obtain this thioether 5, we were satisfied with this result.  
 
Scheme 8:11   Alternative method for formation of linear sulfide 5 in the linear test system. 
As previously mentioned, the aim of this section was to explore the synthesis of the thioether 
functionality and to find reactions which could directly be applied to the more strained CPP linker 
system. However, with the linear thioether 5 in hand, a final reaction was attempted for this system 
in the hopes of obtaining the sulfur-containing linear para-phenylene 6.  
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 ATTEMPTED SYNTHESIS OF 5-ETHYL-4,7-DIPHENYL-6-PROPYL-1,3-
DIHYDROBENZO[C]THIOPHENE 6 
The final step for the linear test system was to subject the linear sulfide 5 to a [2+2+2] cycloaddition 
reaction by using Wilkinson’s catalyst in a mixture of isopropyl alcohol and tetrahydrofuran under 
microwave irradiation (Scheme 8:12).183 The monoyne chosen was hept-3-yne as a previous study 
had shown that it is a good substrate for systems similar to this test system.176  
 
Scheme 8:12   Attempted [2+2+2] cycloaddition in the linear test system. 
Unfortunately, the microwave vial exploded during this attempt. The [2+2+2] cycloaddition reaction 
has previously been investigated in the research group of Prof. Dr Wegner and optimum conditions 
for this cycloaddition have already been determined for similar linear systems.176 Therefore, by 
keeping in mind the time limit associated with this project, it was decided to rather focus on the 
synthesis of the CPP linker system.  
The process involved in the synthesis of the linear test system was very useful as it provided 
successful methods for the Sonogashira coupling reaction, the bromination reaction, as well as the 
formation of the thioether functionality which could all be directly applied to the synthesis of the CPP 
linker system. 
8.2. SYNTHESIS OF THE CPP LINKER SYSTEM 
 SYNTHESIS OF THE L-SHAPED BUILDING BLOCK, 1,4-BIS(4-
IODOPHENYL)CYCLOHEXANE-1,4-DIOL 7 
The first step in the synthesis of the CPP linker system involved the formation of the L-shaped 
building block 7 from 1,4-diiodobenzene and 1,4-cyclohexanedione  (Scheme 8:13).171 The two-fold 
addition of the 4-iodophenyllithium compound (prepared from 1,4-diiodobenzene and nBuLi) to 1,4-
cyclohexanedione provided the desired product 7 in a yield of 24% after purification by re-
crystallization.  
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Scheme 8:13   Synthesis of L-shaped building block 7 in the CPP linker system. 
The formation of both the mono-addition product and the trans-isomer, was suppressed through 
coordination of the 1,4-cyclohexanedione to the CeCl3•(LiCl)2 complex. This L-shaped curvature is 
essential as it pre-organizes the building block in a conformation that facilitates the subsequent 
macrocyclization. The yield could still be further improved as some problems were encountered 
during the transfer of the 4-iodophenyllithium species to the 1,4-cyclohexanedione solution by means 
of cannulation. NMR spectrum 6 in Appendix 2 was used to characterize this compound. In terms of 
evidence, the two protons of the hydroxyl groups were seen as a broad signal at 1.69 ppm and all 8 
protons of the cyclohexane ring appeared as a multiplet at 2.10 – 2.02 ppm. All other proton atoms 
were accounted for and the NMR spectroscopic data was in agreement with literature.169 
 SYNTHESIS OF 1,4-BIS(4-IODOPHENYL)-1,4-BIS(METHOXYMETHOXY)CYCLOHEXANE 8 
A subsequent protection with chloromethyl methyl ether (MOMCl) provided the MOM-protected 
diiodide 8 in a good yield of 71% as depicted in Scheme 8:14.171 The MOM-protecting group was 
chosen as it is known to enhance the solubility of the subsequent products based on this building 
block, thus facilitating their handling and purification.171  
 
Scheme 8:14   Synthesis of the MOM-protected diiodide 8 in the CPP linker system. 
NMR spectrum 7 in Appendix 2 was studied during the characterization of this compound. The two 
protons of the hydroxyl groups seen in the spectrum of compound 7 disappeared, but all 8 protons 
of the cyclohexane ring could still be seen as a multiplet at 2.28- 2.01 ppm. Two additional peaks 
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were also observed, one at 3.39 ppm corresponding to the two methyl carbons of the MOM-
protecting group and one peak at 4.41 ppm corresponding to the two bridged carbons between the 
oxygen atoms of the MOM-protecting group. 
All other proton atoms were noted and the chemical shift values were in accordance with previously 
reported spectra.171 
 SYNTHESIS OF 3,3'-{[1,4-BIS(METHOXYMETHOXY)CYCLOHEXANE-1,4-DIYL]BIS(4,1-
PHENYLENE)}BIS(PROP-2-YN-1-OL) 9 
In the next step, the diol 9 was synthesized by means of a Sonogashira cross-coupling reaction 
between the MOM-protected diiodide 8 and propargyl alcohol (Scheme 8:15), in the presence of 
bis(triphenylphosphine)palladium(II) dichloride and copper iodide in triethylamine.177 The yield of this 
reaction was comparable to the Sonogashira coupling reaction in the linear test system. 
 
Scheme 8:15   Synthesis of diol 9 through a Sonogashira coupling reaction in the CPP linker system. 
NMR spectrum 8 located in Appendix 2 was used to characterize this compound. Two additional 
peaks were present in comparison to the spectrum of compound 8. A peak was observed at 1.62 
ppm which represented the two hydroxyl groups, while the other peak, which corresponded to the 
protons attached to the carbon next to the hydroxyl group, appeared at 4.49 ppm. All other proton 
atoms were accounted for and the chemical shift values were in accordance with literature.177 
 SYNTHESIS OF 1,4-BIS[4-(3-BROMOPROP-1-YN-1-YL)PHENYL]-1,4-
BIS(METHOXYMETHOXY)CYCLOHEXANE 10 
The next reaction involved a functional group transformation from the diol 9 to the dibromo compound 
10. As shown in the linear test system, two methods were available for this transformation; however, 
the method shown in Scheme 8:16 was chosen because it led to a higher yield than the Appel 
reaction in the linear test system.179 The diol 9 was initially transformed into the mesylated compound 
which subsequently underwent a nucleophilic substitution reaction with lithium bromide.  
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Scheme 8:16   Synthesis of dibromo 10 in the CPP linker system. 
NMR spectrum 9 in Appendix 2 was used to characterize this compound. A peak was seen at 4.15 
ppm which represented the protons attached to the carbon adjacent to the bromine atom. Similar to 
the linear test system, this peak moved more upfield in comparison to the corresponding peak for 
the propargylic alcohol 9 due to the fact that the oxygen atom was more electronegative than the 
bromine atom causing these protons of 10 to appear more shielded. 
The biggest challenge in the synthesis of CPPs is the formation of the macrocycle which usually 
contains high levels of intrinsic ring strain, mostly resulting from the connection of benzene rings in 
the para-positions. The macrocyclization step is usually reported in very low yields and often requires 
high dilution to counteract the reduction of entropy. 
As shown in Section 7.2.1.2, the oxygen-containing MOM-protected macrocycle and resulting 
substituted CPP compounds were already access in a previous study in the research group of Prof. 
Dr Hermann Wegner by using a different strategy than designed in this project. This project was 
therefore focused on designing a method which could provide access to the thioether functionality 
and the corresponding sulfur-containing substituted [8]CPP macrocycle, which could also allow 
access different functional groups instead of the thioether linker. To this end, the synthesis of the 
oxygen-containing MOM-protected macrocycle 11 was subsequently explored. 
 ATTEMPTED SYNTHESIS OF THE OXYGEN-CONTAINING MOM-PROTECTED MACROCYCLE 
11 
The macrocyclization was attempted between the diol 9 and dibromo 10 in the presence of the 
sodium hydride in the hope that the nucleophilic substitution reaction would take place to form the 
ether linkages (Scheme 8:17) and provide macrocycle 11.184 Unfortunately, under these conditions, 
formation of the macrocycle was not observed. 
Stellenbosch University https://scholar.sun.ac.za
Chapter 8 – Substituted CPPs – Results and Discussion 
146 
 
 
Scheme 8:17   Attempted synthesis of oxygen-containing macrocycle 11 in the CPP linker system. 
As the synthesis of the oxygen-containing MOM-protected macrocycle was not the main purpose of 
this study, eyes were set on the synthesis of the sulfur-containing MOM-protected macrocycle. 
 SYNTHESIS OF THE SULFUR-CONTAINING MOM-PROTECTED MACROCYCLE 12 
In a first trial to extend the synthetic strategy, the synthesis of the thioether linkage was attempted. 
The method developed for the linear test system was used to provide - what we believe to be - the 
thioether containing macrocycle in a low yield of 2%. In this event, the dibromo compound 10 was 
treated with sodium sulfide in a mixture of tetrahydrofuran and water under phase transfer conditions 
(Scheme 8:18).179  
 
Scheme 8:18   Synthesis of sulfur-containing macrocycle 12 in the CPP linker system. 
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Note that the NMR assignment of this compound is given with caution. A tentative assignment has 
been made based on the NMR spectra at hand, the spectra of the precursors, as well as the spectra 
of the oxygen-containing MOM-protected macrocycle previously synthesized in this group, as 
already mentioned. For a more accurate assignment or to confirm the assignment made in this 
document, additional NMR experiments must be conducted. It should be considered to obtain the 
heteronuclear single-quantum correlation spectroscopy (HSQC) spectrum, as well as the 
homonuclear correlation spectroscopy (COSY) spectrum. These two experiments will provide 
information on the proton-carbon coupling between directly attached proton and carbon nuclei, as 
well as the proton-proton coupling between adjacent proton nuclei, respectively. An additional one-
dimensional NMR experiment that might also be of interest is the attached proton test (APT). This 
experiment will indicate which of these carbons are quaternary or methylene carbons and which of 
these carbon atoms are methane or methyl carbons. These experiments were not conducted during 
the scope of this study, as only 18.7 mg (2%) of compound 12 was obtained, and the time allocated 
to this project and the exchange period had come to an end. 
NMR spectra 10 and 11 in Appendix 2 were studied during the characterization of this compound. 
An important peak was observed at 3.70 ppm in the 1H NMR spectrum. This peak represented the 
protons attached to the four carbon atoms next to the two sulfur atoms. This chemical shift was 
identical to the chemical shift of the corresponding protons for the thioether compound 5 in the linear 
test system. The structure of the sulfur-containing macrocycle 12 and the thioether compound 5 
synthesized in the linear test system indication the relative atoms mentioned above is illustrated 
below: 
 
Unfortunately, an accurate molar mass could not be determined for this compound, even when using 
electron spray ionization and atmospheric pressure ionization. These results are essential for the 
complete characterization of this macrocycle. However, the NMR spectra strongly suggested that 
the desired sulfur-containing macrocycle was formed. Due to the time limit associated with this study 
and the exchange period in Germany, this project could unfortunately not be explored further; 
however, this is an ongoing research project in the group of Prof. Dr Wegner. It should be considered 
of high importance to synthesize this sulfur-containing MOM-protected macrocycle with an improved 
yield so that the following steps could be investigated for the synthesis of the sulfur-containing 
substituted [8]CPP. 
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CONCLUDING REMARKS 
9.1. CONCLUSION 
In conclusion, a successful method for the synthesis of the thioether functionality has been 
developed throughout this project by means of a linear test system. The test system was very useful 
as it provided successful methods for the Sonogashira coupling reaction and the bromination 
reaction, as well as the formation of the thioether functionality which could all be directly applied to 
the synthesis of the CPP linker system. A successful method for the [2+2+2] cycloaddition reaction 
has been developed during a previous project for systems very similar to this linear test system. 
Nevertheless, the [2+2+2] cycloaddition reaction still needs to be tested on the linear test system 
(containing the thioether functionality) before it can be applied to the CPP linker system. 
When considering the CPP linker system, a successful route was developed to obtain the dibromo-
linker compound 10. With this compound in hand, new exciting opportunities will come to light as 
this project progresses as this compound could provide the option of effortlessly transforming the 
substituents throughout the synthesis of future substituted CPPs. The dibromo-linker compound was 
subsequently used to gain access to the sulfur-containing MOM-protected macrocycle 12 by making 
use of the method developed in the linear test system. The novel sulfur-containing substituted 
[8]CPP macrocycle can now be obtain in only a few well-established steps. 
9.2. FUTURE WORK 
Once a successful method for the formation of the oxygen-containing MOM-protected macrocycle 
has also been determined, the [2+2+2] cycloaddition will be performed on both macrocycles to 
introduce the substituents into the macrocyclic structure (Scheme 9:1).175 
 
Scheme 9:1   The [2+2+2] cycloaddition reaction using Wilkinson’s catalyst in the CPP linker system. 
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Finally, the substituted CPPs will be obtained through an aromatization reaction (Scheme 9:2).175 Up 
to now, only very low yields have been reported for this step due to the high strain energy that must 
be overcome.  
 
Scheme 9:2   Deprotection- elimination and Aromatization in the CPP linker system. 
These substituted CPPs can then be subjected to further functionalizations in which the substituents 
can be transformed, and undergo further directed functionalizations onto the neighbouring 
unsubstituted benzene rings (Scheme 9:3).  
 
Scheme 9:3   Post-functionalizations of substituted CPPs.  
The incorporation of functionalities at this late stage of the synthesis will lead to more creative new 
CPP-based structures which will further broaden the application range. Further work can also focus 
on determining the properties of these substituted CPPs, developing a synthetic strategy towards 
longer fragments of carbon nanotubes, and examining possible applications of these CPPs in 
nanoporous materials. 
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EXPERIMENTAL 
10.1. GENERAL INFORMATION 
Reaction glassware was dried by heating under a positive nitrogen pressure, or in an oven at 110 
°C for two hours. Reaction mixtures were heated by placing the reaction flask in a paraffin oil bath, 
set to the correct temperature on a magnetic stirrer hot plate. Solvents were removed in vacuo, by 
using a rotary evaporator followed by the use of a high vacuum pump at ca. 0.08 mm Hg, to remove 
trace amounts of residual solvent. 
All chemicals used in these experiments were purchased from Sigma Aldrich (Merck), Acros, TCI 
Europe, or Alfa Aesar. Anhydrous solvents were dried with a solvent purification system (MBRAUN 
MB-SPS-800) or purchased directly (with crown cap vails over molecular sieves) for small scale 
reactions. Other reagents which required purification was purified according to standard procedures.  
Air and/or moisture sensitive reactions were set up in a nitrogen-filled MBRAUN UNIlab glove box. 
Thin layer chromatography (TLC) was performed using Macherey-Nagel™ POLYGRAM SIL 
G=UV254 Sheets. Visualization of the plates were achieved by using a 254 nm UV light; along with 
staining the compounds with appropriate stains, followed by heating of the stained plate. Column 
chromatography was performed using Macherey-Nagel™ silica gel 60 (particle size 0.063-0.200 
mm) using different ratios of ethyl acetate and cyclohexane.  
NMR spectra (1H, 13C) were either recorded on a Bruker Avance II 400 MHz (AV 400) (101 MHz for 
13C). All spectra were obtained at 25 °C unless otherwise stated, and the NMR spectroscopy data 
was processed using MestReNova. Chemical shifts were recorded using the residual solvent peak 
or external reference. Furthermore, chemical shifts (δ) are given in parts per million (ppm) and J-
values in Hertz (Hz).   
10.2. SYNTHESIS OF THE LINEAR TEST SYSTEM 
 SYNTHESIS OF 3-PHENYLPROP-2-YN-1-OL 1 
Freshly distilled triethylamine (50 mL) was added into a 100 mL three-neck round-bottom flask under 
a N2 atmosphere. Copper(I)iodide (4.0 mg, 0.021 mmol, 0.0050 equiv.) was subsequently added, 
followed by Bis(triphenylphosphine)palladium(II) dichloride (30 mg, 0.042 mmol, 0.010 equiv.). By 
making use of a syringe, iodobenzene (0.47 mL, 4.2 mmol, 1.0 equiv.) was then added through the 
septum. The resulting solution was then stirred and propargyl alcohol (0.27 mL, 4.6 mmol, 1.1 equiv.) 
was added drop-wise. During the addition of the propargyl alcohol, the colour of the reaction mixture 
changed from colourless to a light yellow colour. After allowing the mixture to stir for 1 h the colour 
changed to a milky light yellow colour. The reaction mixture was then stirred for 24 h at RT. The 
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crude product was then partitioned between ammonium chloride and EtOAc and the aqueous phase 
was then extracted with EtOAc (3 × 100 mL). The combined organic layers were then washed with 
brine, dried over MgSO4, filtered and concentrated under reduced pressure. The resulting oily 
residue was purified by flash chromatography (Cyclohexane: EtOAc, 95:5 – 80:20). This afforded 
the pure propargylic alcohol 1 as a yellow brown oil (0.50 g, 3.8 mmol, 90%) 
 
Rf = 0.39 (Cyclohexane: EtOAc, 80:20). 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.41 (m, 2H, ArH), 7.33 
– 7.22 (m, 3H, ArH), 4.48 (s, 2H, 2 × H1), 2.81 (bs, 1H, OH). 13C NMR (101 MHz, CDCl3) δ 131.72 
(ArC), 128.50 (ArC), 128.35 (ArC), 122.60 (ArC), 87.38 (C2), 85.61 (C3), 51.47 (C1). GC-MS: m/z 
calculated: 132; found 132. 
Analytical data was in accordance with previously reported spectra.177 
 SYNTHESIS OF (3-BROMOPROP-1-YN-1-YL)BENZENE 2 
 FIRST SYNTHESIS OF (3-BROMOPROP-1-YN-1-YL)BENZENE 2 
Dry DCM (15 mL) was added into a 100 mL three-neck round-bottom flask under a constant N2 flow. 
The Sonogashira coupling product 1 (489 mg, 3.70 mmol, 1.00 equiv.) was then added through the 
septum via syringe, followed by the addition of carbon tetrabromide (1.86 g, 5.55 mmol, 1.50 equiv.). 
The reaction mixture was then cooled to 0 °C and triphenylphosphine (1.50 g, 5.74 mmol, 1.55 
equiv.) was added slowly. During the addition of the triphenylphosphine, the colourless solution 
initially turned into light yellow solution and then the mixture became a dark orange colour. The 
reaction was then allowed to warm to RT and stirred for 3 h. Within 5 min of stirring, the solution 
turned into a dark brown colour and after 3 h the solution was a light orange colour. After this time, 
EtOH (2.5 mL) was added and the reaction was stirred for an additional 20 min. Thereafter, the 
solvent was removed under reduced pressure and the product was purified by flash 
chromatography (Wet loaded with DCM, 100% cyclohexane). This afforded the pure propargylic 
bromide 2 as a yellow oil (262 mg, 1.34 mmol, 59%). 
An alternative method was subsequently explored for this transformation. This second method will 
be discussed below, followed by the characterization of compound 2.  
 ALTERNATIVE SYNTHESIS OF (3-BROMOPROP-1-YN-1-YL)BENZENE 2 
An ice-cooled solution of the Sonogashira coupling product 1 (252 mg, 1.91 mmol, 1.00 equiv.) and 
triethylamine (0.40 mL, 2.9 mmol, 1.5 equiv.) in THF (10 mL) was prepared in a 100 mL three-neck 
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round-bottom flask. Methanesulfonyl chloride (0.22 mL, 2.9 mmol, 1.5 equiv.) dissolved in THF (5 
mL) was then added dropwise. This mixture was allowed to stir for 20 min to allow the formation of 
the mesylate compound. Thereafter, lithium bromide (838 mg, 9.55 mmol, 5.00 equiv.) was added 
while the solution was kept at 0 °C. The mixture was then stirred for 6 h at RT, after which it was 
poured into distilled H2O, extracted with DCM (3 × 100 mL), washed with brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The resulting oily residue was purified by flash 
chromatography (100% cyclohexane). This afforded the pure propargylic bromide 2 as a yellow oil 
(291 mg, 1.49 mmol, 78%). 
 
Rf = 0.44 (100% cyclohexane). 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.42 (m, 2H, ArH), 7.35 – 7.31 
(m, 3H, ArH), 4.17 (s, 2H, 2 × H1). GC-MS: m/z calculated: 194; found 194. 
Analytical data was in accordance with literature.177,179 
 SYNTHESIS OF S-(3-PHENYLPROP-2-YN-1-YL) ETHANETHIOATE 3 
 FIRST SYNTHESIS OF S-(3-PHENYLPROP-2-YN-1-YL) ETHANETHIOATE 3 
The propargylic bromide 2 (103 mg, 0.526 mmol, 1.00 equiv.) dissolved in dry MeOH (4 mL) was 
added into a 50 mL two-neck round-bottom flask under a N2 atmosphere. Thioacetic acid (0.050 mL, 
0.63 mmol, 1.2 equiv.) was then added via syringe, followed by the addition of potassium carbonate 
(87.2 mg, 0.631 mmol, 1.20 equiv.). The solution was then left to stir for 0.5 h, and then a second 
portion of potassium carbonate (87.2 mg, 0.631 mmol, 1.20 equiv.) was added and the reaction was 
left to stir for another 0.5 h. After this time the solution was neutralized with 1 M HCl (approximately 
1 mL) and extracted with DCM (3 × 100 mL). The combined organic layers were washed with brine, 
dried over MgSO4, filtered and concentrated under reduced pressure. TLC analysis showed the 
presence of two products. GC-MS confirmed that the one product was the thioacetate 3 but the 
second product could not be identified. This crude mixture was used directly in the first attempt at 
the synthesis of the thioether compound 5.  
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 ALTERNATIVE SYNTHESIS OF S-(3-PHENYLPROP-2-YN-1-YL) ETHANETHIOATE 3 
Dry benzene (5 mL) was added into a 50 mL two-neck round-bottom flask under inert conditions, 
followed by DEAD (722 mg, 4.02 mmol, 1.00 equiv.). In a separate 100 mL three-neck round-bottom 
flask, dry benzene (25 mL) was added, followed by triphenylphosphine (1.05 g, 4.02 mmol, 1.00 
equiv.) and the 100 mL flask was cooled to 0 °C. The DEAD solution was then added to this cooled 
triphenylphosphine solution. The solution of DEAD in benzene was an orange colour but when added 
to the triphenylphosphine solution, the mixture became red after 10 min of stirring. The resulting red 
mixture was then left to stir at 0 °C for 20 min. In a separate 50 mL two-neck round-bottom flask, 
dry benzene (5 mL) was added followed by the propargylic alcohol 1 (531 mg, 4.02 mmol, 1.00 
equiv.) and thioacetic acid (312 mg, 4.02 mmol, 1.00 equiv.). This mixture was also cooled down to 
0 °C and then added to the red solution in one portion. The mixture was left to stir for 2.5 h after 
which time the solvent was removed under reduced pressure. After stirring the reaction mixture for 
2.5 h, it was a red-orange colour. Flash chromatography was then attempted (cyclohexane: EtOAc, 
95:5 – 90:10) but the fractions co-eluted. Only part of the clean thioacetate 3 was isolated as a yellow 
oil (262 mg, 1.38 mmol, 34%). 
 
Rf = 0.50 (cyclohexane: EtOAc, 90:10). 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.38 (m, 2H, ArH), 7.30 
– 7.28 (m, 3H, ArH), 3.90 (s, 2H, 2 × H1), 2.39 (s, 3H, 3 × H4). GC-MS: m/z calculated: 190; found 
190. 
Analytical data was in accordance with previously reported spectra.181 
 SYNTHESIS OF BIS(3-PHENYLPROP-2-YN-1-YL)SULFANE 5 
 FIRST ATTEMPTED SYNTHESIS OF BIS(3-PHENYLPROP-2-YN-1-YL)SULFANE 5 
The crude mixture obtained during the first synthesis of the thioacetate from the bromide 2 (103 mg, 
0.530 mmol, 1.00 equiv.) was used to produce the free thiol 4 and subsequently attempt the 
synthesis of the thioether 5. Dry MeOH (8 mL) was added into a 50 mL round-bottom flask containing 
the crude mixture with the thioacetate 3 (98.4 mg, 0.517 mmol, 1.00 equiv.). Potassium hydroxide 
(102.6 mg, 1.83 mmol, 3.45 equiv.) was then added followed by sodium thiosulfate (8.18 mg, 0.0517 
mmol, 0.100 equiv.). The solution was then stirred for 1 h at 0 °C (after this time TLC analysis showed 
complete conversion of the thioacetate 3 to the free thiol 4). Thereafter, the bromide 2 (159 mg, 
0.815 mmol, 1.58 equiv.) was dissolved in 2 mL of dry MeOH and added dropwise to the thiol 
mixture. The solution was then stirred for another 3 h at RT. The solution was then partitioned 
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between H2O and EtOAc and the aqueous layer was then extracted with EtOAc (3 × 50 mL). The 
combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated over 
reduced pressure.  
 
A crude NMR showed a mixture of products and GC-MS analysis confirmed the presence of two 
products, namely the free thiol 4 and an unidentified compound. No reaction took place between the 
free thiol and the bromide compound 2 to form the thioether 5. This mixture was not purified as other 
options were available for the synthesis of the thioether 5.  
 SECOND ATTEMPTED SYNTHESIS OF BIS(3-PHENYLPROP-2-YN-1-YL)SULFANE 5 
Anhydrous MeOH (3 mL) was added into a 50 mL two-neck round-bottom flask under a N2 
atmosphere. Subsequently, sodium sulfide (35.1 mg, 0.445 mmol, 0.500 equiv.) was added followed 
by the bromide 2 (174 mg, 0.890 mmol, 1.00 equiv.) dissolved in 2 mL of dry MeOH. The reaction 
was allowed to stir at RT for 2 h (as situated in literature but after this time only starting material was 
detected). The temperature was then raised to 30 °C and stirred for another 14 h. The solution was 
partitioned between H2O and EtOAc and then the aqueous layer was extracted with EtOAc (3 × 50 
mL). The combined organic layers were then washed with brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. Only 36 mg (21%) of the bromide starting material was 
recovered and none of the thioether 5 was formed during this reaction. 
 
 SUCCESSFUL SYNTHESIS OF BIS(3-PHENYLPROP-2-YN-1-YL)SULFANE 5 
The alcohol 1 (225 mg, 1.70 mmol, 1.00 equiv.) resulting from the Sonogashira coupling reaction 
was added into a 100 mL three-neck round-bottom flask in Dry THF (10 mL) followed by 
triethylamine (0.35 mL, 2.6 mmol, 1.5 equiv.). This solution was then cooled to 0 °C. Thereafter, 
methanesulfonyl chloride (292 mg, 2.55 mmol, 1.50 equiv.) dissolved in 1 mL of THF was added and 
the mixture was left to stir for 20 minutes to allow the formation of the mesylate compound. Sodium 
sulfide (134 mg, 1.70 mmol, 1.00 equiv.) was then added to the solution and the mixture was 
stirred at RT for 16 h. The reaction mixture was then poured into H2O and extracted with DCM (3 × 
100 mL), washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. 
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The resulting oily residue was purified by flash chromatography (Cyclohexane: EtOAc, 100:0 – 98:2). 
This afforded the pure product 5 as a yellow solid (72.7 mg, 0.278 mmol, 28%). 
 
An additional method was explored for the synthesis of this thioether functionality and will be 
discussed below followed by the characterization of 5. 
 ALTERNATIVE SYNTHESIS OF BIS(3-PHENYLPROP-2-YN-1-YL)SULFANE 5 
The bromide 2 (285 mg, 1.46 mmol, 1.00 equiv.) was taken into a THF/H2O mixture (10 mL: 2 mL). 
This solution was then cooled down to 0 °C and then TBAB (47.5 mg, 0.146 mmol, 0.100 equiv.) 
was added followed by sodium sulfide (57.5 mg, 0.730 mmol, 0.500 equiv.). This mixture was stirred 
at RT for 3 h. After this time, a significant amount of 2 was still detected by TLC and GC-MC analyses 
which prompt us to heat the solution to 30 °C while stirring for an additional 1 h. When starting 
material was still detected after this attempt, the reaction mixture was heated to 40 °C and stirred for 
another 1 h, followed by the addition of another portion of sodium sulfide (57.5 mg, 0.730 mmol, 
0.500 equiv.). This mixture was then allowed to stir at 40 °C for 11 h. The mixture was poured into 
H2O and extracted with DCM (3 × 100 mL), washed with brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The resulting oily residue was purified by flash 
chromatography (Cyclohexane: EtOAc, 100:0 – 95:5). This afforded the pure product 5 as a yellow 
solid (152 mg, 0.579 mmol, 58%). 
 
Rf = 0.58 (Cyclohexane: EtOAc, 90:10). 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.41 (m, 4H, ArH), 7.33 
– 7.28 (m, 6H, ArH), 3.72 (s, 4H, 2 × H1 and 2 × H4). GC-MS: m/z calculated: 262; found 262. 
Analytical data was in accordance with previously reported spectra.179 
 ATTEMPTED SYNTHESIS OF THE SULFUR-CONTAINING LINEAR PARA-PHENYLENE, 5-
ETHYL-4,7-DIPHENYL-6-PROPYL-1,3-DIHYDROBENZO[C]THIOPHENE 6 
The thioether 5 (50.1 mg, 0.191 mmol, 1.00 equiv.) was added into a 35 mL microwave vial equipped 
with a magnetic stirrer bar followed by 2-propanol (5 mL) and anhydrous THF (5 mL). This solution 
was then degassed by bubbling N2 through for 15 min. Thereafter, hept-3-yne (568 mg, 5.73 mmol, 
30.0 equiv.) was added followed by Wilkinson’s catalyst, RhCl(PPh3)3, (17.7 mg, 0.0191 mmol, 0.100 
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equiv.). The flask was then place in the microwave reactor at 100 °C for 6 h. Unfortunately, the 
microwave vial exploded during this reaction. The work up would have involved quenching with 
NaHCO3 and extracting the mixture with DCM. The mixture would then have been washed with brine, 
dried over MgSO4, filtered and concentrated under reduced pressure.  
 
The [2+2+2] cycloaddition reaction has previously been investigated in the research group of Prof. 
Dr Wegner and optimum conditions for this cycloaddition have already been determined for similar 
linear systems.176 Therefore, by keeping in mind the time limit associated with this project, it was 
decided to rather focus on the synthesis of the CPP linker system.  
10.3. SYNTHESIS OF THE CPP LINKER SYSTEM 
 SYNTHESIS OF THE L-SHAPED BUILDING BLOCK, 1,4-BIS(4-
IODOPHENYL)CYCLOHEXANE-1,4-DIOL 7 
CeCl3*7H2O (8.35 g, 22.2 mmol, 2.20 equiv.) and LiCl (9.58 g, 226 mmol, 22.0 equiv.) were added 
into a 500 mL three-neck round-bottom flask. The flask was heated to 150 °C under vacuum. 
Thereafter, the flask was left to cool to RT and dry THF (110 mL) was then added. The suspension 
was stirred for 16 h at RT. Dry THF (10 mL) was then added into a dry Schleck-tube under N2 
followed by 1,4-cyclohexanedione (1.14 g, 10.1 mmol, 1.00 equiv.). After the 1,4-
cyclohexanedione was completely dissolved, this solution was added to the 500 mL round-bottom 
flask. The CeCl3-LiCl suspension, after stirring 16 h, was a white suspension. When adding 1,4-
cyclohexanedione the colour of the suspension change to an off-yellow colour. The resulting solution 
was stirred for 2.5 h at RT and cooled down to 78 °C afterwards (acetone/ liquid N2 bath). This 
suspension started to freeze. The round-bottom flask was then removed out of the acetone/liquid N2 
bath and allowed to heat slightly and thaw. Then, an extra 18 mL of THF was added to the 
suspension. Dry THF (60 mL) was then added into a dry 100 mL three-neck round-bottom 
flask under N2 atmosphere followed by 1,4-diiodobenzene (10.2 g, 30.3 mmol, 3.00 equiv.). This 
solution was then also cooled down to 78 °C. n-Butyllithium (1.6 M in Hexane, 21 mL, 34 mmol, 3.4 
equiv.) was then added dropwise. During the addition of n-Butyllithium an extra 6 mL of dry THF was 
added because the solution started to freeze. The diiodobenzene solution turned into a bright yellow 
colour during the addition of n-Butyllithium. This solution was then left to stir at 78 °C for 0.5 h. This 
solution was then transferred to the prepared suspension via transfer cannula (additional THF had 
to be added to the 1,4-diiodobenzene solution during the transfer). During the transfer process of 
Stellenbosch University https://scholar.sun.ac.za
Chapter 10 – Substituted CPPs – Experimental 
157 
 
the diiodobenzene solution to the cyclohexanedione solution, the colour changed from an off-yellow 
(as indicated previously) to a light orange-brown colour. Not everything was transferred, next time 
add THF at the end and transfer with a needle at RT to prevent the mixture from freezing. Afterwards 
the stirring was continued from 17 h. Reaction was quenched with saturated NH4Cl at this point. The 
mixture was then passed through celite and rinsed with EtOAc and the filtrate was concentrated 
under reduced pressure. After adding H2O (300 mL) and EtOAc (400 mL) the organic phase was 
separated and the aqueous phase was extracted with EtOAc (3 × 300 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure. The product was 
recrystallized in chloroform to afford the pure L-shaped building block 7 as an off-white (light pink) 
solid (1.23 g, 2.36 mmol, 24%). 
 
1H NMR (400 MHz, CDCl3) δ 7.70 – 7.65 (m, 4H, ArH), 7.24 – 7.19 (m, 4H, ArH), 2.06 (s, 8H, 2 × H2 
and 2 × H3 and 2 × H5 and 2 × H6), 1.69 (bs, 2H, 2 × OH). 
Analytical data was in accordance with literature.169 
 SYNTHESIS OF 1,4-BIS(4-IODOPHENYL)-1,4-BIS(METHOXYMETHOXY)CYCLOHEXANE 8 
Dry DCM (15 mL) was added into a 50 mL three-neck round-bottom flask under N2 atmosphere 
followed by the L-shaped building block 7 (1.23 g, 2.36 mmol, 1.00 equiv.). To this suspension, N,N-
diisopropylethylamine (1.6 mL, 9.4 mmol, 4.0 equiv.) was added and subsequently, MOMCl (0.76 
mL, 9.4 mmol, 4.0 equiv.) was added dropwise. The suspension of the L-shaped building block 7 in 
DCM was a light pink solution. After the addition of the base, the colour of the suspension changed 
to a white colour. MOMCl reacted vigorously so the flask was placed in an ice bath during the 
addition. After the addition of MOMCl, the reaction was stirred at RT for 30 min and then the mixture 
was no longer a suspension. The solution was now a transparent yellow-brown colour. This mixture 
was then left to stir for 16 h at RT. Thereafter, NH4Cl (80 mL) was added and the mixture was 
extracted with DCM (3 x 100 mL). The combined organic layers were washed with brine, dried over 
MgSO4 and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (cyclohexane: EtOAc, 90:10 – 80:20). This afforded the pure MOM-protected 
diiodo-compound 8 as a white solid (1.01 g, 1.66 mmol, 71%). 
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Rf = 0.62 (cyclohexane: EtOAc, 70:30). 1H NMR (400 MHz, CDCl3) δ 7.66 – 7.64 (m, 4H, ArH), 7.17 
– 7.15 (m, 4H, ArH), 4.41 (s, 4H, 2 × H7 and 2 × H9), 3.39 (s, 6H, 2 × H8 and 2 × H10), 2.28 – 2.01 (2 
× H2 and 2 × H3 and 2 × H5 and 2 × H6). 
Analytical data was in accordance with previously reported spectra.171 
 SYNTHESIS OF 3,3'-{[1,4-BIS(METHOXYMETHOXY)CYCLOHEXANE-1,4-DIYL]BIS(4,1-
PHENYLENE)}BIS(PROP-2-YN-1-OL) 9 
Freshly distilled triethylamine (45 mL) was added into a 100 mL three-neck round-bottom flask under 
N2 atmosphere. Copper(I)iodide (9.1 mg, 0.048mmol, 0.040 equiv.) was then added followed 
by bis(triphenylphosphine)palladium(II)-dichloride (51 mg, 0.071 mmol, 0.060 equiv.). After the 
addition of the palladium catalyst the colour of the solution turned into a yellow colour. The MOM-
protected diiodo-compound 8 (720 mg, 1.2 mmol, 1.0 equiv.) was then added with a syringe via the 
septum. The resulting solution was then stirred and propargyl alcohol (0.28 mL, 4.8 mmol, 4.0 equiv.) 
was added drop-wise. During the addition of propargyl alcohol the yellow solution turned into an 
orange-brown suspension. After leaving the mixture to stir for 1 h the colour changed again to a light 
brown solution. The reaction mixture was then stirred for 23 h under inert atmosphere at RT. The 
crude product was partitioned between ammonium chloride and EtOAc. The aqueous phase was 
then extracted with EtOAc (3 × 200 mL). The combined organic layers were then washed with brine, 
dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography (cyclohexane: EtOAc, 70:30 – 30:70). This afforded the pure 
product 9 as a yellow solid (420 mg, 0.89 mmol, 88%). 
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 Rf = 0.19 (cyclohexane: EtOAc, 50:50). 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.36 (m, 8H, ArH), 4.49 
(s, 4H, 2 × H13 and 2 × H16), 4.41 (s, 4H, 2 × H7 and 2 × H9), 3.39 (s, 6H, 2 × H8 and 2 × H10), 2.39 – 
1.90 (m, 8H, 2 × H2 and 2 × H3 and 2 × H5 and 2 × H6), 1.62 (s, 2H, 2 × OH). 
Analytical data was in accordance with literature.177 
 SYNTHESIS OF 1,4-BIS[4-(3-BROMOPROP-1-YN-1-YL)PHENYL]-1,4-
BIS(METHOXYMETHOXY)CYCLOHEXANE 10 
An ice-cooled solution of the Sonogashira coupling product 9 (197 mg, 0.424 mmol, 1.00 equiv.) and 
triethylamine (0.18 mL, 1.3 mmol, 3.0 equiv.) in THF (10 mL) was prepared in a three-neck round-
bottom flask. Methanesulfonyl chloride (0.010 mL, 1.3 mmol, 3.0 equiv.) dissolved in THF (1 mL) 
was then added dropwise. This mixture was then allowed to stir for 20 min to allow the formation of 
the mesylate compound. Thereafter, lithium bromide (372 mg, 4.24 mmol, 10.0 equiv.) was added 
while the solution was kept at 0 °C. The mixture was then stirred for 17 h at RT. It was then poured 
into H2O (40 mL), extracted with DCM (3 × 100 mL), washed with brine, dried over MgSO4, filtered 
and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (cyclohexane: EtOAc, 95:5 – 70:30). This afforded the pure product 10 as a white 
solid (163 mg, 0.276 mmol, 65%). 
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Rf = 0.67 (cyclohexane: EtOAc, 50:50). 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.36 (m, 8H, ArH), 4.41 
(s, 4H, 2 × H7 and 2 × H9), 4.15 (s, 4H, 2 × H13 and 2 × H16), 3.39 (s, 6H, 2 × H8 and 2 × H10), 2.29 – 
2.05 (m, 8H, 2 × H2 and 2 × H3 and 2 × H5 and 2 × H6). 
 ATTEMPTED SYNTHESIS OF THE OXYGEN-CONTAINING MOM-PROTECTED MACROCYCLE 
11  
At 0 °C, to a suspension of sodium hydride (60% in mineral oil, 13.6 mg, 0.339 mmol, 4.00 equiv.) 
in THF (100 mL) was added a solution of the diol-compound 9 (39.3 mg, 0.0847 mmol, 1.00 
equiv.) and the dibromo-compound 10 (50.0 mg, 0.085 mmol, 1.00 equiv.) in THF (10 mL). The 
reaction mixture was then allowed to warm up to RT and stirred for 16 h. The mixture was finally 
quenched with saturated ammonium chloride and extracted with EtOAc. The combined organic 
layers were washed with brine, dried over MgSO4, filtered and concentrated under vacuum. A crude 
NMR showed only the presence of the two starting materials, so the crude mixture was dissolved in 
THF (125 mL), cooled to 0 °C and sodium hydride (60% in mineral oil, 27.1 mg, 0.678 mmol, 8.00 
equiv.) was added. The mixture was then allowed to warm to RT. After 1 h there was no indication 
that the reaction was taking place after examination by TLC so another portion of sodium hydride 
(60% in mineral oil, 27.1 mg, 0.678 mmol, 8.00 equiv.) was added. The reaction was then left to stir 
for 16 h and the next morning it was heated up to 30 °C and stirred for another 16 h. Then, another 
portion of sodium hydride (60% in mineral oil, 13.6 mg, 0.339 mmol, 4.00 equiv.) was added and the 
mixture was heated up to 40 °C and left to stir over the weekend. The mixture was finally quenched 
with saturated NH4Cl (15 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers 
were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. A 
crude NMR was then compared to that in literature but there was no prove of the formation of the 
macrocycle. 
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 SYNTHESIS OF THE SULFUR-CONTAINING MOM-PROTECTED MACROCYCLE 12  
The dibromo-compound 10 (116 mg, 0.197 mmol, 1.00 equiv.) was added to a mixture of 
THF/H2O (90 mL:18 mL, solvent ratio of 5:1). This solution was then cooled down to 0 °C and 
then TBAB, (12.8 mg, 0.0394 mmol, 0.200 equiv.) was added, followed by sodium sulfide (15.5 
mg, 0.197 mmol, 1.00 equiv.). The reaction was then stirred at RT for 16 h. The solvent was then 
evaporated and the mixture was poured into H2O and extracted with DCM (3 × 200 mL), washed 
with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (cyclohexane: EtOAc, 95:5 – 70:30). This afforded 
the pure product 12 as an off-white solid (18.7 mg, 0.579 mmol, 2%). 
 
Note that the NMR assignment of this compound is given with caution. A tentative assignment has 
been made based on the NMR spectra at hand, the spectra of the precursors, as well as the spectra 
of the oxygen-containing MOM-protected macrocycle previously synthesized in this group. For a 
more accurate assignment or to confirm the assignment made in this document, additional NMR 
experiments must be conducted. After several attempts, HRMS results could not be determined for 
this compound – this should be of high importance to complete characterization of this macrocycle. 
Rf = 0.38 (Cyclohexane: EtOAc, 70:30). 1H NMR (400 MHz, CDCl3) δ 7.36 (m, 16H, ArH), 4.44 
(s, 8H, 2 × H7 and 2 × H9 and 2 × H23 and 2 × H25), 3.70 (s, 8H, 2 × H13 and 2 × H16 and 2 × H29 
and 2 × H32), 3.39 (s, 12H, 3 × H8 and 3 × H10 and 3 × H24 and 3 × H26), 2.27- 2.04 (m, 16H, 2 × 
H2 and 2 × H3 and 2 × H5 and 2 × H6 and 2 × H18 and 2 × H19 and 2 × H21 and 2 × H22). 13C NMR 
(101 MHz, CDCl3) δ 131.92 (16 × ArH-C), 126.87 (4 × ArC), 122.27 (4 × ArC), 92.37 (C11 and 
C14 and C27 and C30), 84.75 (C12 and C15 and C28 and C31), 83.49 (C7 and C9 and C23 and C35), 
78.18 (C13 and C16 and C29 and C32), 56.15 (C8 and C10 and C24 and C26), 33.01 (C1 and C4 and 
C17 and C20), 19.89 (C2 and C3 and C5 and C6 and C18 and C19 and C21 and C22). 
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APPENDIX 2 
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY RESULTS 
 
CPP NMR Spectrum 1   1H NMR spectrum of 3-phenylprop-2-yn-1-ol 1. 
 
CPP NMR Spectrum 2   13C NMR spectrum of 3-phenylprop-2-yn-1-ol 1.     
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CPP NMR Spectrum 3   1H NMR spectrum of (3-bromoprop-1-yn-1-yl)benzene 2. 
 
CPP NMR Spectrum 4   1H NMR spectrum of S-(3-phenylprop-2-yn-1-yl) ethanethioate 3. 
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CPP NMR Spectrum 5   1H NMR spectrum of bis(3-phenylprop-2-yn-1-yl)sulfane 5. 
 
CPP NMR Spectrum 6   1H NMR spectrum of 1,4-bis(4-iodophenyl)cyclohexane-1,4-diol 7. 
Stellenbosch University https://scholar.sun.ac.za
Appendix 2 – Substituted CPPs 
165 
 
 
CPP NMR Spectrum 7   1H NMR spectrum of 1,4-bis(4-iodophenyl)-1,4-bis(methoxymethoxy)cyclohexane 8. 
 
CPP NMR Spectrum 8   1H NMR spectrum of 3,3'-{[1,4-bis(methoxymethoxy)cyclohexane-1,4-diyl]bis(4,1-
phenylene)}bis(prop-2-yn-1-ol) 9. 
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CPP NMR Spectrum 9   1H NMR spectrum of 1,4-bis[4-(3-bromoprop-1-yn-1-yl)phenyl]-1,4-
bis(methoxymethoxy)cyclohexane 10 
 
CPP NMR Spectrum 10   1H NMR spectrum of the sulfur-containing mom-protected macrocycle 12. 
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CPP NMR Spectrum 11   13C NMR spectrum of the sulfur-containing mom-protected macrocycle 12.
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